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This thesis is divided into four sections. Section 1 (Chapter 1) is an introductory 
chapter providing a literature review of the topic followed by rationale, aims and 
objectives of the thesis.  
Section 2 (Chapter 2) is a cross-sectional prospective observational study. This 
chapter was conducted in collaboration with Hana Alloub (BMedSci Student) and 
Professor Derek Burke (Consultant in Paediatric Emergency Medicine at Sheffield 
Children’s Hospital). Dr Amaka C Offiah provided the academic supervision. In 
this chapter, we determined vitamin D intake, calcium intake, physical activity 
levels and their association with fracture risk among children (aged 6 to 15 years) 
with wrist and ankle injuries. This chapter is presented in the format of a paper 
currently undergoing major revision for peer-reviewed publication in Nutrition and 
Health journal.  
Section 3 contains the major work undertaken during my PhD. This section consists 
of four chapters (Chapters 3, 4, 5 and 6). The work in this section was conducted 
by myself under the supervision of Dr Amaka C Offiah (my primary supervisor), 
Professor Nick Bishop and Dr Margaret Paggiosi (my co-supervisors). Statistical 
support was received from Professor Alan Rigby (University of Hull). This section 
is a double blind pilot randomised control trial of the effect of vitamin D and whole 
body vibration on high resolution peripheral quantitative computed tomography 
(HR-pQCT) parameters of the distal tibia. In Section 3, Chapter 3, I provide details 
of the methods used to undertake this study.  In chapter 4, I present the results. In 
Chapter 5, I provide a discussion of the results. In Chapter 6, I provide the 
conclusion, strengths and limitations and potential future directions for the project. 




Vitamin D, calcium and physical activity are important factors for bone health. A 
cross sectional study was conducted in Chapter 2 to assess vitamin D intake, 
calcium intake and physical activity among children with wrist or ankle injuries and 
their association with fracture risk. The majority of children had low vitamin D and 
calcium intake. The logistic regression indicated that there was a small but 
significant relationship between calcium intake and fracture risk (OR per SD 
increase = 0.998; 95% CI, 0.997 – 0.999) but no significant relationship was found 
between vitamin D intake and fracture risk.  
In the following section (Chapters 3, 4, 5 and 6), a randomised controlled trial was 
conducted to determine the effect of whole body vibration and a large single dose 
of vitamin D (150,000 IU) on bone density of the distal tibia as measured by HR-
pQCT. The study consisted of four parallel groups of equal numbers (40 in total). 
WBV and placebo group, placebo group, vitamin D group and vitamin D+ WBV 
group. Measurements (HR-pQCT, serum 25 (OH)D, PTH, bone profile) were 
collected at baseline and after 12 weeks (during week 13).  
The median baseline serum 25(OH)D for all participants was 23 nmol/L. The high 
dose of vitamin D was well tolerated. There was a significant increase in serum 25 
(OH)D in vitamin D and vitamin D+WBV groups relative to the placebo group (all 
p<0.01). There was a significant decrease in PTH in vitamin D group relative to the 
placebo group (p=0.013). After 12 weeks, vitamin D group showed the greatest 
increase in total bone density (increased by 2.7 mg/cm3 relative to the placebo 
group, p= 0.05). The main findings of this study indicated that the large single dose 
of vitamin D and 12 weeks of WBV did not improve bone density, bone 
microarchitecture or bone strength.  
7 
 
Acknowledgements and dedication 
(In the Name of Allah, the Most Beneficent, the Most Merciful) 
 
I would like to acknowledge the many important individuals who have helped me 
during my PhD journey. First and foremost, I would like to express my sincere 
gratitude and appreciation to my supervisors; my primary supervisor Dr Amaka C 
Offiah, and my co-supervisors Professor Nick Bishop and Dr Margaret Paggiosi for 
their support, guidance and encouragement throughout my PhD. Without whom, 
this work would not be possible. It has been a wonderful opportunity to work under 
their supervisions. In addition, I would like to thank Professor Derek Burke and Ms 
Hana Alloub for co-authoring Chapter 2.  My thanks go also to Professor Alan 
Rigby for providing support with the statistical analysis in Section 3 of this thesis.  
 
 I would like to thank all the staff of Sheffield Children’s Hospital (SCH), especially 
those within the clinical research facility (CRF), pharmacy and the clinical 
laboratory for their support. Special thanks to Samya Armoush, Rachel Harrison, 
Susan George, Jayne Clements, Emilia Bettell and Carolyn Clark, for their 
administrative support at various points during my PhD. In addition, I wish to thank 
all volunteers for their participation in this research.    
 
My sincere thanks go to my brothers and sisters for their care. My thanks go also to 
my colleagues and friends; Mohammad, Khalaf, Fawaz and Hani who were the best 




I am especially grateful to the Kingdom of Saudi Arabia government and Najran 
University for giving me the scholarship opportunity and funding my studies. My 
sincere gratitude goes also to Professor Nick Bishop and Dr Amaka C Offiah for 
their financial contribution in section 3 via their research accounts.  
 
Last but not least, I wish to dedicate this thesis to my parents Awed and Shareefa 
Alshamrani in recognition of their praises, encouragement and prayers. I also 
dedicate this thesis to my wife Reem and my children Bassam and Mazin for their 























For the cross-sectional study (Section 2, Chapter 2), Dr Offiah proposed and 
contributed substantially to the study design, provided general supervision, applied 
for and obtained ethical approval, and revised and approved the final version of the 
manuscript. Professor Burke contributed to the study design, and revised and 
approved the final version of the manuscript. Ms Alloub contributed to the study 
design and ethical approval, recruited and interviewed patients, contributed to data 
analysis and revised and approved the final version of the manuscript. I contributed 
to the study design, recruited and interviewed patients, analysed and interpreted the 
entire data set. I wrote the manuscript, and submitted it to the Nutrition and Health 
journal and was responsible for all communication with the journal. I also 
responded to the reviewers' comments and amended the paper accordingly.  
For the randomised control trial (VibeD study) (Section 3, Chapters 3, 4, 5 and 6), 
Dr Offiah and Professor Bishop proposed the study. I wrote the original protocol 
for the VibeD study and the subsequent amendments and I responded to the 
reviewers’ comments regarding the protocol. I also coordinated and liaised with 
various departments including the Research and Development (R&D) and the 
Clinical Research Facility (CRF) at Sheffield Children’s Hospital (SCH) and 
Northern General Hospital (NGH), pharmacy and clinical laboratory at SCH in 
order to set-up and organised the VibeD study. 
I wrote the Participants’ Information Sheets (PIS), consent forms, eligibility 
checklist, the advertising materials and all other supporting documentation and I 
was responsible for adverting the study and participants’ recruitment.  
10 
 
I applied for and acquired the Research Ethics Committee (REC) approval and the 
Health Research Authority (HRA) approvals and I responded to all the queries and 
did all the amendments requested by REC and HRA. I also acquired the Research 
and Development (R&D) approval for the study. I completed the Integrated 
Research Application System (IRAS) and obtained medical imaging and medical 
physics approval for the study. I was responsible for site file maintenance and 
general study management. I sent letters to participants with their vitamin D results 
and wrote to participants’ GPs in case of abnormal results. Dr Offiah approved the 
letters before sending them out.  
I assessed the participants’ eligibility, and I collected the consent forms from them.  
I booked all study visits for all participants and I organised the travel for the 
participants between SCH and NGH. I performed the anthropometry measurements. 
I was also responsible for obtaining and distributing participants' thanks vouchers. 
I booked the venue for the vibration training in the CRF throughout the duration of 
the study, set-up the vibration machines, supervised all the vibration session, and 
recorded all study activities including the vibration visits and the clinical visits.  
I entered the data into the spreadsheet and performed the preliminary data analysis. 
Statistical support was received form professor Alan Rigby (University of Hull). Dr 
Margaret Paggiosi performed all HR-pQCT scanning and analysis.  Bone profile, 
parathyroid hormone and urine samples were analysed by the Clinical Chemistry 
Laboratory Department at SCH. Vitamin D analysis was performed by the 
Biochemistry Department at Bristol Royal Infirmary.  
Dr Amaka Offiah, Professor Nick Bishop and Dr Margaret Paggiosi provided 
general supervision and guidance to the study. 
11 
 
Conferences and publications 
 
HA Alshamrani, H Alloub, D Burke, AC Offiah. Vitamin D intake, calcium intake 
and physical activity among children with wrist and ankle injuries and the 
association with fracture risk. Nutrition and Health journal, 2019 (in press), 
available online at: https://doi.org/10.1177/0260106019826422 
HA Alshamrani, MA Paggiosi, NJ Bishop, AC Offiah. Effect of vitamin D and 
whole body vibration on high resolution peripheral quantitative computed 
tomography (HR-pQCT) parameters of the distal tibia (VibeD study). Bone 
Research Society (BRS) Annual Conference, June 2018, Winchester, UK. Poster 
presentation. JBMR Plus (2018) 2, https://doi.org/10.1002/jbm4.10073 
HA Alshamrani, MA Paggiosi, NJ Bishop, AC Offiah. Correlation between serum 
25 hydroxyvitamin D, parathyroid hormone (PTH) and high resolution peripheral 
quantitative computed tomography (HR-pQCT) parameters of the distal tibia. Bone 
Research Society (BRS) Annual Conference, June 2018, Winchester, UK. Poster 
presentation. JBMR Plus (2018) 2, https://doi.org/10.1002/jbm4.10073 
HA Alshamrani, MA Paggiosi, NJ Bishop, AC Offiah. Effect of vitamin D and 
whole body vibration on high resolution peripheral quantitative computed 
tomography (HR-pQCT) parameters of the distal tibia (VibeD study). Mellanby 
Centre Internal Seminar, May 2018, Sheffield, UK. Oral presentation. 
HA Alshamrani, H Alloub1, D Burke, AC Offiah. Impact of age, sex, location of 
injury, physical activity, vitamin D and calcium intake on the injury outcome of 
wrist and ankle in children. The 8th International Conference on Children’s Bone 
Health (ICCBH), June 2017, Würzburg, Germany, Poster presentation. Bone 




HA Alshamrani, H Alloub, D Burke, AC Offiah. Fracture risk in children and its 
association with physical activity and Vitamin D and calcium intake. United 
Kingdom Radiological Congress (UKRC), June 2016, Liverpool, UK, Oral 
Presentation.  
HA Alshamrani, H Alloub, D Burke, AC Offiah. Inadequate Intake of Vitamin D 
and Calcium among Children with Wrist and Ankle Injury. The 9th Saudi Students 
Conference in the UK, February 2016, Birmingham - UK, Poster Presentation. 
HA Alshamrani, H Alloub, D Burke, AC Offiah. Fracture risk in children and its 
association with physical activity and vitamin D and calcium intake: A cross 
sectional study. The 6th Annual Mellanby Centre Research Day, December 2015, 












List of figures 
Figure 1.1: Cortical and trabecular bone. .............................................................. 24 
Figure 1.2: Diagram of the bone remodelling process. ......................................... 27 
Figure 1.3: Bone mass throughout a human lifespan and the influence of 
suboptimal lifestyle factors.. .......................................................................... 30 
Figure 1.4: Visual comparisons of the trabecular microstructure of normal and 
osteoporotic bones showing healthy (left) and osteoporotic (right) bones. ... 32 
Figure 1.5: Two main types of vibration platform according to their movement 
direction. ........................................................................................................ 45 
Figure 1.6: Simplified diagram of vitamin D metabolism. ................................... 58 
Figure 1.7: The components of bone strength and the role of medical imaging 
modalities  in assessing bone strength non-invasively. ................................. 67 
Figure 1.8: Object size effect on DXA measurements. DXA is limited to two 
dimensions only and therefore the third dimension (depth) cannot be 
assessed.. ........................................................................................................ 71 
Figure 1.9: The power of HR-pQCT as a high-resolution technique. ................... 74 
Figure 2.1: Calcium intake by group .................................................................... 92 
Figure 2.2: Vitamin D intake by group ................................................................. 92 
Figure 2.3:  Distribution of the Total MET’s Score among the two groups ......... 93 
Figure 3.1: Consort flow-chart of the study pathway ......................................... 101 
Figure 3.2: VibeD study timeline ........................................................................ 105 
Figure 3.3: (a); Galileo Advanced platform, (b, c); subjects’ position on the 
platform (from week 3 to week 12). ............................................................ 116 
Figure 3.4: HR-pQCT scanner (XtremeCT, Scanco Medical AG). .................... 118 
Figure 3.5: (a); Leg cast, (b,c,d); scanning procedures ....................................... 120 
Figure 3.6: HR-pQCT scan of the distal tibia. a; scout view, b; axial 2D image 
slice, c; axial 3D image, d; coronal 3D image.. ........................................... 121 
Figure 3.7: Visual grading system for HR-pCQT scan quality (tibia). Arrows point 
to the motion artefact. .................................................................................. 123 
Figure 3.8: Manufacturer’s test object for the XtremeCT scanner ..................... 129 
Figure 4.1: VibeD study profile .......................................................................... 139 
Figure 4.2: Cortical area (left image) and trabecular area (right image) by 
randomization group at baseline and after 12 weeks. .................................. 145 
Figure 4.3: Total density by randomization group at baseline and after 12 weeks
 ............................................................................................................................. 146 
Figure 4.4: Cortical density by randomization group at baseline and after 12 
weeks ........................................................................................................... 146 
Figure 4.5: Trabecular density by randomization group at baseline and after 12 
weeks ........................................................................................................... 146 
Figure 4.6: Meta trabecular density by randomization group at baseline and after 
12 weeks.. .................................................................................................... 147 
Figure 4.7: Inner meta trabecular density by randomization group at baseline and 
after 12 weeks .............................................................................................. 147 
Figure 4.8: Meta/inner trabecular density ratio by randomization group at baseline 
and after 12 weeks ....................................................................................... 147 
14 
 
Figure 4.9: Trabecular BV/TV ratio by randomization group at baseline and after 
12 weeks ...................................................................................................... 147 
Figure 4.10: Trabecular thickness by randomization group at baseline and after 12 
weeks.. ......................................................................................................... 148 
Figure 4.11: Trabecular number by randomization group at baseline and after 12 
weeks. .......................................................................................................... 148 
Figure 4.12: Trabecular inhomogeneity by randomization group at baseline and 
after 12 weeks. ............................................................................................. 148 
Figure 4.13: Trabecular separation by randomization group at baseline and after 
12 weeks ...................................................................................................... 148 
Figure 4.14: Cortical perimeter by randomization group at baseline and after 12 
weeks  .......................................................................................................... 149 
Figure 4.15: Cortical thickness by randomization group at baseline and after 12 
weeks ........................................................................................................... 149 
Figure 4.16: Percentage (%) of cortical porosity by randomization group at 
baseline and after 12 weeks. ........................................................................ 149 
Figure 4.17: Cortical porosity by randomization group at baseline and after 12 
weeks ........................................................................................................... 149 
Figure 4.18: Cortical diameter by randomization group at baseline and after 12 
weeks. .......................................................................................................... 150 
Figure 4.19: SD of mean cortical diameter by randomization group at baseline and 
after 12 weeks  ............................................................................................. 150 
Figure 4.20: Connectivity density by randomization group at baseline and after 12 
weeks ........................................................................................................... 150 
Figure 4.21: Cortical tissue mineral density by randomization group at baseline 
and after 12 weeks ....................................................................................... 150 
Figure 4.22: Stiffness by randomization group at baseline and after 12 weeks. . 151 
Figure 4.23: Estimated ultimate failure load by randomization group at baseline 
and after 12 weeks.. ..................................................................................... 151 
Figure 4.24: Distal ratio of the load taken by the trabeculae in relation to the total 
load by randomization group at baseline and after 12 weeks ...................... 151 
Figure 4.25: Proximal ratio of the load taken by the trabeculae in relation to the 
total load by randomization group at baseline and after 12 weeks .............. 151 
Figure 4.26: Weight (kg) by randomization group at baseline and after 12 weeks
 ..................................................................................................................... 152 
Figure 4.27:  BMI by randomization group at baseline and after 12 weeks. ...... 152 
Figure 4.28: Total 25 (OH)D by randomization group at baseline and after 12 
weeks ........................................................................................................... 153 
Figure 4.29: PTH by randomization group at baseline and after 12 weeks.. ...... 153 
Figure 4.30: Corrected calcium by randomization group at baseline and after 12 
weeks.. ......................................................................................................... 154 
Figure 4.31: Phosphate by randomization group at baseline and after 12 weeks.
 ..................................................................................................................... 154 
Figure 4.32: Albumin by randomization group at baseline and after 12 weeks. 154 
Figure 4.33: Alkaline phosphatase by randomization group at baseline and after 
12 weeks. ..................................................................................................... 154 
15 
 
Figure 4.34: Percentage change in cortical area from baseline ........................... 155 
Figure 4.35: Percentage change in trabecular area from baseline.. ..................... 156 
Figure 4.36: Percentage change in total density from baseline.. ......................... 157 
Figure 4.37: Percentage change in cortical density from baseline. ..................... 158 
Figure 4.38: Percentage change in trabecular density from baseline. ................. 159 
Figure 4.39: Percentage change in trabecular number from baseline. ................ 160 
Figure 4.40: Percentage change in trabecular separation from baseline. ............ 161 
Figure 4.41: Percentage change in trabecular thickness from baseline. ............. 162 
Figure 4.42: Percentage change in cortical thickness from baseline.. ................ 163 
Figure 4.43: Percentage change in cortical tissue mineral density from baseline164 
Figure 4.44: Percentage change in cortical porosity from baseline…………….165 
Figure 4.45: Percentage change in stiffness from baseline. ................................ 166 
Figure 4.46: Percentage change in estimate failure load from baseline. ............. 167 
Figure 4.47: Percentage change in serum 25(OH) D from baseline. .................. 168 
Figure 4.48: Percentage change in serum PTH from baseline. ........................... 169 
Figure 4.49: Left tibia of a 19-year-old female volunteer who was randomised to 
vitamin D + WBV.. ...................................................................................... 172 
Figure 4.50: Left tibia of a 30-year-old male volunteer who was randomised to 































List of tables 
 
Table 1.1: WBV parameters .................................................................................. 43 
Table 1.2: Summary of studies investigating the effect of both WBV and vitamin 
D on bone ....................................................................................................... 54 
Table 1.3: Radiological methods for assessing bone ............................................ 66 
Table 2.1: Patient demographics ........................................................................... 90 
Table 2.2: Logistic regression model (8 independent variables) .......................... 94 
Table 3.1: Summery of activities undertaken during study visits ....................... 106 
Table 3.2: Technical HR-pQCT scanning parameters ........................................ 119 
Table 3.3: Summary of the different HR-pQCT parameters that resulted from the 
standard analysis, extended cortical analysis and µFE Analysis outcome .. 126 
Table 4.1: Participants’ country of origin ........................................................... 140 
Table 4.2: Summary statistics are median, 25th/75th centiles, and range except for 
sex. Calculations subject to rounding errors ................................................ 142 
Table 4.3: Classification of vitamin D levels at baseline .................................... 144 
Table 4.4: Cortical area change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
cortical area, baseline PTH, baseline 25(OH) D and baseline BMI. ........... 155 
Table 4.5: Trabecular area change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
trabecular area, baseline PTH, baseline 25(OH)D and baseline BMI. ........ 156 
Table 4.6: Total density change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline total 
density, baseline PTH, baseline 25(OH) D and baseline BMI. ................... 157 
Table 4.7: Cortical density change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
cortical density, baseline PTH, baseline 25(OH)D and baseline BMI. ....... 158 
Table 4.8: Trabecular density change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
trabecular density, baseline PTH, baseline 25(OH)D and baseline BMI. ... 159 
Table 4.9: Trabecular number change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
trabecular number, baseline PTH, baseline 25(OH)D and baseline BMI. ... 160 
Table 4.10: Trabecular separation change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
trabecular separation, baseline PTH, baseline 25(OH)D and baseline BMI.161 
Table 4.11: Trabecular thickness change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
trabecular thickness, baseline PTH, baseline 25(OH) D and baseline BMI. 162 
Table 4.12: Cortical thickness change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
cortical thickness, baseline PTH, baseline 25(OH)D and baseline BMI. .... 163 
Table 4.13: Cortical tissue mineral density change from baseline: regression 
analysis by randomization group. Means and their differences adjusted by 
baseline cortical tissue mineral density, baseline PTH, baseline 25(OH)D and 
baseline BMI. ............................................................................................... 164 
17 
 
Table 4.14: Cortical porosity (%) change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
cortical porosity (%) baseline PTH, baseline 25(OH)D and baseline BMI. 165 
Table 4.15: Stiffness change from baseline: regression analysis by randomization 
group. Means and their differences adjusted by baseline stiffness, baseline 
PTH, baseline 25(OH)D and baseline BMI. ................................................ 166 
Table 4.16: Estimate failure load change from 12 baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline 
estimated failure load, baseline PTH, baseline 25(OH)D and baseline BMI.
 ..................................................................................................................... 167 
Table 4.17: Total 25(OH)D change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline value 
25(OH) D, baseline PTH and baseline BMI. ............................................... 168 
Table 4.18: PTH change from baseline: regression analysis by randomization 
group. Means and their differences adjusted by baseline PTH plus baseline 
25(OH)D and baseline BMI. ........................................................................ 169 
Table 4.19: Estimates of effect size from linear regression. ............................... 170 






















25 (OH) D 25-hydroxyvitamin D 
A Amplitude 
aBMD Areal bone mineral density  
ACO  Dr Amaka C Offiah  
apeak peak acceleration 
BA bone area 
BHI Bone health index 
BMC Bone mineral content 
BMD Bone mineral density 
BMI Body mass index 
CI Confidence interval 
Conn.D.  Connectivity density  
CONSORT Consolidated Standards of Reporting Trials 
CRF                  Clinical research facility 
Ct.Ar Cortical area 
Ct.Pm Cortical perimeter  
Ct.Po Cortical porosity 
Ct.Po.Dm  Cortical pore diameter 
Ct.Po.Dm.SD SD mean cortical pore diameter 
Ct.Th Cortical thickness  
Ct.TMD Cortical tissue mineral density  
Ct.vBMD  Cortical  density 
CV Coefficient of variation 
D Peak-to-peak acceleration 
Dinn Inner trabecular density 
Dmeta Meta trabecular density 
DXA Dual energy x-ray absorptiometry 
DXR Digital x- ray radiogrammetry 
ED Emergency Department  
EU European Union 
f Frequency 
F.ult Estimated ultimate failure load 
19 
 
FE/ FEA Finite element / finite element analysis 
G Gravity force 
GP General practitioner 
HA Hydroxyapatite 
HRA Health Research Authority 
HR-pQCT High resolution peripheral Quantitative Computed 
Tomography  
HU Hounsfield number 
Hz   Hertz  
ICH GCP International Conference for Harmonisation of Good 
Clinical Practice 
IGF-1 Insulin-like growth factor-1  
IMD Index of Multiple Deprivation  
IOF International Osteoporosis Foundation 
IOM Institute of Medicine 
IU International Units  
JoSLE Juvenile-onset Systemic Lupus Erythematosus 
LFFQ long food frequency questionnaire 
MAP Dr Margaret A Paggiosi 
MENA Middle East and North Africa 
MET Metabolic equivalent of task 
NGH                Northern General Hospital 
NHS National Health Service 
NJB  Professor Nick J Bishop 
OR Odds ratio 
OPG Osteoprotegerin 
PBM Peak bone mass  
PI Public Involvement   
pQCT peripheral Quantitative Computed Tomography 
PTH Parathyroid Hormone 
QC Quality Control 
QCT Quantitative Computed Tomography 
QMRI Quantitative Magnetic Resonance Imaging 
20 
 
QUS Quantitative Ultrasonography 
R&D Research and Development 
RANK Receptor activator of nuclear factor κβ 
RANKL Receptor activator of nuclear factor κβ ligand 
RCPCH Royal College of Paediatrics and Child Health 
RCT Randomised controlled trial 
REC Research Ethics Committee 
RMSCV Root mean square coefficient of variation 
RNI Reference nutrient intake 
SACN Scientific Advisory Committee on Nutrition 
SAE Serious adverse event 
SCH                 Sheffield Children’s Hospital 
SD Standard deviation 
SDS Standard deviation scores 
SFFQ Short Food Frequency Questionnaire 
SOP Standard operating procedure 
Tb.Ar  Trabecular area 
Tb.N  Trabecular number 
Tb.N.SD Trabecular inhomogeneity 
Tb.Sp Trabecular separation  





















List of appendices 
Appendix i 
 
VibeD study Information sheet  
Appendix ii 
 






Advertising email  
Appendix v 
 
Advertising  poster  
Appendix vi 
 
Procedures for identifying contraindications to vitamin D 
Appendix vii 
 
The procedure in case of undesirable effects and reporting via 





































1.1 Bone  
1.1.1 Bone structure, composition and physiology 
Bone is a dynamic and adaptive tissue that has structural and reservoir functions. 
More specifically, the bony skeleton provides the mechanical support for the body, 
protects internal organs, provides the muscles with sites of attachment and 
facilitates the movement of the body (Boskey and Robey, 2013). Bone also 
represents a reservoir for two main minerals; calcium and phosphate ions, both of 
which are essential minerals for all other organs in the body. The skeleton is one of 
the hardest materials in the body and is commonly classified into two types: the 
axial skeleton, which includes the skull, the whole spine and the ribs; and the 
appendicular skeleton, which includes the extremities and the pelvis (Grabowski, 
2015). Aside from its functions, bone has some outstanding features, such as the 
ability to adapt to mechanical loading and its excellent self-repairing ability.  
In terms of its composition, bone is comprised of minerals, water, lipids, collagen 
and collagenous proteins (Boskey and Robey, 2013). Collagen fibres (type 1 
collagen) are the basic and main components of the bone matrix, accounting for 85 
to 90% of the mass with the remainder comprising non-collagenous proteins. The 
collagen matrix itself contains minerals that are deposited on it. In the bone, 
minerals are transformed to hydroxyapatite [Ca10(PO4)6(OH)2], a naturally 
occurring mineral (Boskey and Robey, 2013) . In terms of structure, bone is mainly 
hollow with two compartments: cortical (also known as compact bone) and 
trabecular (also known as spongy or cancellous bone) (Figure 1.1, next page). 
Cortical bone is a thick and dense layer of the bone that surrounds the trabecular 
layer of the bone. This type of bone is found in abundance in the shaft of the long 
bones, provides strength and protection, and represents approximately 75% of the 
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total human bone mass. Trabecular bone is more porous and is found at the end of 
the long bones, in the vertebrae and in the pelvic bones. This porosity and trabecular 
bone’s microstructure impart excellent absorptive ability, which results in a natural 
tendency to distribute external force and to allow the bone to adapt to various 




Figure 1.1: Cortical and trabecular bone. From Geusens et al., (2014) with permission.   
 
Bone is one of the most metabolically-active systems in the body, with trabecular 
bone being considerably more active than cortical bone. According to Grabowski 
(2015), bone physiology in adulthood is related to maintaining the metabolic 
activities of the bone through the process of bone turnover in response to the body’s 
needs. During childhood, bone physiology is related to skeletal increase in size, 
mass and bone mineral density (BMD) until the skeleton reaches its final shape. 
Bone contains several different types of cells that regulate its physiological 
functions. These include osteocytes, osteoblasts, and osteoclasts. Osteocytes are the 
most abundant cell types in the adult skeleton by far, comprising approximately 90-
95 % of all bone cells. Osteoblasts represent 4-6 % and osteoclasts represent a mere 
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1-2% (Bonewald, 2011). These cells are connected to each other and to other cells 
on the surface of the bone via dendritic processes that travel through small canals 
known as canaliculi. The gap junction between them maintains their effective 
communication (Clarke, 2008). It has been reported that osteocytes play a 
significant role in bone resorption and formation as they respond to the mechanical 
loading. Bone turnover is an ongoing process that resorbs the old bone and forms 
new bones in a process known as remodelling.  
1.1.2 Bone modelling and remodelling  
Bone undergoes a continuous modelling and remodelling process at all times during 
a human life. This process is essential for maintaining the integrity of the skeleton 
and its proper metabolic functioning. Bone modelling is the process by which bone 
size and shape is changed as a result of the influence of physiological or mechanical 
stimulation (Clarke, 2008). In the bone remodelling process, bone is renewed at the 
same site in order to maintain skeletal integrity and strength as well as to 
maintaining calcium homeostasis.  
Bone remodelling is a complex and highly organised process involving four stages 
which are regulated by the interaction of two main bone cell types: osteoclasts and 
osteoblasts (Raisz, 1999). These stages follow in sequential order: the activation 
phase is followed by the resorption phase, which is followed by the inversion phase, 
which is followed by the final formation phase (Clarke, 2008). The specific 
processes each stage are as follows. In the activation phase, the osteoclast interacts 
with osteoblast precursor cells. The large osteoclasts are differentiated, migrated, 




Osteoblast-lineage cells produce receptor activator of nuclear factor kappa-Β ligand 
(RANKL), which bind to a recptor on the osreoclats precursors (RANK) and 
stimluaate their devoloment into diffrencteed osteclasts (Dempster et al., 2012). 
Oestoblast celles can also produce another protein called osteoprotegerin (OPG), 
which prevents the binding of RANK to RANKL, thus preventing the recruitment, 
proliferation, and activation of osteoclasts (Schoppet et al., 2002). The 
RANKL/RANK/OPG system plays a vital role in coordinating the bone 
remodelling process, which maintains the balance btween the bone resorption and 
bone formation process. 
During the resorption phase, hydrogen ions and lysosomal enzymes are secreted 
which initiate resorption. This process leads to the breakdown of the bone matrix 
leaving resorptive cavities known as Howship’s lacunae on the trabecular bone and 
Haversian canals in the cortical bone (Clarke, 2008, Raisz, 1999). The inversion or 
reversal phase of the remodelling process represents a transition phase from bone 
resorption to bone formation. During this phase, different cell types such as 
monocytes and osteocytes are seen in the resorption cavities (Clarke, 2008). In 
addition, the rough surfaces of the resorption cavity are made smooth. According 
to Clarke (2008), the exact mechanism of coupling the resorption phase to the 
formation phase is not fully understood. In the final phase, osteoblasts fill the 
cavities created in the resorption phase and begin producing and mineralising 
newly-formed bone matrix. Figure 1.2 in the next page illustrates the bone 
remodelling cycle.  
Bone remodelling occurs in a small units or packets, with each packet usually at a 
different stage of the remodelling process in order that the whole bone is not in the 
resorption phase (Clarke, 2008). Bone remodelling can occur randomly (non-
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targeted) but can also be targeted. Targeted remodelling occurs as a response to 
microdamage of bone while the non-targeted remodelling can occur at any site of 




Figure 1.2: Diagram of the bone remodelling process which consists of 4 stages in a 
complete cycle: 1- Activation phase; 2-Resorption phase; 3- inversion phase; and 4- 
Formation phase. From Brandi, (2009) with permission.  
 
Bone resorption and formation cycle is a highly organised and balanced process 
which is regulated by many factors in response to skeletal needs. Any disassociation 
between the two processes can cause abnormalities such as in the case of 
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osteoporosis, where the ratio of bone loss is significantly higher than bone gain, or 
in osteopetrosis, where bone gain is significantly higher than bone loss (Shabestari 
and Eriksen, 2013).  
It should be noted that bone loss naturally occurs with aging due to a variety of 
factors. These include changes in hormone levels, especially in women; increased 
bone resorption due to suboptimal calcium and vitamin D levels; and defective 
osteoblast functioning which occurs due to aging (Shabestari and Eriksen, 2013). 
Bone health is regulated by several hormones, the most important of which are 
parathyroid hormone (PTH), calcitriol, calcitonin, oestrogen and testosterone, 
human growth hormone, insulin-like growth factor-1 (IGF-1), thyroid hormone and 
cortisol  (U.S. Department of Health and Human Services, 2004). 
1.1.3 Peak bone mass 
The amount of bone tissue accrued once the skeleton becomes mature is known as 
the peak bone mass (PBM), where bones reach their maximum strength. There is 
no absolute age at which PBM is reached by humans (Heaney et al., 2000), but 
according to Welten et al. (1994) it is usually assumed that PBM is achieved 
towards the end of the twenties. This was confirmed in a longitudinal study, which 
showed that although the majority of lumber spine PBM was achieved by the age 
of 18, increases in lumber spine mass and size continue to occur until the third 
decade of life (Walsh et al., 2009). It has been suggested that achieving the 
maximum potential PBM is important as it can protect from fracture and 
osteoporosis later in life (Weaver et al., 2016, Rizzoli et al., 2010).  
Several factors have been noted as influencing the level of PBM including genetics, 
nutrition, lifestyle factors, hormones and exercise. Although some of these factors 
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cannot be modified, such as genetics, other factors such as nutrition and exercise 
can, which eventually can help to achieve maximum PBM (Schonau, 2004). 
Lifestyle factors are the most important modifiable factor for bone mass as it has 
been reported that such factors account for 20-40% of adult PBM (Weaver et al., 
2016). Suboptimal optimisation of lifestyle factors may lead to more fragile bone 
later in life (Figure 1.3, next page). In review of the lifestyle factors that influence 
achieving the full genetic PBM; calcium intake, physical activity and exercise, 
vitamin D and diary intake have all been strongly and positively associated with 
PBM (Weaver et al., 2016). 
PBM can also be influenced by ethnicity. Most studies in this regard have focused 
on the difference between Africans and Caucasians.  There is however a lack of 
studies on the comparison of other ethnic groups. It has been reported that African-
Americans have a greater bone mass compared with Caucasians. This has been 
linked to the lower fracture risk among African-Americans (Norris and Nelson, 
2013). Using peripheral quantitative computed tomography (pQCT), it has also 
been shown that volumetric density and bone geometry is greater in African-
American children than in white children (Wetzsteon et al., 2009, Micklesfield et 
al., 2011). The same conclusion was drawn by another study which demonstrated 
that young African-American adults have more favourable bone microarchitecture 
compared to young white adults. This was concluded using high-resolution 
peripheral quantitative computed tomography (HR-pQCT) to compare the two 








Figure 1.3: Bone mass throughout a human lifespan and the influence of suboptimal 
lifestyle factors. A substantial proportion of bone mass is built between the age of 10 and 
19 years. Bone mass continues to increase until the third decade of life.  Optimal choice of 
life style factors can help in achieving the maximum potential PBM and maintaining good 








1.2.1 What is osteoporosis?  
Osteoporosis is one of the most common diseases to affect the skeleton, especially 
in the elderly population. Osteoporosis causes a progressive decline in bone mass 
and microstructure which leaves the bone weak and increases its susceptibility to 
fracture (Kanis et al., 1994). The microstructure of a healthy trabecular bone 
consists of plates that are well-connected to each other, making a strong network of 
bone tissue which provides protection against fracture (U.S. Department of Health 
and Human Services, 2004). When the connections between these plates weaken 
and become disrupted due to the osteoporotic condition, bone frailty increases, 
reducing its resistance to fracture (Figure 1.4, next page).   
There are number of factors that can contribute to loss of bone mass, which in turn 
may eventually lead to osteoporosis. These are a reduced PBM, excessive 
resorption of bone mass due to genetic and environmental factors, and defective 
functioning of bone formation (Raisz, 1999). In the adult population, osteoporosis 
is diagnosed when the bone mineral density measured by dual energy x-ray 
absorptiometry (DXA) is 2.5 standard deviations below the average adult bone 





Figure 1.4: Visual comparisons of the trabecular microstructure of normal and 
osteoporotic bones showing healthy (left) and osteoporotic (right) bones. From Brandi, 
(2009) with permission.  
 
Osteoporosis is associated with adverse health and socio-economic consequences 
including mortality, morbidity and increases demand on the healthcare system, 
especially in economic terms. For instance, the European Union (EU) countries 
spent €37 billion on osteoporosis treatment in 2010, and in the UK alone around 
3.5% of its healthcare budget was allocated to treating osteoporosis and its 
complications (Hernlund et al., 2013). Of these complications, fragility fractures 
can have fatal consequences, especially when occurring in the hip and vertebrae. 
These types of fractures are associated with a 20% reduction in survival rates for 
sufferers (Harvey et al., 2010).  
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The osteoporosis treatment strategy aims to reduce bone resorption and/or boost 
bone formation. Pharmacological treatment using bisphosphonates is currently the 
main treatment for osteoporosis (Lippuner, 2012). However, bisphosphonates are 
like any other drugs; they are associated with some unwanted side effects such as 
osteonecrosis especially when used for prolonged periods of time (Rizzoli et al., 
2010). Preventative strategies should therefore be implemented, especially in terms 
of optimising lifestyle factors. As such, the overarching goal of this project was to 
investigate the effectiveness of physical stimulation and optimising vitamin D 
status as an alternative non-pharmacological intervention in optimising bone health.  
1.2.2 Prevalence of osteoporosis 
In western countries, osteoporosis prevalence ranges from 9% to 16% for females 
and from 1% to 8% for males (Wade et al., 2014). In terms of geographical variance 
in prevalence, the literature indicates that it is highest in the Middle East and North 
Africa (MENA) region. In Saudi Arabia for example, the prevalence of osteoporosis 
has been reported to be 34% for women (Sadat-Ali et al., 2012). In another example 
from the MENA region, the prevalence of osteoporosis in Jordan and Egypt was 
reported to be 29.6% among Jordanian women and 28.4 among Egyptian women 
(Shilbayeh, 2003, Taha, 2011). Shockingly, it has been claimed that the prevalence 
of osteoporosis is underestimated in males in the MENA region (Al-Saleh et al., 
2015). Several studies have showed significantly higher prevalence of both 
osteoporosis and osteopenia among Saudi males compared to males in 
industrialised nations, ranging from 21% to 38% and 34% to 54% for osteoporosis 
and osteopenia, respectively (Ardawi et al., 2005, Sadat-Ali and AlElq, 2006, El-
Desouki and Sulimani, 2007). The burden of the disease is only expected to rise in 
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the future in the MENA region due to the increase in the proportion of the aging 
population (Maalouf et al., 2007).  
Cultural factors may explain this phenomenon in the MENA region: the code of 
dress in these countries encourages the covering of most of the body. This restricts 
the amount of sun exposure that is necessary for producing vitamin D which can 
lead to poor musculoskeletal health (Edwards et al., 2013). Clearly then, 
intervention is required to optimise bone health and reduce the prevalence of 
osteoporosis and osteopenia in the MENA region. The Saudi Osteoporosis Society 
for instance emphasises the importance of focusing on the encouragement of factors 
that positively influence bone health such as vitamin D and physical activity 
regardless of age and gender (Al-Saleh et al., 2015). There is a lack of studies of 
the minor populations who emigrated from the MENA region to Europe. It is not 












1.3 Bone and physical activity   
1.3.1 Bone adaptation to loading   
Bone is attached to the muscle anatomically and physiologically, and therefore any 
improvement in muscle strength will be matched by an improvement in bone 
strength (Andreoli et al., 2001). Muscle strength plays a dominant role in bone 
mineral density, geometry and microarchitecture (MacDonald et al., 2006).  Muscle 
activities generate a load on bone, which creates adaptive response by bone cells. It 
has been reported that the changes in bone mass are preceded by changes in muscle 
strength (Robling et al., 2009). A suggested mechanism for muscle action on bone 
is that the bone mechanoreceptors in the bone periosteum is activated in response 
to muscle contraction (Cowin and Interactions, 2002). It has also been suggested 
that the Insulin-like growth factor 1 (IGF-1) and insulin receptors in muscle are 
activated in response to the loading placed on the muscle, which leads to the 
activation of the mechanoreceptors in the bone (Bolster et al., 2004).  
As has been stated earlier, bone has an excellent ability to adapt to a variety of 
loading conditions. Wolff’s law explains the relation between bone mass and 
loading in the expression “use it or lose it”. In more scientific terms, bone responds 
to loading by increasing bone formation while stimulating bone resorption in the 
absence of loading on bone (Frost, 1987). When the bone is exposed to external 
loading, the remodelling process adapts the bone’s properties so that it can resist 
the external loading and vice-versa. The Mechanostat Theory refinement of Wolff’s 
law explains that there is a load threshold that the strain has to exceed in order to 
induce bone adaption (Frost, 1997). A small strain below the threshold leads to bone 
loss (disuse mode) while a too high level of strain can cause fracture (Frost, 1997, 
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Frost, 2003). There is therefore a desirable range (2000-3000 μ-strains) between the 
disuse mode and fracture in which the strain should remain to induce bone 
formation (Frost, 1997, Frost, 2003). It has been reported that there are three rules 
for bone adaption to mechanical stimuli. According to Turner (1998), these three 
rules are: 1) dynamic loading drives bone adaption rather than static loading; 2) 
mechanical loading is only necessary for a short period to initiate an adaptive 
response and 3) bone cells accommodate to a customary mechanical loading 
environment, making them less responsive to routine loading signals (Turner, 
1998).  
Physical activity causes repeated strains, which in turn cause microdamage that 
needs to be repaired through bone remodelling. Over time, this leads to more bone 
formation. Mechanotransduction is the process by which the mechanical loading of 
physical activity is converted into metabolic signals (Kohrt et al., 2004). It has been 
suggested that the metabolic signals are transferred through fluid-flow movement 
within the canaliculae (Duncan and Turner, 1995, Turner et al., 1995, Han et al., 
2004). This fluid-flow movement is likely responded to by osteocytes, which (as 
previously noted) are the most abundant cell type in the bone (Huiskes et al., 2000, 
Xiong et al., 2011). Osteocytes are mechanosensory cells that have long processes 
that span in different directions and penetrate the matrix in what is known as 
canaliculi (Bonewald, 2011). It is widely believed that these cells play a major role 
in the process translating the mechanical signal into biological action due to their 
location in bone and their complex dendritic network (Huiskes et al., 2000, Xiong 
et al., 2011, Bonewald, 2011).  
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Mechanical loading has a direct effect on osteocyte secretion of sclerostin. 
Sclerostin decreases in response to mechanical loading and increases in response to 
unloading (Gaudio et al., 2010).  Sclerostin is an antagonist of the Wnt-signalling 
pathway and thus can prevent bone formation by inhibiting osteoblast 
differentiation (Robling et al., 2008). However, mechanical loading can down 
regulate sclerostin allowing for increased osteoblast activity through Wnt/ β-
Catenin signalling, which in turn can lead to increased bone formation  (Lin et al., 
2009).  However, the exact mechanisms of mechanical stimulation of osteocytes is 
not fully understood and there may be factors that influence this process which 
remain to be discovered (Kohrt et al., 2004, Klein-Nulend et al., 2013).  
Since there is a threshold that external loading has to exceed in order to induce bone 
formation, moderate to intensive exercise has been recommended to enhance 
muscle strength, cause a reduction in the risk of falls, and induce bone formation, 
although the resulting increase in bone mass might be modest and site specific 
(Forwood and Burr, 1993, Wallace and Cumming, 2000). However, because most 
people are not exposed to high magnitude loads during normal daily activity it 
possible that a small magnitude may have a role in bone adaption through muscle 
contractions (Fritton et al., 2000). The role of low magnitude at high frequency 
loading on bone adaption was demonstrated in several experimental studies (Rubin 
et al., 2001, Judex et al., 2003, Qin et al., 1998), and technological advances in 
recent decades have led to the utilisation of vibration platforms that can be used to 
provide mechanical loading in the clinical setting. This form of physical stimulation 
is known as whole body vibration (WBV). This type of physical stimulation forms 
the focus of Section 1.4. 
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1.3.2 Physical activity and bone density  
Physical activity and inactivity are well-known factors that influence bone health. 
For instance, observational studies indicate that professional tennis players have 
around 35% more bone mass in their dominant arms compared to their non- 
dominant arms (Jones et al., 1977). On the other end of the activity scale, long-term 
immobilisation has been found to induce bone loss (Uhthoff and Jaworski, 1978, 
Frost, 2003). In addition, astronauts lose bone during long airspace flights due to 
the absence of gravitational force (Lang et al., 2004).  
Several systematic reviews have demonstrated the positive impact of physical 
activity on bone density across all life stages (Hind and Burrows, 2007, MacKelvie 
et al., 2002, Macdonald et al., 2009, Nikander et al., 2010, Behringer et al., 2014, 
Tan et al., 2014, Wallace and Cumming, 2000, Bolam et al., 2013). Weight bearing 
activities in particular, such as jogging and dancing, are the most effective at 
improving bone mass (Kohrt et al., 2004).  
Most of the literature that determines the relation between physical activities and 
bone mass relies on measurements of areal BMD as measured by DXA. The recent 
advance in high-resolution bone imaging allows for deeper evaluation of the effect 
of physical activity on bone structure and strength. In a review of the effect of 
exercise on peripheral quantitative computed tomography (pQCT) parameters in 
postmenopausal women, it has been concluded that bone loss might be preventable 
through exercise with its effects being more obvious in early menopause (Polidoulis 
et al., 2012). To assess the young adult population, two studies used pQCT to 
determine bone response to unaccustomed physical activity. These two studies 
showed a significant increase (from 0.8 to 1.3 mg/cm3) in volumetric trabecular 
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bone mineral density after 13 weeks of training (Evans et al., 2012, Lester et al., 
2009). However, in a recent study that used high-resolution peripheral quantitative 
computed tomography (HR-pQCT) to determine the tibial bone responses of female 
recruits to an army training regimen, volumetric trabecular bone mineral density 
significantly increased by 2% after only 8 weeks of training. It should be noted 
however, that the results of this study are limited in reliability due to the absence of 
a control group (Hughes et al., 2018). Nonetheless, the results of all these studies 
may indicate that anabolic changes in bone occur shortly after starting intensive 
physical activity. Future randomised control trials should consider the value of 
high-resolution imaging in determining the effect of physical activity on bone 
health.  
A few trials have investigated the effect of exercise on bone when combined with 
calcium and vitamin D supplementation and their findings are equivocal. For 
example, there was no advantage of calcium–vitamin-D3-fortified milk plus 
exercise over exercise alone to bone structure and strength at 12 months (Kukuljan 
et al., 2009) and at 18 months (Kukuljan et al., 2011) in a study of older men’s (50 
-79 years) response to exercise and calcium-vitamin D fortified food. In contrast, 
calcium and vitamin D supplementations in addition to 9 weeks of exercise were 
found to significantly improve volumetric bone mineral density at the tibia 
compared to exercise alone in a subset of 46 military recruits who underwent pQCT 
scan among 247 participants (Gaffney-Stomberg et al., 2014). These differences 
between the trials’ results could have arisen from the differences in the age and sex 




Although physical activity has been shown to have beneficial effects on bone, many 
potential confounding factors have to be borne in mind. These factors include the 
intensity and the duration of the training, the hormonal status, the skeletal site where 
the effect of the physical activity is being measured, the exercise history, the initial 
bone mass, and the sex and age of the person undertaking the physical activity 
(Forwood and Burr, 1993, Hind and Burrows, 2007, Boreham and McKay, 2011). 
Given the seeming importance of diet, especially in terms of vitamin D and calcium 
intake, on the effects of physical exercise on bone, Bolam et al. (2013) indicted that 
such data should be included in any future trials on the effects of exercise on bone.  
Another advantage of weight-bearing exercise, especially over pharmacological 
intervention which can only address bone mass, is that fall risk decreases. However, 
there are issues associated with conventional methods of exercising. These issues 
include low compliance, and the risk of stress fracture and tissue injuries which are 
commonly seen in military recruits and marathon runners (Rittweger, 2010). It has 
been shown that low magnitude mechanical stimulus has an anabolic effect on bone 
(Rubin et al., 2001) which might be an alternative and safer approach to 







1.4 Whole Body Vibration (WBV) 
WBV is a relatively new training approach that has garnered interest from the 
fitness industry and the medical community in recent years. The research on WBV 
includes its application to a range of clinical conditions in terms of its efficacy as a 
potential alternative to conventional exercises to stimulate the growth and 
development of muscle and bone (Prisby et al., 2008, Fratini et al., 2016). This form 
of training has been found to be able to overcome some of the issues which are 
associated with conventional methods of exercising such as falls, small injuries and 
stress fractures, especially in elderly and obese populations (Rittweger, 2010). The 
first application of WBV as a scientifically-studied training method was conducted 
in the mid-nineteen eighties by Nazarov and Spivak (1985). However, WBV as a 
training modality only gained the interest of the scientific community more than a 
decade after Nazarov and Spivak’s intial paper, with several publications and 
commercial devices emerging in the 1990s and early 2000s (Dakota, 1998, Issurin 
and Tenenbaum, 1999, Rittweger et al., 2000, Kerschan‐Schindl et al., 2001).  
Since then, the literature on WBV has been diverse in terms of its specific focus, 
with different studies reporting various outcomes of WBV, such as neuromuscular 
performance (Von Stengel et al., 2012), hormonal response (Bosco et al., 2000), 
cardiovascular response (Hazell et al., 2008), body composition (Marín-Cascales et 
al., 2017), balance and mobility (Bautmans et al., 2005), and bone density 
(Verschueren et al., 2004).  The focus of the current thesis is to contribute to this 
field by studying the effect of WBV on bone density, microarchitecture and 
estimated bone strength.  
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1.4.1 Parameters of WBV 
In WBV, a vibration platform is used to generate mechanical stimuli which are 
transmitted through the skeleton and apply mechanical loading to the muscle and 
bone (Verschueren et al., 2004). The parameters associated with WBV are 
summarised in Table 1.1 (next page). In short, the intensity of WBV is controlled 
by its frequency and peak-to-peak displacement (Slatkovska et al., 2011). The 
frequency of the vibration as well as the peak-to-peak acceleration is used to 
determine the peak acceleration of the WBV, which is commonly used to describe 
the intensity of the WBV (Rauch et al., 2010).  Peak acceleration is preferably 
expressed as a g force, which can be calculated by dividing the peak acceleration 
by Earth’s gravity (apeak/9.81g) (Beck, 2015). The following formula can be used to 
calculate the peak acceleration of the WBV (Rauch et al., 2010): 
aPeak = 2 x π
2 x f2 x D 
aPeak ≈ 20 x f
2 x D  
aPeak: peak acceleration 
f: frequency 
D: peak-to-peak acceleration 
 
It is not certain what is the strain induced by WBV.  It has been reported that strain 
depends on other factors such as the type of the vibration (horsetail or vertical), the 
anatomical site where the strain is being measured and the positioning/posture of 
the body on the platform and musculoskeletal stiffness (De Zepetnek et al., 2009). 
However, some instruments can be used to determine the strain that is induced by 
WBV such as the strain gauge.  Nonetheless, this is outside the scope of this project 
due to the limited timescale and the financial resources available for the project.  
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The WBV training protocols vary widely among studies. In addition, WBV has 
been applied to different age groups including children, adults and elderly and to 
samples that comprise apparently healthy people and people with different bone 
diseases such as osteopenia, osteoporosis and osteogenesis imperfecta. However, 
despite using various WBV training protocols and targeting various populations, no 
ideal WBV training protocol has been identified nor any specific population which 
benefits most greatly from WBV (Wysocki et al., 2011). Thus, research is ongoing 
to find an ideal training protocol and determine a target group that can benefit most 
significantly from such intervention.  
 
Table 1.1: WBV parameters 
Parameter Definition Unit Symbol 
Frequency The number of oscillations 
per second   
Hertz (H)    f 
Peak to peak 
displacement  
Distance between the bottom 
and the peak points in 
vibration excursion 
Millimeter (mm) D 
Amplitude  The range of perpendicular 
displacement from the 
equilibrium condition 
Millimeter (mm) A 
The peak 
acceleration 







1.4.2 Types of WBV 
WBV platforms can be broadly classified either based on their vibrating technique 
or on their intensities. When based on the former, WBV platforms can be divided 
into two categories (Figure 1.5, next page). The first category includes platforms 
that produce sinusoidal vibration (side-alternating) which have a greater effect on 
the lateral axis, and platforms that produce vertical vibration (synchronous) and 
have greater effect on the vertical axis (Beck, 2015). In the side-alternating 
platforms, the vibrating plate oscillates around the central axis, and therefore, peak 
acceleration depends on the peak-to-peak displacement and differs according to the 
distance of the feet from the centre of the platforms (Rauch et al., 2010). In contrast, 
the peak acceleration and peak-to-peak displacement in synchronous platforms are 
the same and therefore the intensity of WBV is not affected by the position of the 
feet on the platforms (Rauch et al., 2010). There have been some attempts to 
introduce a third type which involves random movement, but this type is not yet 
been fully commercialised (Rittweger, 2010). In a recent systemic review of the 
effect of WBV on bone density in postmenopausal women, side-alternating 
platforms were associated with heterogonous outcomes, specifically at lumber 
spine and trochanter, while the results of synchronous platforms were more 
homogenous (Oliveira et al., 2016). Despite this heterogonous outcome of side 
alternating platforms, a recent meta-analysis found side-alternating platforms to be 
more effective in enhancing bone density (Fratini et al., 2016)  
The alternative classification system of WBV platforms is based on the magnitude 
of the WBV. Depending on the magnitudes of WBV protocol, it can be grouped 
into two categories: low intensity (g force < 1 g) and high intensity platforms (g 
force >1g) (Beck, 2015). The intensity of WBV is determined by the peak 
45 
 
acceleration (g) regardless of its frequency (Wysocki et al., 2011). The “Galileo” is 
an example of the high intensity platform while “Juvent 1000” is an example of a 
low intensity platform (Elmantaser et al., 2012). It has been reported that the high 
magnitude platforms are associated with greater effects of the WBV on bone and 
this effect is more pronounced when the intensity of the WBV was more than 3 g 
(Fratini et al., 2016). A possible explanation for this could be that the high intensity 
WBV protocol generates more intense signals which have more of an ability to 




Figure 1.5: Two main types of vibration platform according to their movement 





1.4.3 Transmission of WBV 
In spite of the numerous publications that have studied WBV in the past decade, the 
mode of action of WBV is not clearly understood. However, it has been suggested 
that WBV stimulates the bone directly by transmitting the mechanical signals into 
bone cells, which in turn change the flow of the fluid in the bone and produce an 
osteogenic effect (Lam et al., 2013). This osteogenic effect may occur through 
osteocytes or by activation of skeletal muscles, perhaps due to the stretch reflex 
(Ozcivici et al., 2010). It has been also hypothesised that the low intensity vibration 
signals are amplified inside bone tissue and act as mechanosensors for bone cells 
(Rubin et al., 2006). It has been also suggested that WBV may indirectly alter bone 
remodelling by affecting the hormones that can influence bone mass such as 
testosterone and growth hormone (De Zepetnek et al., 2009). Regardless of the 
specific mechanisms, it has been convincingly argued that the general mode of 
action of WBV is driven through a series of pathways and involves a complex set 
of several parallel mechanisms, as is the case with other biological systems (Beck, 
2015).  
It should be noted that there are also many factors that can affect the transmission 
of WBV signals from the vibration platform to the body. These factors include the 
vibration intensity and frequency, the subject’s posture on the platform, and the 
tissues’ attenuation to the vibration signals. For instance, Rubin et al. (2003) 
investigated the transmission of the vibration signals at certain frequencies (15 to 
35 Hz) to the hip and lumbar spine. The authors reported that at frequencies of 15 
Hz and 35 Hz when the subject was standing in a relaxed stance, the transmission 
was 130% and 60%, respectively to the hip and was 80% and 60% at 15 Hz and 25 
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Hz to lumbar spine, respectively (Rubin et al., 2003). However, when the position 
of the subject was changed to a bent knee posture, the transmission to the hip 
decreased to below 50% at 15 Hz and below 30% at 35 Hz (Rubin et al., 2003). 
Kiiski et al. (2008) further expanded these findings by investigating a wider range 
of frequencies (10 to 90 Hz) at multiple anatomical sites (ankle, knee, hip, and 
lumbar spine). The authors found that peak acceleration is site-specific and it is 
greatest at the feet at frequencies between 10 and 40 Hz. However, at higher 
frequencies (> 40 Hz), the transmission declines with the greatest decline observed 
in the lumbar spine, suggesting that high frequency vibration signals are attenuated 
by soft tissue during the journey inside the body. 
1.4.4 Experimental studies of WBV  
The first studies of the effect of WBV on bone density were carried out on animal 
models. For instance, Flieger et al. (1998) vibrated ovariectomised rats for five 
weeks and reported a significant increase in bone density in rats that underwent 
vibration compared to the control group. The strongest evidence regarding the 
anabolic effect of WBV on bone density has been provided by two studies that were 
carried out on sheep for 12 months (Rubin et al., 2001, Rubin et al., 2002). The 
vibration protocol consisted of low-magnitude high frequency WBV for 20 minutes 
daily for 12 months. The two studies reported significant increases in BMD in the 
tibia of sheep that underwent vibration compared to the sheep in the control group. 
In addition, a 34.2 % increase in tibial volumetric BMD was found in the active 
group compared to the control group (Rubin et al., 2001). However, these 
improvements were observed in the hind limbs, not in the front limbs, which may 
suggest that the osteogenic effects of WBV are more pronounced at weight-bearing 
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sites when translating this into the clinical context (Rubin et al., 2002). Since then, 
several animal studies have reported anabolic effects of WBV on bone in rats and 
mice (Xie et al., 2006, Garman et al., 2007, Oxlund et al., 2003).  
Various additional bone outcomes have been reported in animal studies that focus 
on the anabolic effect of WBV on bone. For instance, a significant increase in the 
trabecular bone volume of the proximal tibia in mice that were vibrated for five 
weeks was observed. No other significant changes were detected at distal sites away 
from the vibration surface (Christiansen and Silva, 2006). In another study, Judex 
et al. (2007) reported a significant increase in the trabecular bone volume (22% to 
25% and trabecular thickness (11% to 12%) in rats that were subjected to high 
frequency (95 Hz) WBV for 28 days. Several studies have also reported 
improvement in bone formation rates (Oxlund et al., 2003, Garman et al., 2007, 
Judex et al., 2007).  
It should be noted that most recent animal studies have used a low intensity, high 
frequency WBV protocol due to two studies which compared different magnitude 
and frequencies on bone indicating that the low magnitude high frequency WBV 
protocols were more effective in enhancing trabecular bone (Judex et al., 2007, 
Garman et al., 2007). This finding suggests that the frequency of WBV plays a more 
important role than WBV magnitude in animal studies.  
Furthermore, factors such as vitamin D status may also alter the bone’s response to 
mechanical loading. In a recent study, vitamin D deficient or replete pregnant mice 
were used to determine the effect of early vitamin D status on skeletal health later 
in life (Borg et al., 2018). The offspring of the mice in the two groups received a 
vitamin D-sufficient diet at weaning and were loaded at 10 weeks and 18 weeks of 
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age. The offspring of the replete mice showed an increase in both trabecular and 
cortical bone mass in the younger animals, but only in the cortical bone of the older 
animals suggesting a positive role of early vitamin D on the response to loading 
(Borg et al., 2018).  
1.4.5 Clinical studies of the effect of WBV on bone  
Due to the promising results of the effect of WBV on bone in animal studies, a 
significant number of clinical studies have been conducted in the past 15 years. 
However, the results of the clinical studies have not matched the encouraging 
results of experimental models, and so the role of WBV in enhancing bone health 
in humans is currently debated in the literature. It is not surprising that most of the 
clinical trials that investigated the effect of WBV on bone density were conducted 
on postmenopausal women (Russo et al., 2003, Rubin et al., 2004, Verschueren et 
al., 2004, Iwamoto et al., 2005, Gusi et al., 2006, Ruan et al., 2008, Beck and 
Norling, 2010, Bemben et al., 2010, Von Stengel et al., 2011, Verschueren et al., 
2011, Slatkovska et al., 2011, Karakiriou et al., 2012, Lai et al., 2013, Slatkovska 
et al., 2014, Leung et al., 2014, Kiel et al., 2015, Liphardt et al., 2015, Marín-
Cascales et al., 2017, Zha et al., 2012b). This is because postmenopausal women 
have a greater risk of developing osteoporosis and thus WBV might be a non-
pharmacological strategy to preserve their bone mass and reduce their risk of 
osteoporosis. Nevertheless, WBV trials have also included different populations 
such as men (Elmantaser et al., 2012), children with osteogenesis imperfecta (Ward 
et al., 2004, Högler et al., 2017), children with cerebral palsy (Wren et al., 2010, 
Ruck et al., 2010, El-Shamy, 2017), young women with low bone mass (Gilsanz et 
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al., 2006, Lam et al., 2013) and apparently healthy populations (Torvinen et al., 
2003, Ligouri et al., 2012, Elmantaser et al., 2012, Gómez-Bruton et al., 2017).  
The results of these studies are inconsistent. For instance, two trials involving 
postmenopausal women obtained differing results. In one, a high frequency (30 
Hz), high magnitude (3.2 g) WBV protocol significantly improved lumbar spine 
BMD in postmenopausal women after 6 months of training (Lai et al., 2013). In the 
other, 18 months of high frequency (35 Hz), low magnitude (0.3 g) WBV did not 
lead to any significant change in BMD at lumbar spine or hip (Leung et al., 2014). 
Nevertheless, Zha et al. (2012a) used a higher frequency (45 – 55 Hz) and low 
magnitude (0.5 – 0.8 g) and found a significant increase in BMD at lumber spine 
and femoral neck after 6 months of WBV training. However, this study was limited 
due to its heterogeneous population (n= 68) of males and females across a wide age 
range (from 51 to 93 years) with and without osteoporosis. Due to this, the numbers 
within each subgroup were extremely limited. The apparently contradictory results 
observed thus far in studies may have been caused by several factors. These include 
the different populations under investigation, different durations of the intervention, 
the imaging technique that was used to determine the effect of intervention, the 
anatomical site where the effect was reported, the duration of the WBV, and the 
wide variation of the WBV protocols used. 
While most studies in the literature have focused on the effect of WBV on areal 
BMD, it is clear that the full extent of such an effect has not yet been investigated. 
This is because BMD measured by DXA is only a surrogate measure of the amount 
of minerals in the bone and does not reflect the true BMD or the bone 
microstructure, which is overlooked when using only DXA to determine the effect 
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of WBV. Very few studies have used high-resolution peripheral quantitative 
computed tomography (HR-pQCT) to determine the full extent of the effect of 
WBV on bone quality. Slatkovska et al. (2011) published one of the earliest studies 
to use both DXA and HR-pQCT to determine the effect of WBV on bone but no 
significant changes were detected after 12 months of high frequency (30 to 90 Hz) 
and low magnitude (0.3 g) WBV on bone parameters at the distal tibia and the distal 
radius. In another trial that used this combination of measurement techniques, Lam 
et al. (2013) investigated the effect of low magnitude (0.3 g), high frequency (32– 
37 Hz) WBV on bone quality in osteopenic girls. Although there was a significant 
improvement in areal BMD, there was no significant improvement in HR-pQCT 
parameters after 12 months of WBV. In a recent study that used HR-pQCT, no 
significant changes in bone outcome in postmenopausal women with osteopenia 
was found after 12 months of WBV even when using higher magnitudes (2.4 –3.2 
g) (Liphardt et al., 2015). However, Verschueren et al. (2011) found a significant 
improvement in volumetric hip BMD after 6 months of high magnitude (2.2 g) 
WBV in institutionalised elderly females without osteoporosis or osteopenia. 
Clearly, the results of these studies point to the fact that it is hard to define an 
effective WBV protocol or specify a target population despite the significant 
number of studies that have investigated the effects of WBV on the human skeleton.  
Due to the great interest in WBV as evidenced by the number of studies on its 
effects on the skeleton, there have been several systematic reviews published of the 
effects of WBV on bone density as primary or secondary outcome (Merriman and 
Jackson, 2009, Slatkovska et al., 2010, Mikhael et al., 2010, Lau et al., 2011, Ma et 
al., 2016, Oliveira et al., 2016, Fratini et al., 2016, Marín-Cascales et al., 2018, 
Jepsen et al., 2017, Luo et al., 2017). The results of the systematic reviews are 
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inconclusive. Some reviewers have reported improvement at one or more 
anatomical sites where other reviews have reported no overall effect. Significant 
improvements in hip BMD were reported in three reviews (Merriman and Jackson, 
2009, Slatkovska et al., 2010, Fratini et al., 2016) and significant improvements in 
lumber spine BMD were reported in four reviews (Fratini et al., 2016, Ma et al., 
2016, Oliveira et al., 2016, Marín-Cascales et al., 2018). Additionally, (Slatkovska 
et al., 2010)) reported significant improvements in spine and tibia of children and 
adolescents. However, no significant effect of WBV on bone density was found in 
four systematic reviews (Mikhael et al., 2010, Lau et al., 2011, Jepsen et al., 2017, 
Luo et al., 2017). This contradiction in the results of these systematic reviews could 
have resulted from the authors of the reviews using different inclusion/exclusion 
criteria. For instance, Oliveira et al. (2016) reviewed effects of WBV on BMD in 
postmenopausal women and included 15 studies in their analysis while a later 
review by Luo et al. (2017) was limited to women diagnosed with postmenopausal 
osteoporosis and included only 9 studies.   
Nonetheless, some patterns regarding the effect of WBV have started to emerge 
which may aid in designing more robust future trials or help in identifying an 
effective WBV training protocol. The lumbar spine for instance has been found to 
be more sensitive to WBV as significant improvement in the lumbar spine was 
found when analysing BMD for all WBV magnitudes (Ma et al., 2016, Marín-
Cascales et al., 2018) and when analysis was repeated after excluding the low 
quality studies (Oliveira et al., 2016). Furthermore, side-alternating platforms seem 
to have had a greater impact in bone density, especially when knees were slightly 
bent during the vibration sessions (Oliveira et al., 2016, Fratini et al., 2016). This 
could be due to the side-alternating movement resembling normal gait which would 
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then lead to greater muscle contractions (De Zepetnek et al., 2009, Fratini et al., 
2016).  
Nutritional status, especially in respect of vitamin D, may alter the response to 
physical activity. In studying the benefits of supplementing personnel undergoing 
military training with calcium (2000 mg) and vitamin D (1000 IU) delivered as 2 
snack bars per day, it was found that significant improvement in volumetric BMD 
at tibia was observed in the group who received vitamin D and calcium snack bars 
(Gaffney-Stomberg et al., 2014). In addition, the early animal model revealed a 
positive role for vitamin D status in early life in bone’s response to mechanical 
loading (Borg et al., 2018). However, very few WBV studies had supplemented 
their participants with vitamin D (Slatkovska et al., 2011, Verschueren et al., 2011, 
Kiel et al., 2015).  
These three studies are summarised in Table 1.2 (next page). There were no 
significant advantages for adding vitamin D to WBV in terms of improving bone 
density in three studies. However, there were limitations for these trials. These 
limitations include the absence of the baseline serum vitamin D outcomes in two 
trials, the absence of control groups for vitamin D in all three trials and self-reported 
adherence to vitamin D supplements in all three trials. Furthermore, the fact that the 
majority of participants were postmenopausal women with osteopenia and thus 
could be less responsive to mechanical stimulation because this population typically 
loses bone density over time (Slatkovska et al., 2010). Therefore, it is not currently 
clear if the positive effect of physical activity and vitamin D on bone, which was 
reported by (Gaffney-Stomberg et al., 2014) will be observed with regard to WBV 
and vitamin D.  
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Table 1.2: Summary of studies investigating the effect of both WBV and vitamin 
D on bone 
 
 
1. HR-pQCT = high resolution peripheral quantitative computed tomography  
2. DXA = dual energy x-ray absorptiometry  
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1.5 Vitamin D  
1.5.1 The role, forms and sources of vitamin D  
Vitamin D is one of the most important dietary components for bone health and is 
a fat-soluble vitamin, vital for many metabolic processes in the body such as 
effective absorption of calcium, calcium and phosphate homeostasis and bone 
mineralisation (DeLuca, 2004, Tsiaras and Weinstock, 2011). Vitamin D deficiency 
has been linked to several musculoskeletal and non-musculoskeletal diseases such 
as osteoporosis cardiovascular disease, diabetes and cancer (Holick, 2004, Holick, 
2007).  
There are two forms of vitamin D: vitamin D3 (cholecalciferol) and vitamin D2 
(ergocalciferol). These two forms have the same biological function but slightly 
different structures relating to their side chains. Vitamin D3 is transformed into 25 
(OH) D3 and then into 1, 25 (OH)2D3, and vitamin D2 is transformed into 25 (OH) 
D2 and then 1,25(OH)2D2. Vitamin D3 is synthesised in the skin by exposure to 
ultraviolet B (UV-B) and found in some oily fish, such as salmon, while vitamin 
D2 is naturally found in some plants (Holick et al., 2011). Although the two forms 
have the same biological effects, it has been reported that vitamin D3 is more 
effective than vitamin D2 in increasing serum 25 (OH) D, and vitamin D2 may be 
better for reducing fracture risk (Kearns et al., 2013). 
Exposure to UV-B at a wavelength of 280-320 nm is the primary source of vitamin 
D due to the cutaneous synthesis of vitamin D3 (Holick, 2007, Cranney et al., 2007, 
Lehmann and Meurer, 2010, (SACN), 2016). It has been reported that vitamin D 
production is more effective in a narrower wavelength band of 295- 300nm with 
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peak production at wavelength of 297 nm (MacLaughlin et al., 1982). However, in 
high latitude countries, such as in the UK, dietary products become the main source 
of vitamin D during the winter period due to the limited sunlight (Cranney et al., 
2007, (SACN), 2016). Additionally, there are limited natural dietary sources for 
vitamin D (Spiro and Buttriss, 2014). Oily fish such as salmon, egg yolk and sun-
exposed mushrooms are among these dietary sources (Holick, 2007, Holick et al., 
2011).  
In spite of the fact that sources of vitamin D have been known for several decades, 
there are several factors that might have been overlooked in terms of the amount of 
vitamin D obtained from these sources. For instance, the amount of vitamin D 
produced from sun exposure depends on several factors such as time of day, season, 
pollution level, skin pigmentation (melanin), use of sunscreen and obesity status 
(Cranney et al., 2007, Tsiaras and Weinstock, 2011). Moreover, it has been reported 
that the amount of vitamin D in some naturally rich dietary sources of vitamin D is 
significantly affected by the origin of these foods, as well as the way they are 
prepared for intake. For example, a comparison between the same amount of farmed 
salmon and wild caught salmon revealed that farmed salmon contains only 25% of 
the vitamin D that is present in wild caught salmon (Lu et al., 2007). Furthermore, 
the amount of vitamin D in the farmed salmon is affected by the cooking method. 
When the farmed salmon was baked, approximately 98% of the original vitamin D 
concentration was recovered compared to approximately 50% when the salmon was 
fried (Lu et al., 2007).  
The Scientific Advisory Committee on Nutrition (SACN) recommends a 10 µg/day 
(400 IU) of vitamin D as a Reference Nutrient Intake (RNI) for the UK general 
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population during the winter months. However, some groups with limited sun 
exposure during the summer months should aim to achieve this RNI level year-
round. Due to the limited resources of food rich with vitamin D, food fortified with 
vitamin D or vitamin D supplements may be the only alternatives to achieve this 
RNI. However, although vitamin D supplementation can be a good strategy to 
maintain an adequate level of vitamin D, adherence to daily supplements may not 
be maintained over a long period. Therefore, large doses given at regular intervals 
might be an alternative option to daily doses. More research regarding the effect of 
large doses of vitamin D is needed in order to accumulate robust evidence that can 
be used as a basis for future recommendations and practical advice.  
1.5.2 The metabolism of vitamin D   
Vitamin D - either from sun exposure or from diet - has to undergo several 
metabolic processes in order to be converted to its active biological form. When the 
UV-B penetrates the skin between wavelengths 280-320, it is absorbed by 7-
dehydrocholesterol which leads to the production of previtamin D3 due to breaks 
in the chemical bonds of the 7-dehydrocholesterol molecule which are caused by 
the absorbed energy (Tsiaras and Weinstock, 2011). The resulting previtamin D3 is 
not thermodynamically stable and at body temperature it is converted to vitamin 
D3, enters the circulation and is transported to the liver where it is hydroxylased to 
25-hydroxyvitamin D (25(OH)D), a major circulating form of vitamin D (Holick, 
2007, Lehmann and Meurer, 2010). The resulting 25-hydroxyvitamin D is bound to 
vitamin D binding protein and transported to the kidneys where it is further 
metabolised by 25-hydroxyvitamin D-1α- hydroxylase and is then finally converted 
into its biologically active form, 1,25-dihydroxyvitamin D (Lehmann and Meurer, 
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2010). The production of 1,25-dihydroxyvitamin D is tightly regulated by several 
factors: most importantly the presence of parathyroid hormone, calcium, phosphate, 
calcitonin, and fibroblast growth factor 23 (Lehmann and Meurer, 2010, Allgrove 
and Shaw, 2015). Figure 1.6 (below) summarises the pathway for vitamin D 
metabolism.  
 
Figure 1.6: Simplified diagram of vitamin D metabolism. Adapted from (Nair and Maseeh, 
2012). 
 
1.5.3 The measurement and concentration of vitamin D  
Sufficient concentration of vitamin D is important to optimise bone health over a 
lifespan with vitamin D deficiency being associated with a number of skeletal 
fragilities including rickets, osteomalacia and osteoporosis. It is highly 
recommended that vitamin D status is assessed by measuring the total serum 25- 
hydroxyvitamin D ((25(OH) D)), which is the most useful indictor for vitamin D 
and represents vitamin D from both diet and sun exposure (DeLuca, 2004, Calvo et 
al., 2005, Holick et al., 2011). Testing for 1,25-dihydroxyvitamin D, the active form 
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of vitamin D, can be challenging due to its relatively short half-life of around 4 
hours (Holick et al., 2011) compared to the 2-3-week half-life of 25 (OH) D 
(Holick, 2009). In addition, 1,25-dihydroxyvitamin D circulates at an extremely 
low level in the blood and does not reflect the true reserve of vitamin D in the body 
(Holick et al., 2011). Approximately 85% of total 25(OH) D is bound to vitamin D 
binding protein and 10 to 15% is bound to albumin. Only a very small amount of 
total 25(OH)D is unbound (free 25-OH-D). The clinical importance of free 25-OH-
D is yet to be established and future research should focus on determining such 
importance according to a recent study by (Schwartz et al., 2018). 
Significant debate is evident in the literature regarding the optimal level of vitamin 
D, and indeed regarding the level at which vitamin D deficiency occurs. For 
instance, vitamin D deficiency has been defined as levels of serum 25(OH) D below 
50 nmol/L and the optimal level as serum 25(OH) D above 75 nmol/L by the Task 
Force of the Endocrine Society in the United State (US) and Canada (Holick et al., 
2011). This high level of optimal vitamin D concentration was reinforced in a 
review of vitamin D and bone in the following year (Bikle, 2012). Recently, a group 
of experts in Saudi Arabia similarly defined vitamin D deficiency as a level of 
serum 25 (OH)D below 50 nmol/L in an attempt to establish local guidelines (Al-
Daghri et al., 2017). However, the Institute of Medicine (IOM) in the US opposes 
this interpretation of serum 25(OH) D levels (Rosen et al., 2012). The IOM report 
(based on bone health outcomes) defines vitamin D deficiency as serum 25(OH) D 
< 30 nmol/L, vitamin D inadequacy as serum 25(OH) D in the range of 30 to 50 
nmol/L, and vitamin D sufficiency as serum 25(OH) D > 50 nmol/L (Del Valle et 
al., 2011, Ross et al., 2011). The UK National Osteoporosis Society supports the 
use of the IOM classification system for vitamin D levels and suggests that these 
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levels should be adopted for UK clinical purposes (Francis et al., 2013). Recently, 
the global consensus recommendations on prevention and management of 
nutritional rickets used the same levels that were used by the IOM in order to define 
vitamin D sufficiency, insufficiency and deficiency in their report (Munns et al., 
2016).  
However, the British Paediatric and Adolescent Bone Group’s position statement 
on vitamin D deficiency defined vitamin D deficiency as levels of serum 25(OH) D 
below 25 nmol/, vitamin D insufficiency as levels between 25-50 nmol/L and a 
sufficiency level of above 50 nmol/L (Arundel et al., 2012). The latest report of The 
Scientific Advisory Committee on Nutrition (SACN) in the UK agrees with the 
British Paediatric and Adolescent Bone Group’s conclusion regarding the plasma 
level at which vitamin D deficiency occurs. The SACN report states that vitamin D 
level should not fall below 25 nmol/L for the UK general population and below this 
level, there is an increased risk of poor musculoskeletal health ((SACN), 2016).  
These variations in finding an agreed definition and interpretation for vitamin D 
levels have arisen for several reasons. One reason being the health outcomes that 
were used for defining vitamin D deficiency (i.e. osteomalacia prevention, fall 
prevention, fracture risk, PTH suppression or non-musculoskeletal health). It has 
been reported that defining vitamin D deficiency should be based on skeletal 
outcomes due to the limited number of studies regarding vitamin D and non- 
skeletal health (Arundel et al., 2012, Ross et al., 2011). Another possible reason is 
the absence of standardised methods for measuring serum 25 (OH) D due to the 
variations in the assays used by different labs. A further possible reason is the 
differing opinions held by experts in interpreting the data in their clinical contexts.  
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For instance, wide variations (up to 30 nmol/L) were reported between six experts 
regarding the minimum level of serum 25 (OH) D based on fracture prevention 
(Dawson-Hughes et al., 2005). For the purpose of vitamin D level classification in 
this thesis, the IOM definition of vitamin D levels, as supported by the UK 
Osteoporosis Society, will be used.  
1.5.4 Prevalence of vitamin D deficiency  
Low vitamin D level is very common worldwide and regarded as a common public 
health concern (Calvo et al., 2005, Holick, 2007, Holick and Chen, 2008, Mithal et 
al., 2009). In the UK, the SACN report indicated that around one quarter of the UK 
population aged 19 – 64 years have a level of serum 25(OH) D below 25 nmol/L 
based on the data of the National Diet and Nutrition Survey ((SACN), 2016). There 
are however seasonal variations in the level of serum vitamin D. For instance, the 
prevalence of vitamin D at a level below 25 (OH) D in the UK population age 19 – 
64 years was 39% in the winter months compared to 8% in the summer months 
((SACN), 2016). Nonetheless, certain groups among the UK population have been 
found to be at a greater risk of vitamin D deficiency regardless of the season of the 
year. These groups include pregnant and breastfeeding women, elderly people, 
people with limited sun exposure, such as those who cover their skin for religious 
or cultural purposes, and those with indoor lifestyles (Hirani et al., 2005, Ford et 
al., 2006, Francis et al., 2013).  
Furthermore, some ethnic groups in the UK population have a greater risk of 
vitamin D deficiency. The UK population is a diverse population and there have 
been several waves of migration to the UK from South Asian, African, and Middle 
Eastern regions in past decades. It is well documented in the literature that South 
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Asians tend to have a lower concentration of vitamin D compared to Caucasians 
(Preece et al., 1973, Shaw and Pal, 2002, Ford et al., 2006, Farrar et al., 2011, 
Gopal‐Kothandapani et al., 2018). However, there is a general lack of data 
regarding the prevalence of vitamin D deficiency among the MENA ethnic groups 
in the UK. Nevertheless, the high prevalence of vitamin D deficiency in the MENA 
region is well documented in the literature over the past 30 years, despite there 
being an abundance of sunshine year-round (Sedrani et al., 1983, Fuleihan and 
Deeb, 1999, Ghazi et al., 2004, Meddeb et al., 2005, Saadi et al., 2006, Elsammak 
et al., 2010, Ardawi et al., 2012, Botros et al., 2015, Chakhtoura et al., 2018). In 
fact, populations from the MENA region registered the lowest value in serum 
25(OH) D in some of the most recent international studies (Mithal et al., 2009, 
Arabi et al., 2010, Hilger et al., 2014).  
Due to the widespread low vitamin D levels in the MENA region as well as the 
limited sunshine most of the year in the UK, it could be hypothesised that the 
MENA population living in the UK has the same pattern as the original MENA 
population in terms of the prevalence of vitamin D deficiency. There are several 
reasons for the high prevalence of vitamin D deficiency among MENA individuals 
such as the conservative clothing style that covers much of the skin, limited dietary 
intake of calcium and vitamin D, an indoor lifestyle and absence of national 
regulations regarding vitamin D food fortification. It has been proposed that these 
factors account for around 50% of vitamin D deficiency (El‐Hajj Fuleihan et al., 
2015). Vitamin D deficiency is a complex issue caused by many potential factors 
as noted in a previous section, and tackling this issue globally is both challenging 
and time-consuming. In order to do so, educating healthcare professionals and 
populations at high risk of vitamin D deficiency, and introducing a more efficient 
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system for monitoring vitamin D deficiency are clearly essential steps (Ahmed et 
al., 2011).  
1.5.5 Vitamin D and bone density   
As mentioned earlier, most of the literature investigating the optimal level of 
vitamin D is based on its effects on bone health and more specifically on 
determining the effect of conventional and high doses of vitamin D supplementation 
on bone density. For instance, 400 IU of daily vitamin D has been found to increase 
areal BMD at the femoral neck in elderly women (Ooms et al., 1995).  In another 
one-year trial, 400 IU of daily vitamin D did not lead to significant prevention of 
areal BMD loss at the hip, while a higher dose of 1000 IU of daily vitamin D led to 
a significant reduction in areal BMD loss at the hip in elderly women (Macdonald 
et al., 2013). In another two studies (Dawson-Hughes et al., 1991, Dawson-Hughes 
et al., 1995), various doses (100 IU to 700 IU) were associated with significant 
benefits in terms of bone density in postmenopausal women. Another trial reported 
a significant increase in total hip and femoral neck BMD following vitamin D 
intervention, but this result might not be generalisable as the participants were 
Asian women with darker skin colour and low baseline vitamin D, unlike 
participants in other trials (Islam et al., 2010). It has also been suggested that 
vitamin D is effective when combined with calcium supplements in the elderly 
population. In two trials which lasted three years by Dawson-Hughes et al. (1997) 
and Kärkkäinen et al. (2010), daily supplements of 700 IU of vitamin D plus 500 
mg calcium and 800 IU of vitamin D plus 1,000 mg of calcium, respectively, led to 
a significant increase in total BMD in men and women over 65 years.  
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Several studies have investigated the effect of single high dose vitamin D on bone 
density. The baseline level of serum 25 (OH) D may be an important determinant 
for the effectiveness of vitamin D supplements in improving bone density. For 
instance, Harwood et al. (2004) reported a positive effect of a large dose of vitamin 
D2 (300 000 IU administered by injection) in the neck of femur and total hip BMD 
BMD, in elderly women with low vitamin D at baseline. In contrast, Jorde et al. 
(2010) found the no positive effect with high weekly doses of vitamin D3 
supplementation (40,000 IU or 20,000 IU) in a population of overweight women 
who were vitamin D sufficient at baseline. Moreover, vitamin D3 supplementation 
of 100,000 IU/month for two years did not lead to significant improvement in the 
lumber spine and total body BMD in subjects with serum 25 (OH) D above 30 
nmol/L at baseline (Reid et al., 2017). Overall though, two systematic reviews and 
meta-analysis of the effect of vitamin D supplements on bone density in both the 
elderly and in adolescents indicate that vitamin D supplementation in a population 
with an adequate level of vitamin D is unlikely to improve bone density (Reid et 
al., 2014, Winzenberg et al., 2011). Nevertheless, vitamin D combined with calcium 
supplements for the prevention of bone loss in elderly populations has been 
recommended (Tang et al., 2007).  
A common issue in reporting the effect of vitamin D on bone density is the fact that 
most studies have relied on areal BMD (as measured by DXA) to determine the 
effect of the treatment. More advanced techniques in bone densitometry such as 
high-resolution imaging may lead to a better understanding of the relationship 
between vitamin D and bone structure. In a recent trial of horse jockeys, 400 IU of 
vitamin D supplementation and 800 mg of calcium in a population of those with 
sufficient vitamin D were found to significantly improve several pQCT parameters 
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at the proximal tibia (66%) (Silk et al., 2015) but no significant positive effect was 
detected at the radius in young male jockeys (Silk et al., 2017). However, the result 
of this trail may not be generalisable since the participants were professional 
jockeys who have weight restrictions plus the fact that the study contained a small 
sample size (n= 17).  
The recent utilisation of HR-pQCT may potentially lead to an even deeper 
understanding of the effect of vitamin D supplementation on bone microstructure 
and quality. However, trials studying the effects of vitamin D using HR-pQCT are 
very limited in number due to its cost and very recent availability. Of those which 
have been conducted, Boyd et al. (2015) investigated the relationship between 
serum 25(OH)D and HR-pQCT parameters in three groups with different vitamin 
D levels (low= >75 nmol/L, medium= 75-175 nmol/L and high >175 nmol/L). The 
authors reported no significant relationship between serum 25(OH) D and bone 
microarchitecture parameters. In another cross-section study in patients with 
primary hyperparathyroidism, vitamin D deficiency and insufficiency was not 
found to significantly affect volumetric bone density, bone microarchitecture, or 
strength (Walker et al., 2016). However, the cross-sectional design of the study 
should be noted in considering the results.  In another recent trial on the effect of 
high doses of vitamin D (50,000 IU/ week for 24 weeks) on HR-pQCT parameters 
in juvenile-onset systemic lupus erythematosus (JoSLE) patients who were mostly 
vitamin D insufficient, a significant increase in trabecular number and a significant 
decrease in trabecular separation was reported in the vitamin D group (Lima et al., 
2018). A recent proposal by Burt et al. (2018) to administer 3 different doses of 
vitamin D (1000 IU/day or 4000 IU/day or 10,000 IU/day) over 3 years and to use 
HR-pQCT to longitudinally determine any change in bone density and 
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microstructure looks promising to enhance our understanding of the effect of 
various doses of vitamin D on bone.  
1.6 Radiological methods for assessing bone 
Radiological techniques play a pivotal role in assessing bone density. There are 
several techniques for assessing bone density, from basic techniques available at 
most hospitals, to very advanced techniques available only at limited centres 
worldwide. These techniques are listed in Table 1.3 (below) with their technical 
parameters. The following section provides explanations of the working principle 
of each of these methods along with a discussion of their applicability, advantages 
and drawbacks. 
Table 1.3: Radiological methods for assessing bone 
Modality  Resolution 
(μm)  
Time (min) Effective Radiation Dose 
(μSv)  
Conventional Radiography <50  <1 10 
DXA  1,000–2,500 <1 1 – 6  
QUS 200–500  <10 0 
High-resolution MRI 150–200 10–30 0 
QCT 250–300 < 1 Wrist <10 
Hip, Spine 1500-2900 
HR-pQCT 82 3 3-5 
 
DXA= Dual-energy x-ray absorptiometry 
QUS= quantitative ultrasonography  
MRI= magnetic resonance imaging   
QCT= quantitative computed tomography 






The choice of the radiological method for assessing bone depends on several 
factors: the availability of the technique, the clinical or research question being 
asked, the radiation dose, the age of the patient and the cost of the scan. However, 
comprehensive assessment of bone may require combining more than one 
technique. The term bone strength is often used to refer to bone status. The 
measurement of bone strength involves an assessment of bone mineral (areal or 
volumetric), bone quality (including bone geometry and bone microarchitecture 
parameters), and bone material. Figure 1.7 (below) illustrates the different 
components of bone strength and imaging modalities that can be used to determine 
the parameters of bone strength.  
 
 
Figure 1.7: The components of bone strength and the role of medical imaging modalities 
(bottom row) in assessing bone strength non-invasively. Adapted from Adams, (2013). 
BMC= bone mineral content  
BMD= bone mineral density 
DXA= dual-energy x-ray absorptiometry 
QMRI= quantitative magnetic resonance imaging  
QCT= quantitative computed tomography 
HR-pQCT= high resolution peripheral quantitative computed tomography  
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1.6.1 Conventional radiography (including radiogrammetry) 
Methods were developed in the 1960s to conduct quantitative assessment via 
conventional radiographs. These techniques are known as radiogrammetry. 
Radiogrammetry is mainly applied to the second metacarpal, particularly to the mid 
shaft of the bone. The outcome of this technique is expressed as a metacarpal index 
which is simply the percentage of the bone’s diameter in the mid-shaft area (Adams, 
2013). Although this technique is simple, quick to apply and to interpret, it has very 
poor precision (Adams, 2013).  
Although radiogrammetry is a not a popular technique for assessing BMD, 
especially with the introduction of other more robust methods, there have been 
some attempts to modernise and digitise radiogrammetry (digital X-ray 
radiogrammetry (DXR)), particularly since the introduction of digital imaging 
technology. Automated modules have been developed in order to detect the edge of 
the metacarpal bones (2nd to 4th) and automatically produce metacarpal BMD 
(Jørgensen et al., 2000). Fracture risk is predicted by DXR at different anatomical 
sites including hip, wrist and vertebra (Bouxsein et al., 2002). More recently, an 
automated software called ‘BoneXpert’ has been developed to determine bone mass 
from hand radiographs. The software can be used in the clinical and research 
settings and the bone mass outcome are expressed as the bone health index (BHI) 
(Thodberg et al., 2010). The BoneXpert measurements are taken from the three 
middle metacarpal bones including the cortical thickness, width and length. The 
resulted BHI are compared with standard deviation scores (SDS), which is based 
on large cohort of healthy Caucasian children (Thodberg et al., 2010).  
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1.6.2 Dual-energy x-ray absorptiometry (DXA) 
DXA is by far the most common imaging modality for assessing bone density and 
is regarded as the gold standard for bone densitometry in the clinical setting (Wren 
and Gilsanz, 2006). DXA was developed in the 1980s and relies on the physical 
principles of x-ray ionising radiation and its attenuation by the different tissues in 
the body (Crabtree and Ward, 2015). In DXA, two photons with different energies 
- one low and one high - are transmitted through the body. Soft tissues attenuate 
both the high and low energy photons while bone attenuates only the high energy 
photons. The amount of bone mineral can be calculated by subtracting soft tissue 
from soft tissue and bone in the whole scanned area (Ward et al., 2016). By using 
software with an edge-detection algorithm, pixels that represent the start and end of 
bone in the scan area are determined and bone density can be calculated for each 
pixel. Areal bone mineral density (aBMD) can be obtained for the scanned area by 
summing the average values of all pixels in the images, and then by comparing with 
a mineral phantom (Ward et al., 2016). In addition to BMD, DXA can also measure 
bone area (BA) by summing all pixels in the image and so bone mineral content 
(BMC) can be calculated by multiplying BMD by BA (Crabtree et al., 2007). DXA 
measurements can be taken at various anatomical sites including lumbar spine, 
femoral neck, hip, forearm and whole body (Wren and Gilsanz, 2006, El Maghraoui 
and Roux, 2008).  
It has been reported that areal BMD accounts for around 60–70% of  the variation 
in bone strength and can be used a surrogate measure for the prediction of fracture 
risk (Adams, 2013). The BMD generated by DXA is represented in scores of 
standard deviation compared to the reference data.  Two scores can be generated: 
T-score and Z-score. The T-score is based on the BMD for a young adult 
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(comparing the patient’s BMD with that of a healthy young adult) while the Z-score 
is based on the BMD for a group of people with similar age and sex (comparing the 
patient’s BMD with that of a similar age and sex) (Cummings et al., 2002, Bachrach 
et al., 2011). The T-score is mainly used for osteoporosis diagnosis in adults and 
the Z-score for children but note that DXA is unreliable in children because it is 
affected by size and given the wide variation in bone size in children (Bishop et al., 
2014). 
Although DXA is the gold standard for bone densitometry, it has several 
limitations. Above all, since DXA measures BMD in two dimensions, volumetric 
density cannot be obtained (Binkovitz et al., 2008). Moreover, the BMD measured 
by DXA is a ratio between the scanned area and the bone, and therefore BMD can 
be underestimated in small bones and vice versa, causing it to present difficulties in 
accurately diagnosing osteoporosis in children (Jones et al., 2006).  Figure 1.8 (next 
page) illustrates the effect of object size when using 2-dimensional techniques such 
as DXA to represent 3-dimensional objects such as bone. Furthermore, all tissues 
with high density in DXA scans, such as abdominal aortic calcification and surgical 
metal implants, are assumed to be bone and contribute to BMD, which causes 
potential overestimation of the bone’s mineral status (Adams, 2013). Finally, DXA 
does not different cortical from trabecular bone. Despite these limitations, DXA has 
excellent reproducibility, a short examination time, low radiation dose, low cost and 





Figure 1.8: Object size effect on DXA measurements. DXA is limited to two dimensions 
only and therefore the third dimension (depth) cannot be assessed. Object A has a similar 
volumetric BMD to Object B despite the fact that Object B has a bigger volume. From 
Adams, (2013) with permission.  
1.6.3 Quantitative computed tomography (QCT) 
QCT is a cross-sectional imaging method based on the interaction between x-rays 
and body tissues and has the ability to visualise a range of tissue densities. In QCT, 
x-rays are transmitted by a rotating x-ray tube and the resulting intensities are 
detected by x-ray detectors on the opposite side. These signals are then converted 
into an attenuation profile (Donnelly, 2011). The attenuation profile contains 
different tissue densities gathered from individual voxels, which can then be 
transformed to a corresponding CT number (Hounsfield number). CT number 
represents a wide range of tissue densities where air is equivalent to a CT number 
of -1000, water is equivalent to a CT number of 0, bone has a CT number in the 
range of 400 to 1000 and with soft tissues having densities somewhere in between 
(Wren and Gilsanz, 2006).  
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These HU numbers are used to reconstruct a CT image where bone geometry can 
be obtained using special software and BMD can be obtained by transforming bone 
CT numbers to BMD (Donnelly, 2011). A bone equivalent phantom is used to 
calculate cortical and trabecular BMD and the measurements can be taken at central 
or peripheral sites. However, due to the trabeculae being smaller than the voxel size 
in QCT, in what is known as partial volume effect, the trabecular BMD obtained by 
QCT is a combination of bone and marrow (Crabtree and Ward, 2015).  
One of the major advantages of QCT is its ability to truly measure volumetric BMD 
as mg/cm3 (D'Elia et al., 2009). Moreover, QCT can separate the cortical and 
trabecular components of bone, which means cortical and trabecular BMD can be 
assessed separately. This is an important feature for determining the change in 
BMD as trabecular bone is significantly more active than cortical bone in terms of 
the metabolic process (Adams, 2013). Additional parameters of bone quality, such 
as its geometry, can be generated with QCT (Wren and Gilsanz, 2006). The vast 
advancement in CT technology including spiral and multi-detector CT has led to 
much more widespread and easy assessment of bone.  
However, one of the biggest limitations of QCT is radiation dose. Although the 
radiation dose can be minimised to ~100 μSv by adjusting exposure factors since 
image quality required for quantitative assessment of skeleton is less than the image 
quality for standard analysis, it is still significantly greater than DXA (Adams, 
2013). Moreover, access to CT may represent a drawback in some hospitals since 
the demand for CT scanners for other CT procedures is greater than DXA, which 
can lead to a long delay between scans in longitudinal assessment of BMD 
(Crabtree and Ward, 2015).  
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1.6.4 Peripheral quantitative computed tomography (pQCT) 
pQCT is based on the same principles as QCT but uses a dedicated imaging machine 
for peripheral sites. pQCT can be used at anatomical sites along radius and tibia, 
typically at distal parts, mid-shaft and proximal parts of radius and tibia (Adams, 
2013). The possible measurements that can be obtained by pQCT include trabecular 
BMD, cortical BMD, BMC, and bone geometrical parameters.  The most important 
advantages of pQCT compared to standard QCT are the lower radiation dose 
(≈3µSv) and portability (D'Elia et al., 2009). Although pQCT is a precise technique 
(Swinford and Warden, 2010), it does have some limitations. The most obvious is 
that it is restricted to peripheral imaging (Wren and Gilsanz, 2006). In addition, 
pQCT operates using a “rotate translate” model which is relatively slow (Crabtree 
and Ward, 2015); therefore patient motion artefact can be a major problem (Adams 
et al., 2014). Furthermore, positioning the reference line can be technically 
challenging in the longitudinal assessment of bone in children and adolescents 
especially for those treated for metabolic bone diseases. 
1.6.5 High resolution peripheral quantitative computed tomography (HR-
pQCT) 
HR-pQCT is another form of imaging based on the same physical principle as QCT 
but with a very high resolution that allows for the determination of bone 
microstructure (Nishiyama and Shane, 2013). In short, HR-pQCT is a powerful 
technique for assessing bone strength in a non-invasive manner using a low 
radiation dose. Its power lies in its ability to discriminate between two patients with 
identical areal BMD as measured by DXA (Figure 1.9, next page). Due to the high 
resolution of HR-pQCT (82 µm), it is the only method that has a spatial resolution 
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similar to the resolution required to assess trabecular bone in vivo (Geusens et al., 
2014). Moreover, HRpQCT allows assessment of several parameters of bone 
microstructure that are not measurable by more conventional imaging modalities 
(Digby et al., 2016).  
 
Figure 1.9: The power of HR-pQCT as a high-resolution technique. A, B; images of radius 
for two individuals with identical areal BMD as measured by DXA. However, the cross-
sectional HR-pQCT revealed significant differences at the trabecular and cortical levels. 
From (Burghardt et al., 2011) with permission.  
With HRpQCT, the patient’s limb is secured inside the gantry of the machine using 
a special Carbone cast to minimise movement. An x-ray tube rotates around the 
patient’s limb to accrue 110 slices in a scanning time of around 3 minutes. 
XtremeCT, Scanco Medical, Brüttisellen, Switzerland is the only commercial HR-
pQCT scanner (Cheung et al., 2013, Nishiyama and Shane, 2013). Several 
parameters relating to bone quality can be assessed using HR-pQCT, which include 
total, cortical and trabecular volumetric BMD and various parameters to assess bone 
structure (Geusens et al., 2014). These parameters are explained in more detail in 
the relevant section of Chapter 3 (Table 3.3, Pages 126 and 127). The mechanical 
properties of bone can also be assessed by the application of finite elements analysis 
(FEA). However, this is a time consuming process (takes approximately 30 minutes 




Although HRpQCT is the state-of-the-art for assessing bone quality, this imaging 
method suffers from some limitations. First of all, patient motion is a common issue. 
Using a cast and good positioning helps to overcome this issue. Furthermore, as 
with pQCT, it is limited to peripheral sites, thus making it impossible to directly 
assess other anatomical sites, such as the thoracolumbar spine, which is a common 
site of bone fragility (Burghardt et al., 2011). Some studies have assessed the 
correlation between measurements at peripheral skeleton and central skeleton and 
reported a strong correlation between the same skeletal sites, but weak to moderate 
correlation between central and peripheral sites (r = −0.27 to 070) (Cohen et al., 
2010, Liu et al., 2010, Amstrup et al., 2016). Nonetheless, the radius is a common 
site for fracture and the tibia is a weight-bearing site which makes HR-pQCT a 
valuable and meaningful tool for assessing these two skeletal sites (Cheung et al., 
2013). A further limitation of HRpQCT is that it cannot assess the mid-shaft of adult 
long bones due to the design of the scanner. Moreover, although the voxel size is 
82 μm, the actual resolution of images is approximately 130 μm, meaning trabecular 
microarchitecture, such as trabecular thickness, has to be derived rather than 
directly measured (Cheung et al., 2013). However, the recent launch of a new 
generation HR-pQCT scanner (XtremeCTII, Scanco Medical, Brüttisellen, 
Switzerland) with higher resolution (61 μm) may help overcome these issues as the 
measurement can be taken from further proximal parts of the bone and trabecular 
microarchitecture can be directly measured (Manske et al., 2015).  
It should be mentioned that HR-pQCT is predominantly a research tool. Many 
studies using HR-pQCT have focused on the age, sex and ethnic differences of bone 
microarchitecture. For example, a reduction in the cortical BMD has been found to 
occur with aging due to an increase in cortical porosity in a Canadian population-
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based sample (Macdonald et al., 2011). Few other studies have investigated the 
related racial difference in bone microarchitecture. In one recent study, several 
parameters related to the radius such as cortical area, trabecular BMD and stiffness, 
were found to be greater in African-American girls compared to Caucasian and 
Asian-American girls (Misra et al., 2017). Recently, HR-pQCT is becoming 
increasingly used in the change in bone microarchitecture as an objective end point 
in the assessment of interventions, but its use is hindered by its significant cost. 
1.6.6 High-resolution magnetic resonance imaging (QMRI) 
In contrast to DXA and QCT techniques, high-resolution MRI is a non-ionising 
imaging modality, a feature which presents an advantage, especially in the imaging 
of children. A strong magnetic field is required in high-resolution MRI where 
sequences of radiofrequency pulses can be applied in each direction in three-
dimensional space to obtain high-resolution MRI images (Link and Majumdar, 
2004). High-resolution MRI can produce the trabecular structure at distal sites of 
the appendicular skeleton such as distal radius and distal tibia (Wren and Gilsanz, 
2006).  
Although trabecular bone microarchitecture can be obtained and bone strength can 
be estimated at high quality, the result obtained for cortical bone is less perfect 
(Chapurlat, 2016). In addition, MRI can be technically challenging to perform and 
optimise (Bauer and Link, 2009, Adams, 2013). The relatively long scanning time 
(around 15 minutes) can increase motion artefact due to voluntary and involuntary 
motion (D'Elia et al. 2009). Furthermore, claustrophobic patients might be 
unsuitable candidates for this technique as they are required to be stationary for this 
length of time in a restricted space (open-bore machines will overcome this 
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disadvantage). Additionally, the high costs and limited availability of this imaging 
modality represent further limitations. 
1.6.7 Quantitative ultrasonography (QUS) 
QUS is another non-ionising imaging modality. In this technique, high frequency 
ultrasound waves (200 kHz and 1.5 MHz) are transmitted through the body and 
then reflected by bone tissues, which can then be received and analysed by an 
ultrasound machine (D'Elia et al., 2009). The calcaneus is a common site for bone 
assessment using QUS. Ultrasound measurements using this technique include 
parameters that are mainly related to BMD but also reflect elements of bone 
structure. These parameters include speed of sound, broadband ultrasound 
attenuation, stiffness index and quantitative ultrasound index (Adams, 2013). QUS 
has some advantages over other imaging methods such as having a lack of ionising 
radiation, being low cost, as well as being more portable. In addition, QUS can be 
more convenient for scanning patients with restricted mobility and children not able 
to keep still during DXA, QCT or QMRI scanning (Tong et al., 2018).  However, 
QUS can sometimes produce unreliable data if it is performed by an inexperienced 
operator (Wren and Gilsanz, 2006). Moreover, a recent systematic review found a 
non-consistent correlation between biochemical bone markers and anthropometric 
measurements, and QUS parameters in preterm infants (Tong et al., 2018). 
According to Adams (2013), the application of QUS is not clearly defined in clinical 




1.7  Summary  
Nutrition status especially vitamin D and calcium intake are important determinant 
of bone health across all life stages. The SCAN report on vitamin D intake has 
recently introduced a RNI of vitamin D (400 IU/day) but it is not clear if general 
population are achieving this RNI. The positive effect of physical activity on bone 
health is well documented in the literature. WBV is a relativity new training 
approach that may overcome some of the issues associated with conventional 
methods of exercising such as falls, minor injuries and stress fractures.  With many 
WBV devices on the market and several studies on its effects in the literature, the 
precise role of WBV in bone health is still under investigation with many studies 
demonstrating conflicting results. No optimal WBV protocol or target group has 
been identified. The effect of such vibration may be influenced by several factors, 
importantly nutritional status and particularly vitamin D as demonstrated in some 
exercise and animal studies. The effect of WBV on bone can be measured using 2-
dimentional imaging modalities such as DXA, which is the most commonly used 
modality to determine the effect of WBV on bone in the literature. The recent 
utilisation of HR-pQCT has revolutionised bone-imaging technology and allowed 







1.8 Rationale, aims and objectives   
1.8.1 Rationale, aims and objectives for Section 2 (Chapter 2): 
Adequate levels of vitamin D, calcium and physical activity are important 
modifiable factors for bone accrual in children. It is not clear if children presenting 
to the emergency department with wrist and ankle injuries are consuming enough 
amount of vitamin D, calcium and engaging in physical activities.  
Aim:  
1. To determine the strength of the association between injury outcome 
(fracture or no fracture) and vitamin D intake, calcium intake and physical 
activity in children aged between 6 years and 15 years presenting to the 
Emergency Department (ED) of Sheffield Children’s Hospital following 
injury to their wrist or ankle 
Objectives: 
1. To assess vitamin D intake among children presenting to the ED of Sheffield 
Children’s Hospital with wrist and ankle injuries  
2. To assess calcium intake among children presenting to the ED of Sheffield 
Children’s Hospital with wrist and ankle injuries  
3. To assess the physical activity levels among children presenting to the ED 






1.8.2 Rationale, aims and objectives for Section 3 (Chapters 3, 4, 5 and 6): 
While several studies have investigated the effect of WBV on bone health, the 
results of these studies are ambiguous and equivocal. The need to include vitamin 
D data when interpreting bone response to physical stimulation has recently been 
highlighted, particularly due to the significant issue of widespread vitamin D 
insufficiency. Some exercise and animal studies suggest a positive role for vitamin 
D in bone’s response to mechanical loading, but the extent of this role has not been 
fully investigated.  
With regard to WBV trials, there are only three – as far as we are aware – which 
have investigated the effect of both WBV and vitamin D on bone density and 
structure. Of these, in only one study was the primary outcome related to HRpQCT 
parameters of the distal radius and tibia. There were also several issues with this 
study such as not controlling for vitamin D – the entire study population received 
vitamin D supplements. Moreover, the vitamin D intake reported in this study was 
not assessed for all volunteers and more seriously, baseline serum 25 (OH) D was 
not known. In addition, the findings of this study might not be generalisable to the 
public as the study was limited to postmenopausal women with osteopenia.  
Thus, there is a need for a well-designed trial to ascertain how bone responds to 
WBV and vitamin D. The present study aimed to ascertain the role of high dose of 
vitamin D, on bone’s response to WBV as measured by HR-pQCT. The target 
population for the current study was the MENA population who live in the UK. 
This is due to the limited research on this ethnic group with regard to WBV and 
vitamin D despite the high prevalence of osteoporosis and vitamin D deficiency 
among this ethnic group.  
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The hypothesis of the proposed research was that a large oral dose of 150,000 IU 
of vitamin D and 12 weeks of high intensity WBV would improve the bone 
parameters of the distal tibia as measured by HR-pQCT beyond improvements seen 
with either vitamin D or vibration alone in a population of young MENA adults 
living in the UK. The results of this pilot study will allow us to power a larger 
definitive study.  
 
Primary aim: 
1- To determine the effect of a single large dose of vitamin D (150,000 IU of 
vitamin D3) and 12 weeks of side-alternating WBV on HR-pQCT 
parameters of the distal tibia 
 
Secondary aims: 
1- To determine the change in total serum 25 (OH) D 12 weeks after 
administering 150,000 IU of vitamin D3 as a single dose 
2- To assess the impact of administering 150,000 IU of vitamin D3 on PTH 
level 12 weeks after administering 150,000 IU of vitamin D3 as a single 
dose 
3- To assess the safety of a large single dose of vitamin D on a selection of the 
MENA population living in the UK 
4- To assess the compliance and safety of side-alternating WBV on individuals 





Primary objectives:  
1. To determine baseline HR-pQCT parameters of the distal tibia in a young adult 
MENA population 
2. To determine the effect of three months of WBV on volumetric bone density 
and microarchitecture of the distal tibia as measured by HR-pQCT  
3. To determine the effect at three months of a single large dose of oral vitamin 
D on bone strength determined by FEA of the distal tibia  
4. To compare the effect at three months of a combination of WBV and a single 
large dose of vitamin D on HR-pQCT parameters of the distal tibia 
 
Secondary objectives: 
1. To measure calcium intake at baseline 
2. To determine the effect of a single large dose of vitamin D on calcium 
creatinine level one week after dosing  
3. To measure baseline serum vitamin D, bone profile and PTH 
4. To determine the effect at three months of a single large dose of oral vitamin 
D on vitamin D levels, bone profile and PTH 
5. To compare the effect at three months of a combination of WBV and a single 
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2.1 Abstract  
Objective: To assess the strength of the association between suggested risk factors 
and fracture prevalence in children. 
Materials and Method: A cross sectional observational study. Children aged 6 to 
15 years and their guardians presenting to the Emergency Department of a single 
tertiary paediatric hospital were recruited. Self-reported data on vitamin D intake, 
calcium intake, and physical activity were collected. All participants had a 
radiograph of their injured limb reported by a consultant radiologist, on the basis of 
which they were classified into fracture or no fracture groups. Statistical analysis 
included descriptive statistics and binary logistic regression. 
Results: Of the 130 patients recruited, 53 (41%) had sustained a fracture. The 
overwhelming majority of children (98%) did not consume the recommended daily 
dietary amount of vitamin D (400 IU/day). Low calcium intake and low levels of 
physical activity were also ascertained. However, there were no significant 
differences between fracture and no fracture groups for vitamin D intake, calcium 
intake or physical activity. Both site of injury (wrist) and sex (males) were 
associated with increased fracture risk (p=0.001 and p=0.05, respectively). Logistic 
regression showed a statistically significant relationship between calcium intake 
and fracture risk (every additional unit of calcium consumption (mg/day) decreased 
the likelihood of fracture by 0.002, 95% CI, 0.001 - 0.003).  
Conclusion: Low dietary intake of calcium and vitamin D and low levels of 
physical activity were evident. Fracture risk was significantly associated with 






Several epidemiological studies have revealed a substantial increase in the 
incidence of fractures in children in the past few decades (Cooper et al., 2004; 
Mathison and Agrawal, 2010; Clark, 2014). Indeed, it has been estimated that 
around one third of children in the United Kingdom (UK) will suffer from at least 
one fracture during their childhood (Cooper et al., 2004). While bone health and 
fracture risk are relatively well understood in the adult population, and in particular 
in postmenopausal women (Borges and Brandao, 2006), less is understood about 
this issue in children (Farr et al., 2014). There are several factors that can influence 
bone health in children including non-modifiable factors such as genetics, age, 
ethnicity and sex, and modifiable factors such as calcium and vitamin D intake, and 
physical activity (Golden et al., 2014). Optimising the modifiable factors protects 
against poor skeletal health and thus reduces fracture risk. For instance, low intake 
of calcium and milk was found to increase fracture risk (Wyshak and Frisch, 1994; 
Goulding et al., 2004), while vitamin D supplementation was found to reduce 
fracture risk (Anderson et al., 2017) in children. In recognition of the importance of 
vitamin D for skeletal health, the Scientific Advisory Committee on Nutrition 
(SACN) on vitamin D in the UK has introduced a Reference Nutrient Intake (RNI) 
of 400 International Units (IU) of vitamin D per day (equivalent to 10 micrograms) 
for the general UK population aged 4 years and above throughout the year ((SACN), 
2016). A final key factor in determining skeletal health is level of physical activity. 
For example, in a long-running study, a 4-year exercise program was found to 
increase bone mass (Löfgren et al., 2012).  
Although calcium intake, vitamin D and physical activity are important modifiable 
lifestyle factors for bone health in children, the strength of their impact on fracture 
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risk in children presenting to an Emergency Department (ED) is not clear. A fall on 
to the outstretched hand for example is a common occurrence; but it is not 
understood whether there is a difference in any of the modifiable factors between 
children who subsequently sustain a fracture compared to those who do not. 
Therefore, the purpose of this study was to determine calcium intake, vitamin D 
intake and physical activity among children aged between 6 and 15 years attending 
the Emergency Department (ED) of Sheffield Children’s Hospital following injury 
to their wrist or ankle and to assess the strength of the association between injury 
outcome (fracture or no fracture) and these modifiable factors.   
 
2.3 Materials and methods 
This was a non-interventional, prospective, questionnaire-based observational 
study, with questionnaires administered independently by two researchers in the ED 
of Sheffield Children’s Hospital between March and August 2015.  Full patient and 
guardian assent/consent was obtained prior to enrolment and the study received 
Local Research Ethics Committee and NHS Research and Development approvals. 
The conditions of ethical approval for this study in a busy ED was that 
children/families would first be approached by a Triage Nurse. Only those 
interested were then approached by the researchers. Therefore, the number or 
characteristics of those approached who withheld consent was not recorded. The 
inclusion criteria were children aged between 6 and 15 years with no known 
underlying disease or long-term medication use. They had to be able to speak and 
read English and they were required to have undergone a wrist or ankle radiograph 
following acute injury to the relevant site. Patients were not eligible if they had been 
involved in high-energy trauma (e.g. road traffic accidents, falls from a significant 
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height), because in such circumstances, fracture is more likely to occur regardless 
of other modifiable factors (Blades et al., 2010). Patients were guided through the 
questionnaire. Older children (aged 10 years and above) answered the questionnaire 
themselves, while younger children (aged under 10 years) answered the 
questionnaire with the aid of their parent(s)/guardian(s). A consultant radiologist 
with extensive experience in musculoskeletal imaging reported the radiographs, 
allowing patients to be classified into two groups: “fracture” or “no fracture”. The 
consultant radiologist had no knowledge of the patients’ intake of vitamin D and 
calcium, nor of their level of physical activity.  
The questionnaire consisted of four parts. Part 1 related to patient demographics 
and the mechanism of injury. Patients’ age and weight in kilograms were retrieved 
from their ED notes. Height was recorded to the nearest 0.1cm using a wall-
mounted stadiometer. Body mass index (BMI) for each patient was then calculated 
as weight (kg)/height (m)2. An age and sex specific BMI chart provided by the 
Royal College of Paediatrics and Child Health (RCPCH) was used to establish BMI 
percentiles for children (RCPCH, 2013). Patients’ ethnic group was self-reported.  
Socioeconomic status was determined using the English index of multiple 
deprivation (IMD) 2015 (Department of Communities and Local Government), 
extracting patients’ postcodes from their ED notes to determine their IMD scores. 
IMD scores for England are ranked from 1 (most deprived area) to 32,844 (least 
deprived area). IMD scores below 10,894 are considered areas of low 
socioeconomic status, IMD scores between 10,895 and 21,788 are considered areas 
of average socioeconomic status, and IMD scores above 21,789 are considered 
areas of high socioeconomic status. Site and side of injury were retrieved from 
patients’ ED notes and confirmed by inspecting the imaging request cards/images.  
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Pubertal stage was established in Part 2 of the questionnaire and was self-reported 
using the Tanner score (Carskadon and Acebo, 1993). Patients under 10 years old 
were assumed to have a Tanner stage of 0, because onset of puberty is not expected 
to occur before this age in apparently healthy girls and boys (Rubin et al., 2009; 
Sørensen et al., 2012). Parts 1 and 2 of the questionnaire were piloted to ensure that 
there were no issues with the format and that language was appropriate for children.  
Part 3 used two previously validated questionnaires to assess vitamin D and calcium 
intake. The “validated short food frequency questionnaire” (SFFQ) - specifically 
designed for children - was used to assess vitamin D intake in IU (Nucci et al., 
2013). The patients’ daily calcium intake was assessed in milligrams (mg) using the 
“calcium calculator” created by the International Osteoporosis Foundation (IOF) 
(IOF, 2015). This calcium calculator is validated and accounts for age and sex of 
the child.  
The final part of the questionnaire used the validated “previous day recall 
questionnaire” to assess physical activity (Children’s Physical Activity Research 
Group, 2002). This generates a metabolic equivalent of task (MET) score from a 
table of MET scores provided by the Arnold School of Public Health (Ainsworth et 
al., 2000). Three variables are generated from this physical activity questionnaire: 
total MET score, number of 3-5 METS (moderate activity) and number of 6/6+ 
METS (vigorous activity).  
Statistical analysis was carried out using the IBM Statistical Package for the Social 
Sciences (SPSS), version 23. Descriptive statistics were used to summarise the 
variables including means and standard deviations. To test for any association 
between the suggested risk factors and injury outcome, the Chi-squared test was 
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used for categorical variables and an independent t-test for continuous variables. If 
data were not normally distributed, the non-parametric Mann-Whitney test was 
used. Finally, binary logistic regression was carried out to calculate odds ratios 
(ORs) and 95% CIs to assess the impact of individual risk factors on injury 
outcome. The logistic regression model contained 8 independent variables (vitamin 
D (IU/day), calcium intake (mg/day), total MET score, number of 3-5 METS 
(moderate activity), number of 6/6+ METS (vigorous activity), joint affected (wrist, 
ankle), sex (male, female), age (years). Multicollinearity between the explanatory 
variables was checked including collinearity between the total MET score, the 
number of 3-5 METS (moderate activity) and the number of 6/6+ METS (vigorous 
activity). Since 85% of participants were Caucasian, ethnicity did not significantly 
contribute to the logistic regression model and hence was removed. Similarly, 
socioeconomic status did not significantly contribute to the logistic regression 
model and was removed.  
2.4 Results 
A total of 134 interviews (each taking approximately 30 minutes) were conducted. 
All interviews were carried out while the patient was still in the ED setting. 4 
patients were excluded (3 because the radiographs were of sites other than wrist or 
ankle, 1 because this was a re-attendance for a previously sustained injury). In total 
then, 130 datasets were analysed. Of the 130 patients, 53 (41%) sustained a fracture. 
Patient demographics are summarised in Table 1. Patients’ age ranged from 6 to 15 
years, and 110 (85%) were Caucasian, 19 (14.5%) Asian and only one (0.5%) was 
Afro-Caribbean. There were no significant differences between fracture and no 
fracture groups in terms of age (p=0.07) or ethnicity (p=0.23). However, sex was 
found to be have an impact on injury outcome, with boys sustaining more fractures 
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than girls (p=0.05). The wrist accounted for 90 injuries (69%) and wrist injuries 
were significantly associated with an increased positive fracture outcome compared 
to ankle injuries (p <0.001). Among the 130 children recruited, 37 (28.5%) (16 in 
the fracture group) were from areas of high socioeconomic status, 38 (29.2%) (17 
in the fracture group) were from areas of average socioeconomic status and 55 
(42.3%) (20 in the fracture group) were from areas of low socioeconomic status. 
There was no significant difference in the socioeconomic status between the 
fracture and no fracture groups (p= 0.67).  Moreover, there were no significant 
differences in vitamin D intake (p=0.77), calcium intake (p=0.59) and the level of 
physical activity (p=0.61) between the three socioeconomic classes.  
 
Table 2.1: Patient demographics 
 Fracture  No Fracture Total p value 
Number  53 77 130  
Number of boys  36 (28%) 39 (30%) 75 (58%) 0.99 
Number of girls  17 (13%) 38 (29%) 55 (42%) 0.73 
Mean age in years  (SD) 10 (2.5) 11 (2.4) 10.6 (2.5) 0.07 
Boys mean age in years 
(SD) 
10.5 (2.5) 11.3 (2.5) 10.9 (2.5) 0.18 
Girls mean age in years 
(SD) 





A total of 96 patients (40 in the fracture group) were in the healthy weight range 
(9th to 90th BMI centile), 17 patients (6 in the fracture group) were in the 91st to 97th 
centile, 9 patients (5 in the fracture group) were in the 0.04th to -8.99th centile, 4 
patients (one in the fracture group) were in the 98th to 99.5th centile and 4 patients 
(one in the fracture group) were in the 99.6th centile. There was no significant 
difference in BMI centile between the two groups (p= 0.75).  
There were 63 patients (27 in the fracture group) with a pubertal score of 0, 13 
patients (8 in the fracture group) with a pubertal score of 1, 17 patients (7 in the 
fracture group) with a pubertal score of 2, 6 patients (2 in the fracture group) with 
a pubertal score of 3, 8 patients (2 in the fracture group) with a pubertal score of 4 
and 23 patients (7 in the fracture group) with a pubertal score of 5. The distribution 
of Tanner staging was similar across the two groups (p =0.50).  
Mean daily calcium intake for both groups was 713 mg (SD= 283). Overall daily 
calcium intake was greater in the no fracture group (Figure 1) but did not reach 
statistical significance (p=0.08). The overwhelming majority of children (98%) did 
not consume the recommended dietary amount of vitamin D (400 IU/ day), with 
mean daily vitamin D intake for both groups being 145 IU (SD= 201). Since dietary 
Vitamin D intake was negatively skewed, the Mann Whitney test was used to 
investigate any difference between the fracture and no fracture groups. There was 
no significant difference (p=0.81) in the median vitamin D intake between the two 










Figure 2.2: Vitamin D intake by group 
 
 
Most children achieved a low total MET score. The distribution of MET scores was 
similar between the fracture and no fracture groups (Figure 3). 72 (55%) patients 
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did not attain any 30-minute blocks of 3-5 MET (moderate activity), while 61 (47%) 
patients did not attain any 30-minute blocks of 6/6+ MET (vigorous activity) during 
the day before their injury. There was no significant difference between the two 
groups in terms of total MET (p=0.07), the number of undertaken moderate 
activities (p=0.80), or the number of undertaken vigorous activities (p=0.08). 
 
Figure 2.3:  Distribution of the Total MET’s Score among the two groups 
 
Logistic regression was performed to determine the association between 8 
explanatory variables and fracture risk. Multicollinearity between the explanatory 
variables was checked; high correlation was not found between any variables. For 
the physical activity parameters, the correlation analysis showed no high correlation 
between the total MET score and the number of 3-5 METS (r=-0.327), the total 
MET score and the number of 6/6+ METS (r=-0.655) or the number of 3-5 METS 
and the number 6/6+ METS (r= 0.393). The logistic regression model indicated that 
there was a significant relationship between 4 variables (age, sex, site of injury and 
calcium intake) and fracture risk (Table 2). Site of injury was the strongest predictor 
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of injury outcome (p=0.001), with injury to the wrist being 12 times more likely to 
cause fracture than ankle injuries. Sex was also a significant predictor of injury 
outcome (p=0.016). Males were almost 3 times more likely to fracture than females 
after adjusting for all other variables in the model. The regression model also 
showed that for every year increase in age, the likelihood of fracture decreases by 
0.21 (p=0.016). Every additional unit of calcium consumption (mg/day) was found 
to decrease the likelihood of fracture by 0.002 (p=0.021).  
 
Table 2.2: Logistic regression model (8 independent variables) 
Variables p value OR 95% C.I. for OR  
Lower Upper 
Age (years) 0.016* 0.791 0.653 0.957 
Sex (female) 0.032* 2.650 1.087 6.459 
Joint (ankle) 0.001* 11.884 3.442 41.028 
Total MET score  0.862 0.996 0.949 1.045 
Moderate activity  0.994 0.999 0.799 1.249 
Vigorous activity  0.341 0.864 0.639 1.168 
Calcium intake 
(mg/day)  
0.021* 0.998 0.997 0.999 
Vitamin D intake 
(IU/day) 
0.174 1.002 0.999 1.004 
  
Variables were considered significant predictors for fracture if p value <0.05.  
* indicates a significant p value  
OR = odds ratio 
 
2.5 Discussion   
The present study indicates that among three modifiable factors for bone health, 
namely vitamin D intake, calcium intake, and physical activity, only one (calcium 
intake) has a small but statically significant association with reduced risk of 
fractures. However, there were significant associations between the non-modifiable 
factors, sex and site of injury. We showed that girls were less prone to have an 
injury and, if injured, less likely to fracture (boys’ relative risk of fracture was 
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approximately 3 times that of girls). This finding is consistent with the literature, 
which indicates that boys are more prone to fracture (Khosla et al., 2003; Cooper et 
al., 2004; Clark, 2014). While this may be due to the fact that males are more 
inclined towards dangerous activities which then increases their risk of injury and 
fractures as a result of high impact accidents (Rennie et al., 2007), we specifically 
excluded children who attended following major trauma, suggesting that it is the 
tendency towards risky behaviour rather than the severity of the trauma that is 
important. Socioeconomic status may have a role in determining fracture risk, as 
children from deprived areas potentially have an unhealthier diet and may be less 
engaged in sports activities. However, we found no significant differences in 
vitamin D intake, calcium intake and physical activity between children from the 
most deprived areas and children from least deprived areas neither was there an 
association between socioeconomic status and injury outcome.  
It has previously been concluded that upper limb fractures are more prevalent than 
lower limb fractures in children and adolescents (Mathison and Agrawal, 2010; 
Rennie et al., 2007). Our study showed that injury to the wrist is 12 times more 
likely to be associated with fracture than injury to the ankle. This probably reflects 
the different mechanisms of injury of the wrist and ankle: the majority of wrist 
injuries occur as a result of falls onto an outstretched hand, conferring significantly 
more force to the wrist than that conferred to the typical ankle injury (most 
commonly an inversion injury).  
As expected, the mean calcium intake in the fracture group was lower than in the 
no fracture group (Figure 1). However, this did not reach statistical significance 
(p=0.08), which may reflect our relatively small sample size. In the regression 
model, for each additional unit of calcium intake (mg/day), the likelihood of 
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fracture decreased by 0.002 when controlling for all other variables.  This finding 
needs to be further investigated in a larger study. The low calcium intake may 
increase the risk of future fracture (Bachrach, 2001), particularly in the fracture 
group, given that Manias et al. (2006) found lower calcium intake among children 
with recurrent fractures. 
Similarly, we found that children did not consume the recommended amount of 
dietary vitamin D, with no significant differences between children in the fracture 
and no fracture groups. The low dietary vitamin D intake may be partially mitigated 
because sunlight is a major source of vitamin D; however, vitamin D synthesis from 
sunlight depends on several factors including local climate, time of day, age, skin 
pigmentation and sunscreen use (Lips et al., 2014). The recent introduction of 400 
IU of daily vitamin D as the reference nutrient intake (RNI) by SACN highlights 
the importance of adequate vitamin D intake. Although the SACN recommendation 
is 200 IU below the recommendation of the Institute of Medicine (IOM) in the 
United States (Prentice, 2008), the average daily vitamin D intake in both groups in 
our study was similar and well below even the SACN guideline levels. Based on 
our results, we conclude that as far as the skeletal effects of isolated low vitamin D 
are concerned (none of our patients showed radiographic rickets and we excluded 
patients with known underlying disease), increased fracture risk does not appear to 
be an issue. 
Physical activity has been proven to increase bone mass, thus reducing fracture risk 
(Tan et al., 2014). Therefore, we sought to establish whether this impacts upon the 
outcome of injury. For all three measures of exercise within this study, (total MET 
score, 3-5 METS and 6/6+ METS), there were no significant differences observed 
between the two groups.  
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We have shown no major association between these modifiable factors and fracture 
risk, however, our results should be interpreted with caution, since any associations 
(particularly between calcium intake and fracture risk) may become significant in a 
larger sample size.  
Apart from the sample size, the further limitation of this study was the questionnaire 
format, which may have introduced bias in terms of dietary and exercise recall, with 
parents/patients overestimating their consumption of healthy foods and physical 
activity (Cade et al., 2002). It is also possible (but less likely) that values were 
underestimated. However, a questionnaire design was felt to be the most pragmatic 
and (using the results from this study), we can now power a larger definitive study, 
in which food intake and exercise can be recorded prospectively in relevant diaries 
or perhaps even on an app. To improve the robustness of our results, all 
questionnaires used have previously been validated in children. Moreover, the 
number or characteristics of children who declined to participate in the study were 
not recorded due to the condition of the ethical approval. This may have produced 
selection bias. 
2.6 Conclusion  
To conclude, although a majority of children and adolescents were below 
recommended guidelines for exercise levels and vitamin D and calcium intake, only 
increased calcium intake showed a small but statistically significant relationship 
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3.1 Study design  
The current study is an educational PhD project. This project was a prospective 
double-blind placebo pilot randomised controlled study of the effects of WBV and 
a large dose of vitamin D on bone density and microstructure as measured by HR-
pQCT at distal tibia with four parallel study groups. There were 10 participants (5 
males, 5 females) in each group. The participants in this study were apparently 
healthy adult volunteers who emigrated from the MENA region to the UK. They 
were recruited mainly from the University Of Sheffield, UK. WBV training was 
delivered using a Galileo platform, which is a side alternating WBV technique 
(Galileo Advanced platforms). The single high dose of vitamin D (150,000 IU) 
consisted of 3 mls of Invita D3 50,000 IU oral solution (1 ml per ampoule). 
The four groups of the current study were: 
1. WBV group: this group received WBV and a placebo.  
2. Placebo group: this group received the placebo only and served as the 
control group in this study. 
3. Vitamin D group: this group received one intervention only, namely the 
high dose of vitamin D.  
4. vitamin D +WBV group: this group received both interventions, WBV and 
a high single dose of vitamin D 
This study is a registered trial on a public database which is ClinicalTrials.gov. 


























Figure 3.1: Consort flow-chart of the study pathway 
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The period of the intervention was 12 weeks. HR-pQCT scans of the distal tibia, 
vitamin D, bone profile and PTH measurements were taken at baseline (week 0) 
and 12 weeks after administering either vitamin D or the placebo (at week 13). 
Taking measurements at these points was vital. This is because establishing the 
baseline characteristics determines any imbalance between the different study 
groups while the post-intervention measurements allow for a comparison of groups’ 
responses to the intervention.   
The 12 weeks’ study duration was chosen in order to strike a balance between the 
ability to detect changes in HR-pQCT and vitamin D parameters, while successfully 
recruiting the required number of participants and maintaining their interest in 
completing the study, since it is well known that dropout rates increase when the 
study duration increases.  Moreover, the 12 weeks’ period seems sufficient for 
vitamin D (in large doses) to be metabolised and any changes in its levels can be 
still detected. For instance, the concentration of serum 25(OH)D was found to be 
above 50 nmol/L at 8 weeks (Martineau et al., 2009) and at12 weeks (Ilahi et al., 
2008) after administering 1,000,000 IU of vitamin D as a single dose. However, the 
dose used in this study is greater by 50,000 IU and its effect is expected to last for 
at least 12 weeks.   
In addition, from the WBV prospective, Vibration can stimulate the bone 
remodelling and can lead to more bone formation, perhaps through one of the 
suggested mechanisms, which has been previously discussed in chapter one. When 
the bone remodelling is activated, the resorption phase takes around 2 weeks 
followed by the reversal phase, which lasts for around 4 weeks. This phase is 
followed by the formation phase, which can last for up to 120 days (Hadjidakis and 
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Androulakis, 2006). However, the bone remodelling cycle is shorter in the cortical 
bone compared to the trabecular bone (it takes around 120 days) (Agerbaek et al., 
1991). The post-intervention measurements in the current study were taken during 
week 13 after the bassline measurements, which is in the bone formation phase. 
Previous studies reported significant improvements in BMD after similar period of 
WBV. For instance, significant improvements were in BMD were after 12 weeks 
of WBV in children with haemophilia (El-Shamy, 2017), and in another study, a 
similar period of WBV significantly prevented bone loss in elderly women (Lee et 
al., 2017). In addition, another study showed significant increase in hip BMD after 
only 10 weeks of WBV (Prioreschi et al., 2012). It has been reported that the 
minimum period of WBV to have a measurable effect on bone density is 8 weeks 
(Mikhael et al., 2010). Therefore, it seems that the 12 weeks’ intervention period is 
sufficient to detect any interaction between WBV and vitamin D.  
3.2 Study procedures  
The study consisted of 7 visits in total to the Clinical Research Facility (CRF) at 
Sheffield Children’s Hospital (SCH) and to the Clinical Research Facility (CRF) at 
the Northern General Hospital (NGH). In addition to the 7 visits for all participants, 
participants randomised to WBV were informed that it was expected they would 
commit to the WBV protocol and undertake a total of 36 WBV sessions over 12 
weeks. The vibration sessions were undertaken at the CRF- SCH. There was at least 
one-day rest between vibration sessions (whenever possible).  
HR-pQCT scans and blood measurements were taken in the same week but not 
necessarily on the same day. This was due to the journey time between NGH where 
the HR-pQCT scanner is based, and SCH which is the primary study site (around 
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30 minutes by bus) as well as due to the availability of the scanning machine. Figure 
3.2 (next page) illustrates the study timeline and Table 3.1 (page 106) summarises 
the research activities undertaken during these visits. 
Due to the significant commitment that was expected form the volunteers in this 
study (especially those randomised to WBV), they were offered thank you vouchers 
of £150 each for participants randomised to WBV and £50 each for participants 

















Table 3.1: Summery of activities undertaken during study visits 
Visit Location  Procedures   
Visit 1 SCH 1. Explaining the study to the potential participant 
2. Providing the information sheet (Appendix i) 
3. Answering any questions related to the study 
4. Assessing volunteer’s eligibility using the study 
standard screening form  
5. Arranging next visit to sign the informed  consent 
form (Appendix ii) 
Visit 2 SCH 1. Signing the informed consent form 
2. Arranging the future study visits 
 
Visit 3 CRF at 
NGH 
1. Obtaining baseline HR-pQCT scans of the non-
dominant distal tibia 
 
Visit 4 CRF at 
SCH 
1. Performing pregnancy test in female participants  
2. Measuring the volunteer’s baseline height and weight  
3. Obtaining baseline blood samples for vitamin D, bone 
profile and PTH measurements  
4. Providing breakfast to the participant 
5. Administering vitamin D or placebo 
6. Assessing dietary intake of calcium 
7. Providing the participant with a urine bottle for 2nd 
void urine sample 
 
Visit 5 CRF at  
SCH 
1. Participant to provide the 2nd void fasting urine (one 
week after visit 4) 
 
Visit 6 CRF at 
NGH 
1. Obtain follow-up HR-pQCT scans of the non-
dominant distal tibia 
 
Visit 7 CRF at 
SCH 
1. Measuring volunteer’s height and weight at follow-
up 
2. Obtaining follow-up blood samples for vitamin D, 
bone profile and PTH measurements  








The participants were given at least 24 hours from receiving the information sheet 
before signing the consent form in order to give them sufficient time to think about 
the study and ask any further questions. Full informed consent was obtained in 
writing by the PhD student in accordance with good clinical practice.  
Participants were asked to fast (except for water) from midnight of the night before 
until blood samples were taken. A urinary pregnancy test was performed by a 
member of the CRF nursing staff with experience of performing the test and 
offering support should they prove unexpectedly positive. This was performed to 
avoid the possibility of administering a high dose of vitamin D to a pregnant 
woman, which is not recommended by the manufacturer of the vitamin D used in 
the current study. The result of the test was documented by the research nurse.  
Participants were reminded about their scheduled visits by email/text message. The 
clinical study visits were attended by the PhD student who recorded the visit 
number, date and the study activity/activities undertaken. WBV platforms were set-
up for each session in the CRF-SCH by the PhD student. All WBV sessions were 












3.3 Participant selection and recruitment 
Inclusion criteria:  
1. Males or females aged 18 to 40 years who emigrated from any of the MENA 
countries to Sheffield, UK (this is the ethnicity of interest for this study). 
The definition of the MENA countries was based upon the World Bank 
definition of the MENA countries which include: Algeria, Bahrain, 
Djibouti, Egypt, Jordan, Iran, Iraq, Kuwait, Lebanon, Libya, Malta, 
Morocco, Oman, Palestine/Israel, Qatar, Saudi Arabia, Syria, Tunisia, 
United Arab Emirates (UAE), and Yemen. This approach for defining the 
MENA countries was previously used in reviewing vitamin D studies in the 
MENA region (Chakhtoura et al., 2017a, Chakhtoura et al., 2017b) and it 
was felt suitable to be used for defining the MENA countries in the current 
study  
2. Able to give full informed consent 
3. Able to attend for scans, blood tests and/or vibrating sessions at various 
agreed points during the study 
Exclusion criteria:  
1. Previous fracture or surgery to any leg  
2. Any allergy or hypersensitivity to vitamin D or any of the other ingredients 
in invitaD3 
3. Known metabolic or hereditary bone disease  
4. Known to have any of the following; hypercalcaemia, hypercalciuria, 
pseudohypoparathyroidism, hypervitaminosis D, sarcoidosis, renal calculi 
(kidney stones) or kidney damage or disease 
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5. Using, have recently used or might use any other medicines likely to interact 
with vitamin D  
6. Taking vitamin D supplementation at the time of recruitment 
7. Any chronic disorder/medication that might affect bone strength 
8. Pregnant and breastfeeding women (pregnancy was excluded in all female 
subjects by performing urinary pregnancy test)  
9. Known to have epilepsy or dizziness (in order to avoid falling while standing 
on the platform)  
10. Serious cardiovascular or pulmonary disease or using a pacemaker 
11. Restricted mobility (not able to stand on the vibration platform)  
12. Allergy or intolerance to dairy products (due to the yoghurt drink which was 
administered with or without vitamin D)  
An eligibility checklist was used for each subject to identify any of the above 
exclusion criteria (Appendix iii). 
In order to advertise the study to potential volunteers, two recruitment strategies 
were used: 
1. The study was advertised to University of Sheffield students and staff using 
the University Of Sheffield email database, asking any from MENA 
countries interested in receiving more information to contact either the PhD 
student or his main supervisor (ACO), should they wish to volunteer 
(Appendix iv) 
2. Posters advertising the study were distributed by the PhD student across the 




Although the current study required commitment over a relativity long period and 
involved several procedures including some minimally invasive procedures, 
recruitment seemed feasible based on our Department’s experience from previous 
studies. For instance, a similar study was carried out in our Department over a 3-
month period, in which participants were asked to attend 3 hammering sessions 
each week. The compliance of the participants was good and 16 out of 18 
participants completed the study. Furthermore, a public involvement (PI) event was 
undertaken by the PhD student, which included 5 subjects (3 males and 2 females) 
to determine their opinions about attending for vibration training sessions and 
attending for blood and radiological procedures at various points during the study. 
The feedback received from the PI event was in general positive. The participants 
in the PI event were also given the opportunity to give their opinion about the 
wording of the information sheet and study documents. 
From personal interaction with the student community at the University Of 
Sheffield, it seemed that the number of students from the MENA region would be 
large enough to achieve the required sample size. Nevertheless, information was 
sought from the University of Sheffield about precise numbers of students from the 
MENA region, and their number (711 students) confirmed that recruitment of the 
required number was feasible within the PhD timeframe.   
3.5 Randomisation 
Randomisation was performed using one of the online tools that is reported in the 
literature (Saghaei, 2011). A random list was generated by the PhD student’s second 
supervisor (NJB), who was not involved in undertaking the study visits or assessing 
the outcome. This individual used the online tool; Randomization.com 
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(Randomization.com.).  A block randomisation technique was used with a block 
size of 8. This was performed to ensure that participants were fairly distributed in 
the trial arms should the trial have to be terminated early for any reason. Once the 
eligibility of a volunteer was confirmed and consent had been obtained, ACO, who 
held the randomisation codes, assigned a study ID number. Randomisation codes 
were only to be broken in the case of an emergency. 
It was explained in the advertising material that volunteers would be randomised 
into groups. In addition, it was explained to the volunteers in the information sheet 
why they could not choose their group, and why it was important to randomise them 
to groups by chance. 
3.6 Blinding and other measures taken to avoid bias 
In terms of allocation to receive vitamin D or the placebo, the study was double-
blind. For WBV, a sham device was not used due to the difficulty in obtaining such 
a device and the limited funding for the current study, therefore, this aspect of the 
study was not blinded. Failing to obtain a sham device is a well-known limitation 
in trials involving the use of a device (Fregni et al., 2010).  
Having randomised them to their groups, participant study ID numbers were written 
by ACO onto a sealed opaque envelope containing a signed and dated sheet of 
paper, completed by ACO, indicating whether the participant had been allocated to 
vitamin D or placebo.  The participant’s allocation into WBV or no WBV groups 
was written on the sealed envelopes alongside the study ID number. Sealed 
envelopes were handed to the PhD student. Participants’ allocation into WBV or no 
WBV was recorded by the student then the sealed envelopes were taken to the 
clinical trials team at SCH pharmacy. Sealed envelopes were opened by the clinical 
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trials staff who communicated with the lead research nurse in this study.  The 
unblinded research nurse in the CRF at SCH collected vitamin D (if applicable), 
prepared vitamin D or the placebo, checked the participant’s identity against the 
record and administered either vitamin D or placebo. Neither the student nor the 
volunteer knew whether they had been given vitamin D or placebo. 
3.7 Withdrawal of subjects 
Participants were informed that they could withdraw from the study at any stage 
without giving a reason. However, to provide researchers with an opportunity to 
understand their reasons, participants who withdrew from the study were asked if 
they could give a reason and they were reassured that they did not have to give an 
answer. Data collected up to the point of their withdrawal were retained and 
analysed.  
3.8 Study interventions 
3.8.1 Vitamin D supplementation 
A single dose of 150,000 IU of Vitamin D3 [3 mls of Invita D3 50,000 IU oral 
solution (1 ml per ampoule)] was administered to those participants randomised to 
receive vitamin D. The 150,000 IU of Vitamin D3 (Invita D3) was dispensed by the 
clinical trial team in the SCH pharmacy. The Vitamin D3 or placebo was prepared 
and administered by a research nurse not involved in the trial assessment within a 
safe clinical environment at SCH. In order to mask the taste of vitamin D3, it was 
mixed with a small amount (30 mls) of raspberry flavoured yoghurt drink. 
Participants who were randomised to receive the placebo also had the same amount 
of raspberry flavoured yoghurt drink, but no vitamin D was mixed within. The 
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raspberry flavoured yoghurt was tested by the investigators and two senior members 
of the clinical trial team in SCH pharmacy using a smaller volume of the same 
concentration (1 ml of Invita D3 50,000 IU added to 10 ml of raspberry flavoured 
yoghurt drink or just 10 ml of raspberry flavoured yoghurt drink), and it was agreed 
that the raspberry flavoured yoghurt drink tasted and looked the same with or 
without the added vitamin D.  
The Invita D3 was supplied by the Pharmacy Department at SCH and was sourced 
via usual local NHS procurement arrangements. Invita D3 50,000 IU is a licenced 
product produced by Consilient Health Ltd. Each Invita D3 50,000 IU is a 1 ml 
solution (1 single-dose oral solution) and contains 1.25 mg colecalciferol, 
equivalent to 50,000 IU Vitamin D3. 3 ml Invita D3 were given in total per subject. 
Reported undesirable effects of Invita D3 include hypercalcaemia and 
hypercalciuria (uncommon, affect <1/100) and pruritus and urticaria (rare, affect 
<1/1,000). The active metabolite of vitamin D increases calcium absorption from 
the gut, and acts on bone cells to help maintain calcium homeostasis. In this 
formulation (Invita D3, Consilient), a 1 ml solution (1 single ¬dose oral solution) 
contains 1.25 mg colecalciferol, equivalent to 50,000 IU Vitamin D3. The 
excipients are tocopherol acetate, polyglyceryl oleate (E475), refined olive oil and, 
refined, sweet orange peel oil.  
The administration of the vitamin D or placebo was documented. The advantage of 
using a single dose is to avoid the issue of non-compliance to the prescribed daily 
dose. It has been reported that a high single dose should give the same effect of 
weekly or daily doses over the same period of time (Ish-Shalom et al., 2008). 
Therefore, 150,000 IU vitamin D3 over the 12 weeks is equivalent to 1785 IU a 
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day. This daily dose is consistent with the conclusion of a recent systematic review 
which indicated that individuals from the MENA region need between 1000 IU and 
2000 IU of daily vitamin D in order to achieve a concentration of serum 25(OH)D 
> 50 nmol/L (Chakhtoura et al., 2017b). Ideally, we would have preferred to 
conduct the study in winter months (October to April) to avoid sun exposure that 
allows skin synthesis of vitamin D. However, even in the summer months (May to 
September), sun screen was not used for cultural and religious reasons and because 
the dress code of people from the MENA region which means that skin is not 
exposed to much sunlight (Chakhtoura et al., 2017a).  
Procedures for identifying contraindications to vitamin D, special warnings and 
precautions and interactions with other medicinal products are explained in 
Appendix vi. The procedure in case of undesirable effects and reporting via the 
Yellow Card Scheme is explained in Appendix vii. Safety aspects of vitamin D are 
also discussed in more detail in the safety section 3.13. 
3.8.2 Whole Body Vibration (WBV) 
Galileo Advanced platforms were used to deliver high intensity WBV vibration 
(Figure 3.3 a). The WBV regimen consisted of three supervised training sessions 
each week for a period of 12 weeks. Each session consisted of three bouts, and each 
bout lasted for three minutes with a one-minute rest between bouts. The Galileo 
Advanced platform is a side-alternating WBV machine. It was chosen because it 
has been shown that side-alternating platforms are more effective in improving 
BMD than vertical platforms (Fratini et al., 2016). The follow parameters for WBV 
were used: Frequency = 22 Hz, Peak-to-peak displacement = 4 mm, Acceleration = 
3.8 g.  
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The selected WBV parameters were based on a study conducted by Elmantaser et 
al. (2012) who used a similar vibration platform in a young adult population and 
reported that the WBV protocol was well tolerated by participants. Moreover, the 
authors showed that a Galileo platform was associated with more measurable effect 
on the endocrine system when compared with a Juvent platform (Elmantaser et al., 
2012). More recently, it has been concluded that WBV is more effective when the 
magnitude of the platform is higher than 3 g and / or the frequency is lower than 25 
Hz (Fratini et al., 2016). Taking all of the above into consideration, it was felt that 
the chosen WBV platform and parameters in the current study could lead to 
measurable effects on HR-pQCT measurements.  
However, since it was expected that the majority of participants would never have 
used such machines before, and in order to give them the opportunity to get used to 
the training regimen, the peak-to-peak displacement was increased gradually over 
the first three weeks. In the first week, displacement was 2 mm; 3 mm in the second 
week, and from week 3 to week 12, displacement was 4 mm.  
Participants stood on the platform shoeless with their knees slightly flexed (Figure 
3.3 b, c). This training regimen is compliant with the recommendations of the 
International Society of Musculoskeletal and Neuronal Interactions (Rauch et al., 







   
              a                                          b                                         c 
Figure 3.3: (a); Galileo Advanced platform, (b, c); subjects’ position on the platform 
(from week 3 to week 12). 
 
Each participant’s adherence to the WBV protocol was calculated using the 
following formula to evaluate his/her compliance:  
1. The percentage adherence to WBV training (%) =  
(Number of sessions performed ÷ total number of planned sessions*) ×100 
* Total number of planned sessions = 36 







3.9 Measurements  
3.9.1 Demographic and anthropometric data 
Date of birth, sex, address, country of origin and GP name and address (in order to 
contact participants’ GP in case of abnormal results requiring their attention) were 
recorded at baseline.  Height (m) and weight (kg) were measured at baseline (visit 
4) and post–intervention (visit 7) using the same procedure and same instruments 
on both occasions. An electronic wall-mounted stadiometer (Seca, Birmingham, 
UK) was used to measure height to the nearest 0.1 cm. Participants were asked to 
stand with their heels against the wall-mounted stadiometer, combining their feet 
together and wearing no shoes. Weight was measured to the nearest 0.1 kg using an 
electronic scale (Seca, Birmingham, UK).  
3.9.2 HR-pQCT   
3.9.2.1 Scanning procedure for the distal tibia  
HR-pQCT scans of the non-dominant distal tibia were acquired using a first 
generation HR-pQCT scanner (XtremeCT, SCANCO AG, Brüttisellen, 
Switzerland, Figure 3.4) on the high resolution mode. HR-pQCT scans were 
performed in accordance with the well-established standard operating procedures 
of the Mellanby Centre for Bone Research, University of Sheffield as previously 
published (Paggiosi et al., 2014). Table 3.2 (Page 119) summarises the technical 



















Table 3.2: Technical HR-pQCT scanning parameters 
Parameters Value  
Image matrix 1536x1536 
Source potential  60 kVp 
Tube current 900 mA 
Integration time 100 ms 
Number of slices acquired  110 slices  
Scanned area  150 mm  
Stack height  9.02 mm 
isotropic resolution  82 µm 
Total scan time  ~ 3 minutes  
   
A pre-calibration test was performed prior to positioning the subject’s leg inside the 
scanner. A special leg cast (Figure 3.5 (a)) was used to position the subject’s leg 
inside the gantry of the scanner. This is an essential part of the scanning procedures 
and is used to reduce movement artefact. Pads and supporting cushions were used 
for proper positioning when necessary in order to ensure the comfort of the subject 
and to eliminate movement during the scan. After immobilising the leg in the cast, 
the chair was raised up to the level of the scanner gantry and the leg cast was placed 
and secured inside the scanner. The subject was asked to keep as still as possible 
during the scan. Figure 3.5 (a,b,c,d) illustrate the cast and the positioning 





a                                       b                                  c                                         d 
Figure 3.5: (a); Leg cast, (b,c,d); scanning procedures 
 
Before running the HR-pQCT scan, a scout view was acquired in order to identify 
the anatomical landmarks in the ankle joint and to place the reference line. The 
reference line was placed on the cortical endplate of the distal tibia (Figure 3.6). 
The first slice was obtained 22.5 mm from the reference line. A total region of 9.02 















Figure 3.6: HR-pQCT scan of the distal tibia. a; positioning the reference line on the 
scout view. The single green line represents the reference line. The Solid green area (9.02 
mm) represents the location where 110 slices where acquired. b; axial 2D image slice, c; 






3.9.2.2 Image grading 
Once the scan was completed, the operator visually inspected the quality of the 
images acquired and validity for analysis. The scans were classified into 4 
categories based on a visual grading system reported previously (Engelke et al., 
2012). There are 4 grades in this classification. 
(i) Grade 1 – a ‘perfect’ scan with no evidence of movement artefact 
(ii) Grade 2 – slight movement artefact was apparent on the images 
(iii) Grade 3 – more pronounced movement artefact was apparent on the images 
(iv) Grade 4 – very pronounced movement artefact was apparent on the images 
(‘unacceptable quality’ as described by (Paggiosi et al., 2014). 
If the quality of the scan fell into categories 1 to 3, the scan was deemed valid and 
the subject was released. If the quality of the scan fell into category 4, a repeated 
scan was obtained. If the quality of the repeated scan was still poor (grade 4), it was 
deemed not valid for assessment and the scan was excluded from further analyses 
(Figure 3.7, next page). A maximum of 2 scans were performed at any one 
anatomical site.  Within our study, we managed to obtained acceptable scans for all 





Figure 3.7: Visual grading system for HR-pCQT scan quality (tibia). Arrows point to the 
motion artefact.  
G1: Perfect scan (desirable), G2: Small degree of motion (acceptable), G3: Moderate 
degree of motion (acceptable), G4: Significant degree of motion (rejected) 
 
3.9.2.3 HR-pQCT Analysis  
The analysis was performed by an experienced operator (Dr Margaret Paggiosi) at 
NGH. HR-pQCT image analysis involved the following analysis; i) standard image 
analysis, which provided densitometric, geometric and microstructural parameters, 
ii) extended cortical analysis, which provided additional cortical parameters, iii) 
Micro finite elements (µFE) analysis to estimate measures of bone strength.  
i: Standard image analysis 
This analysis was performed using Scanco standard software (version 6). The bone 
was separated from the soft tissue by drawing a contour around the periosteal region 
of the cortical bone in the first slice of the whole HR-pQCT stack. Contours were 
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applied semi-automatically for the subsequent 109 slices by the software. The HR-
pQCT operator checked all the image slices manually and made any adjustments to 
the periosteal contours as required. Following this step, the cortical compartment 
was separated from the trabecular compartment by applying an automatic 
segmentation algorithm (Burrows et al., 2010). Trabecular and cortical densities 
were then determined separately by plotting the CT linear attention values against 
known densities obtained from a calibration phantom. In addition, trabecular bone 
microarchitectural properties were evaluated during the standard analysis stage.  
ii: Extended cortical analysis 
The software used for the extended cortical analysis was developed by Burghardt 
et al. (2010). The analysis consisted of three stages. In the initial stage, bone was 
extracted from the surrounding soft tissues using the same approach that were used 
in the standard analysis. The cortical bone was then automatically segmented using 
an automated contour algorithm. This process generated two bone compartments: 
the cortical compartment and the trabecular compartment. The second stage 
involved cortical porosity segmentation. This process was performed by using the 
cortical compartment (generated in stage one) to mask to the grey scale images in 
order to characterise the background voxels. Initially, all voids voxels that were 
surrounded by bone in cortical compartments were considered as intracortical pore 
space. A second 2D connectivity algorithm was used to enhance the ability of the 
software to detect the pore space that were not captured in the previous step. In the 
final stage, a refined image including all mineralised bone and intracortical pores 
in the cortical compartment was obtained by digitally combining the cortical 
compartment (obtained in stage one) and the intracortical porosity segmentation 
(obtained in stage 2) (Burghardt et al., 2010). The HR-pQCT operator checked all 
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the image slices manually and made any adjustments to the endosteal contours as 
required. 
iii: Micro finite elements (µFE) Analysis 
Micro Finite element (µFE) analysis was performed in order to estimate bone 
strength measures in-vivo. µFE modelling was performed using the extended µFE 
software (version 1.13; FE-solver included in the Image Processing Language, 
Scanco Medical AG, Zurich, Switzerland) which is fully automated and has been 
previously validated (MacNeil and Boyd, 2008, Nishiyama et al., 2013). The 
application of the µFE involved a simulation process in which the µFE model 
simulates a fall from standing height onto an out-stretched hand. Young’s modules 
were applied to the cortical and trabecular bone separately (a Young’s modulus of 
20 GPa for cortical bone and Young’s modulus of 17 GPa for trabeculae bone) 
(Walsh et al., 2012). A force representing 1000 N was applied to the distal part of 
the tibia in the axial direction while the proximal part was fixed. It was assumed 
that load failure occurs when 2% of the bone tissue strained beyond a critical level 
of 7000 µstrain based in criteria described by Pistoia et al. (2002). However, this critical 








Table 3.3: Summary of the different HR-pQCT parameters that resulted from the 
standard analysis, extended cortical analysis and µFE Analysis outcome 
(Burghardt et al., 2010, Wang et al., 2010, Fuller et al., 2015) 
Parameter  Abbrev. Unite  Description 
 
Bone areas 
Total area Tt.Ar  mm2 The average cross-sectional area of the 




Tb.Ar  mm2 The average cross-sectional area of the 
trabecular compartment circumscribed by 
the endosteal contour 
Cortical area Ct.Ar mm2 The average cross-sectional area of the 
cortical compartment between the 
periosteal and endosteal contours 
 
Bone densities 
Total density  Tot.vBMD mg/cm3 Mean mineralization of 
the total volume of interest 
Cortical  
density 
Ct.vBMD  mg HA/cm3 Mean mineralization of 
the cortical volume of interest 
Trabecular 
density 
Tb.vBMD mg HA/cm3 Mean mineralization of 
the trabecular volume of interest 
 
Trabecular bone microarchitecture 
Trabecular 
number 
Tb.N  1/mm Mean number of trabeculae per unit length 
Trabecular 
thickness 
Tb.Th mm Mean thickness of trabeculae 
Trabecular 
separation  
Tb.Sp mm Mean space between trabeculae 
Trabecular 
inhomogeneity 
Tb.N.SD mm SD of the intra-individual distribution of 
trabecular separation 
Trabecular 




% Trabecular bone volume fraction divide 




Meta/Inn % Ratio between outer and inner 












Cortical bone microarchitecture 
Cortical 
thickness  
Ct.Th mm Mean 3D distance from periosteal 
boundary to endosteal boundary, 
disregarding intracortical pores 
Cortical 
perimeter  
Ct.Pm mm Distance covered by the perimeter of 
the periosteal surface 
Cortical tissue 
mineral density  
Ct.TMD mg HA/cm3 Mean mineralization of the segmented 




Ct.Po % The volume of the intracortical pore space 
normalized by the sum of the pore and 
cortical bone volume 
Cortical pore 
diameter 





Ct.Po.Dm.SD µm Standard deviation of the 3D diameters of 
the intracortical pore space 
Connectivity 
density  
Conn.D.  mm-3 Extent of trabecular connectivity 
normalized by tissue volume   
 
µFE Analysis outcome 
Stiffness  
 




F.ult kN Maximum load applied on the bone before 
a fracture can occur; when 2% of the bone 







% Ratio of the load taken by the trabeculae 





Tb.F/TF prox  % Ratio of the load taken by the trabeculae 









The previous published work by researchers at the Mellanby Centre for Bone 
Research, University of Sheffield demonstrated that the XtremeCT scanner has 
excellent precision (Paggiosi et al., 2014). In this study, percent root mean square 
coefficient of variation (RMSCV) was calculated as the percent short-term root 
mean square coefficient of variation (%RMSCV) (Paggiosi et al., 2014). Precision 
(RMSCV) values for tibia measurements ranged from 0.2% for densitometric 
variables to 6.6% for cortical porosity (Paggiosi et al., 2014).  
 
3.9.2.5 Quality Assurance  
The quality assurance of the HR-pQCT scanner was checked on a daily and weekly 
basis. The daily calibration (QC1) was performed using the manufacturer’s test 
object (Scanco Medical AG) in order to monitor the stability of the scanner. The 
weekly calibration (QC2) was performed, again using the manufacturer’s test 
object, in order to ensure the XtremeCT’s ability to measure bone microstructural 
properties (Figure 3.8, next page).  
The manufacturer’s test object consisted of five hydroxyapatite-resin compartments 
of different densities. The densities of these compartments mimicked different 
physiological bone mineral densities and started from 0 mgHA/cm3, representing 
soft tissue, and gradually increased (100 mgHA/cm3, 200 mgHA/cm3, 400 
mgHA/cm3 and 800 mgHA/cm3). The mean attenuations (in Hounsfield units) of 
each of the five compartments were calculated from the images slices of the 
phantom.  These were then converted into BMD values (mgHA/cm3). This QC step 
was essential and ensured that total, cortical and trabecular volumetric BMD were 
measured accurately by the XtremeCT scanner. This quality assurance approach is 
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part of the SOP procedures for Mellanby Centre for Bone Research at the University 
of Sheffield. and has been briefly reported in a previous publication (Paggiosi et al., 
2014).  
     





3.9.3 Vitamin D, PTH, bone profile and 2nd void fasting urine sample 
measurements  
 
Vitamin D, PTH bone profile (includes calcium, corrected calcium, phosphate, 
alkaline phosphate and albumin) were measured and documented at two time points 
during the study: at the baseline and at the end of the intervention. These elements 
were measured as they are strongly related to bone health. Evaluating these 
elements in the current study will allow for a broader evaluation of the impact of 
the interventions and could provide additional interpretations of the trial results. At 
the baseline test, blood samples were taken just before administering the vitamin D 
or placebo and before providing any food to the participants. All baseline 
measurements were taken between November 2017 and January 2018 for males, 
and between November 2017 and March 2018 for females. At the post-intervention 
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tests, the blood samples were taken within 7 days after the last WBV session and 
after taking HR-pQCT scans.  HR-pQCT scans and the blood samples were taken 
at the same day if possible or during the same week if it was not possible to take at 
the same day. The post-intervention samples were collected between February and 
April 2018 for males and between February and June 2018 for females (12 weeks 
after administering the vitamin D or placebo, Figure 3.2, Page 105).   
The blood samples were collected following an overnight fast and the samples were 
collected between 8 am and 11 am. Around 8 ml of blood were withdrawn at each 
visit. The samples were collected by a qualified research nurse with the safe 
environment of the CRF at SCH. After withdrawing the samples, they were taken 
immediately by the PhD student to the lab. Bone profile and PTH were analysed on 
the same day by the Clinical Chemistry Laboratory department at SCH. Serums for 
vitamin D tests were frozen and then sent to Bristol for analysis where they were 
analysed by Biochemistry department at Bristol Royal Infirmary. This is because 
this centre has a well-established protocol for analysing vitamin D.   
 
A fasting 2nd void urine sample for spot urine calcium:creatinine ratio were 
collected from all participants one week after taking the baseline blood samples, 
regardless of the participants had taken the vitamin D or placebo. Written 
instructions on how to provide a second void fasting urine sample were provided to 
participants, and were also explained verbally. In order to provide these samples, 
participants were asked to avoid eating and drinking anything except water from 
midnight until they passed the 2nd void urine sample. They were instructed to pass 
urine once shortly after they got up/woke up, and then to drink tap water before 
providing a second sample in the bottle provided to them (5 ml of urine).  
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An Acquity Ultra Performance LC/Quattro MS (Waters) analyser was used for 
measuring vitamin D studies using UPLC/Mass Spectrometer Semi-automated 
hexane extraction methods. There were three results for vitamin D analysis; 25-
hydroxyvitamin D2, 25-hydroxyvitamin D3 and total 25-hydroxyvitamin D. The 
vitamin D analyser has good sensitivity. The lower limits of detection of 25-
hydroxyvitamin D2 and 25-hydroxyvitamin D3 are 6nmol/L and 3.5nmol/L, 
respectfully. Precisions are as following; for vitamin D2: With-in Run CV 4.4-6.7% 
and total CV 5.2-6.4%, for vitamin D3: With-in Run CV 4.3-4.5% and total CV 5-
6.2%. PTH was measured using the 8K25 ARCHITECT intact PTH assay kit. The 
system was calibrated as per manufacturer’s instruction. Serum sample collected 
from patients’ blood was loaded and the sample was run on the Architect i1000 
System (Abbott) analyser.  Architect intact assay is a two-step sandwich 
immunoassay for the quantitative determination of intact PTH in human serum and 
plasma using Chemiluminescent Microparticle Immunoassay technology with a 
PTH analytical sensitivity ≤1 ng/L and PTH precision ≤ 7-9%, With-in Run CV 
4.1-8.7%, and total CV 4.1-8.7%.  
Bone profile (calcium, albumin, phosphate, alkaline phosphatase) and urine 
creatinine and calcium were analysed by Vitros 5,1 FS System (Ortho Clinical 
Diagnostics) analyser using Micro Slide Technology. Calcium levels were 
measured by the VITROS Ca Slides and the VITROS Chemistry Products 
Calibrator Kit 1. To measure serum albumin, the VITROS Chemistry Products 
Calibrator Kit 4 and VITROS albumin slide method was employed. Serum 
phosphate was measured using the VITROS PHOS Slides and the VITROS 
Chemistry Products Calibrator Kit 1. Alkaline phosphatase (AKLP) was measured 
using the VITROS ALKP Slides and the VITROS Chemistry Products Calibrator 
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Kit 3. To measure the urine creatinine level, the VITROS CREA Slides and the 
VITROS Chemistry Products Calibrator Kit 1 was used. All analysis was performed 
by qualified lab technicians following the manufacturers’ instructions.  
3.9.4 Calcium intake 
The “calcium calculator” created by the International Osteoporosis Foundation 
(IOF) was used to assess participants’ calcium intake in milligram (mg) ((IOF), 
2015). This calcium calculator is a web-based food frequency questionnaire that 
asks how frequently certain foods are consumed per week and then combines all 
answers to give an estimated daily calcium intake. 
3.10 Data handling and record keeping 
Data was collected and retained in accordance with the Data Protection Act 1998 
until 25th May 2018, and then with Data Protection Act 2018 from 25th May 2018 
(in accordance with the change in the Data protection law in the UK). Study 
documents (paper and electronic) have been retained in a secure location during and 
after the study.  All source documents will be retained for a period of 5 years 
following the end of the study.  Where study related information is documented in 
the medical records – those records will be retained for 5 years after the last subject 
last visit. 
3.11 Statistical analysis 
CONSORT Statement guidelines were followed when analysing and presenting the 
study results (Moher et al., 2001). Baseline continuously distributed data was 
summarised by the median (25th/75th centiles); categorical data by n (%). 
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Percentages were rounded to the nearest whole number for ease of reading, thus 
giving rise to rounding errors. Given that the four treatment groups were 
randomised, baseline values were not compared statistically (Senn, 1989, Senn, 
1994). Any between-group differences are assumed to have occurred by chance. 
Graphical presentation was by box and whisker plots. Missing values are given but 
not considered otherwise in our statistical analyses. Data was analysed by intention-
to-treat. We used analysis of variance (ANOVA) to compare between-group 
differences from baseline to 12 weeks. Predicted means (plus 95% confidence 
intervals) from ANOVA were presented graphically with the controls as the 
reference group. A nominal level of 5% statistical significance (two-tailed) was 
used. We did not adjust p-values for multiple comparisons (Rothman, 1990). Given 
the exploratory nature of the trial statistical comparisons were kept to a minimum 
(Lancaster et al., 2004). Effect sizes for key outcome measures were estimated for 
future trial planning. The Stata statistical computer package was used to analyse the 
data (StataCorp, 2007).  
3.12 Sample size calculation 
The choice of the sample size is pragmatic, and not informed by power. There are 
no prior data on which to base a formal power calculation for changes in HR-pQCT 
parameters after the intervention with vibration training and a large dose of vitamin 
D. Therefore, this pilot study should be regarded as exploratory in nature.  Different 
approaches to determine the sample size for a pilot clinical study have been reported 
in the literature. For example, 10 patients per group (40 maximum); (Birkett and 
Day, 1994), minimum of 20 patients in total; (Sandvik et al., 1996), 12 patients per 
group (Julious, 2005); or at least 9% of the main study’s sample size; (Cocks and 
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Torgerson, 2013) were all reported. The first approach (10 per group) was chosen 
to determine the sample size for the current study as this approach fits best with the 
timescale and resources of this project. As such, 40 subjects were recruited (10 per 
group, 5 males and 5 females per group). Drop-out rates were monitored, and 
sample size will be revised accordingly for the main study.  
3.13 Safety assessments and ethical considerations 
The safety of participants in the current study was paramount. The PhD student 
monitored participants throughout the study and any adverse events that could be 
related to the study were recorded.    
Many publications have shown the 150,000 IU dose of vitamin D to be safe. For 
instance, a single dose of vitamin D of up to 300,000 IU at intervals of 3 months or 
longer would not be expected to cause adverse effects in adults according to the 
latest report (July 2016) of SACN ((SACN), 2016). It has been reported that a single 
dose of 150,000 IU of vitamin D is effective in maintaining adequate blood levels 
of vitamin D without causing hypercalcaemia or hypercalciuria in children (Oliveri 
et al., 1996). In a recent systematic review of a large, single-dose of vitamin D in 
adults, it was concluded that the increase in 25(OH) D concentration occurred safely 
without adverse effects at doses less than 200,000 IU (Kearns et al., 2013). Indeed, 
the previous research conducted in our Department showed that a single dose of 
150,000 IU of Invita D3 (the same product which was used in the current study) is 
safe and effective in increasing vitamin D without causing hypercalcaemia or 
hypercalciuria (Gopal‐Kothandapani et al., 2018). 
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Although there was no evidence in the literature to suggested that the proposed dose 
may cause any harm to the participants, it was decided to perform a 2nd void urine 
sample one week after administering the vitamin D or placebo as a safety procedure. 
This is because there is a lack in the literature regarding the effect of high doses of 
vitamin D on this ethnic group (MENA ethnicity). In addition, any subject who may 
have contraindications for vitamin D was not recruited.  
The vibrating platform has been used extensively both in clinical practice and sold 
‘over the counter’ in countries within the EU including the UK. Minimal adverse 
events have been reported in the use of vibrating platforms. In a previous vibration 
study conducted by our research group, WBV was well tolerated with only mild 
effects being reported. A few of the participants experienced an itching type 
response in the feet and legs during the vibration (Harrison et al., 2015). In this 
previous vibration study in boys (aged 9 to 12 years), one subject felt dizzy whilst 
standing on the platform, and one felt faint after having blood taken -both issues 
were resolved after the subjects sat for a while (Harrison et al., 2015). However, 
participants in the current study are young adults who may have more ability to 
adapt to study procedures. It is possible that someone could fall off the platforms. 
Handles designed by the manufacturer for WBV platforms were used to support the 
participants during the WBV session (Figure 3.3 (a, b), page 116).  
WBV training sessions were undertaken at the CRF at SCH, so that clinical staff 
could intervene in case of any emergency. A maximum of two participants were 
allowed to be present in the vibration room at the same time. Participants were not 
allowed to eat or drink while standing on the vibration platform. Participants 
allocated to WBV were monitored at each WBV session and were asked to report 
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any side effects during or after the session. Participants who reported an adverse 
event were followed until the adverse event was resolved 
The radiation dose from HR-pQCT is negligible with an effective dose of only 3µSv 
per scan, which is less than the UK daily background radiation. All scans were 
performed by a trained operator (MAP).  
Pregnant and breast-feeding women were excluded. Female participants consented 
to take some measures to avoid pregnancy during the study, and to have a pregnancy 
test as required for this study. The procedure for managing adverse events complies 
with the Pharmacovigilance Standard Operating Procedures of the sponsor, 
Sheffield Children’s NHS Foundation Trust. The criteria set in advance to 
discontinue the trial were, if a subject experiences a serious adverse event (SAE) 
that it is considered at least possibly related to the study intervention. Nevertheless, 
no adverse events happened as a result of this study. 
3.14 Ethical approval  
The study was given a favourable ethical opinion by the South Yorkshire Research 
Ethics Committee (REC reference: 17/YH/0254). Health Research Authority 
(HRA) approval was obtain prior commencing the study (HRA reference: 225440). 
The local Capacity and Capability approvals were also obtained from SCH and 
NGH. The PhD student completed all research ethics forms and applied for all 
approvals with the assistance of the primary supervisor (ACO). The study was 
conducted in accordance with the International Conference for Harmonisation of 
Good Clinical Practice (ICH GCP), and the Research Governance Framework for 


























The primary aim of the current study was to determine the effects of a large single 
oral dose of vitamin D3 and 12 weeks of WBV on HR-pQCT parameters of the 
distal tibia. Participants in the current study were healthy male and female 
volunteers who emigrated from the MENA region to the UK.  Measurement 
variables included volumetric bone densities, bone microarchitecture, FEA of bone 
strength, vitamin D, bone profile, anthropometric measurements and calcium intake 
at baseline.  
4.1 Overview of recruitment, dropout and adherence  
4.1.1 Recruitment and dropout rates 
After writing the study protocol and getting it peer-reviewed, all study documents 
(attached as Appendices) were written and all ethics forms were completed in order 
to apply for the HRA approval. After gaining the HRA approval and the local 
research and development (R&D) approvals, recruitment began in October 2017. 
The target was to recruit the required sample size (n=40) within one year. In the 
event, recruitment was completed by March 2018, and all study visits were 
completed by the end of June 2018. Among the 77 subjects who were assessed for 
eligibility, 37 were excluded for various reasons (Figure 4.1, next page). Among 
the 40 participants who were enrolled and who underwent baseline assessment, two 
participants subsequently withdrew (5% dropout rate). Both of these participants 
were females, and provided no reason for not completing the study.  
4.1.2 Adherence  
All WBV sessions were supervised by the PhD student and adherence to WBV was 
recorded for every participant. The mean adherence to WBV training was 84% 
(range 66%–100%). All participants received either vitamin D or placebo. The 
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administration of vitamin D or placebo was witnessed and documented by the PhD 




















Figure 4.1: VibeD study profile 
Assessed for eligibility (n=77) 
Excluded (n= 37) 
Not meeting inclusion criteria (n= 20) 
Using vitamin D supplements (n= 7) 
Not of the required ethnicity (n= 5) 
Travel planned during the study (n= 4) 
Previous leg fracture (n= 2) 
Not willing to avoid pregnancy  (n= 2) 
 
No HR-pQCT scan at baseline (n=1) 
Declined to participate (n= 16) 
 
Allocation 
WBV Group  
 
Allocated to receive 
WBV and placebo 
(n=10) 
 Received the allocated 
intervention  




Placebo Group  
 
placebo only (n=10) 
 
 




Vitamin D Group  
 
Allocated to receive 
vitamin D only (n=10) 
 




Vitamin D +WBV 
Group  
Allocated to receive 
WBV and Vitamin D 
(n=10) 




Withdrawal (n= 0) 
 
Withdraw (n= 1) 
 No reason given 
 
Withdraw (n= 0) 
 
Withdraw (n= 1) 
 No reason given 
 
Analysed (n=10)  
 Excluded from 
analysis (n=0) 
Analysed (n=9) 
 Excluded from 
analysis (n=0) 
Analysed (n=10) 
 Excluded from 
analysis (n=0) 
Analysed (n=9) 
 Excluded from 
analysis (n=0) 
Randomisation (40)  
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4.2 Baseline characteristics of participants 
Participants were originally from 10 of the 20 countries identified as MENA 
countries, as described in Chapter 2, nearly two-thirds of whom were from just three 
countries (Saudi Arabia, Iraq and Libya), as illustrated in Table 4.1 (below).   
 
Table 4.1: Participants’ country of origin 
Country of origin Number (n=40) % 
Saudi Arabia 13 32.% % 
Iraq 7 17.5% 
Libya 6 15% 
Egypt 3 7.5% 
Syria 3 7.5% 
United Arab Emirates (UAE) 
 
2 5% 
Iran 2 5% 
Djibouti 2 5% 
Palestine 1 2.5% 







All baseline scans and blood samples were collected between November 2017 and 
March 2018. All participants had valid HR-pQCT scans at baseline and all 
participants who completed the study had valid HR-pQCT scans at the end of the 
study. Although it was possible to obtain a blood sample for one participant at the 
end of the study, a baseline blood sample was not obtained due to difficulty in 
finding a suitable site for venepuncture. PTH could not be measured for one 
participant due to an insufficient volume of blood.  
Table 4.2 (next page) summarises the baseline variables for the four groups and for 
the whole sample. There were similar numbers of males and females in each group. 
vitamin D only had lower calcium intake compared to the other groups. However, 
the corrected serum calcium level for this group was similar to that of the other 
groups. The median baseline total 25 (OH)D levels were in the category of vitamin 
D deficiency for all groups. Furthermore, results for individual participants showed 
that the majority were vitamin D deficient (25 (OH)D < 30 nmol/L) (Table 4.3, 
Page 144). In addition, a slightly elevated PTH was evident in all groups. Other 
biochemistry data were similar for all groups and were within the normal range, 
except for one participant who had a slightly lowered corrected calcium level and 











Table 4.2: Summary statistics are median, 25th/75th centiles, and range except for 
sex. Calculations subject to rounding errors 




Vit D  
(n=10) 







 22.4  
(18.6, 28.5) 
(18.5, 38.5) 
 32  
(30.3, 32.3) 
(20.1, 36.3) 
 29.3  
(19.1, 35.5) 
(18.5, 37.6) 








 5  
(50%) 
 5  
(50% 














 1.69  
(1.59, 1.75) 
(1.51, 1.80) 








 65.1  
(57.1, 89.1) 
(53, 125.3) 
 78.8  
(60.2, 86) 
(41.3, 111.3) 
 66.1  
(55.1, 76) 
(42, 116.1) 
 76.1  
(62.3, 94.10) 
(47.7, 100.2) 





 23.4  
(20.2, 26.9) 
(19.2, 37.4) 
 28.3  
(21.6, 30.3) 
(16.6, 37.8) 
 23.8  
(19.8, 26.3) 
(16.6, 35.8) 
 25.8  
(22.1, 33.1) 
(19.8, 38.6) 








 1037  
(967, 1320) 
(800, 1533) 
 1038  
(893, 1093) 
(785, 1597) 
 862  
(736, 1322) 
(514, 1685) 
 1029  
(818, 1274) 
(753, 1350) 





 15.5  
(11, 25) 
(10, 95) 
 28  
(16, 38) 
(12, 61) 
 22  
(12, 42) 
(10, 71) 
 23  
(17, 32) 
(13, 64) 

















 61.3  
(47.1,82.6) 
(28.7, 199.2) 








 2.27  
(2.14, 2.30) 
(2.13, 2.34) 
 2.24  
(2.17, 2.33) 
(2.14, 2.37) 











 1.2  
(1.04, 1.27) 
(0.96, 1.31) 
 1.16  
(1.01,1.29) 
(0.87, 1.32) 
 1.17  
(1.06, 1.27) 
(0.83, 1.59) 
Alk Phos (U/L)  57  
(44, 82) 
(36, 105) 
 69.5  
(49, 92) 
(46, 93) 
 56  
(52, 74) 
(41, 93) 
 60.5  
(49, 92) 
(44, 93) 
 59.5  
(49,87) 
(36, 105) 
Albumin (g/L)  44.5  
(43, 46) 
(41, 48) 
 44  
(44, 47) 
(42, 48) 
 44.5  
(42, 46) 
(42, 47) 
 45.5  
(44, 48) 
(41, 49) 




HR-pQCT parameters of the distal tibia 
 












 679  
(606, 760) 
(389, 1054) 
Cortical area (mm2) 122.4  
(113.9, 138.3) 
(100.3, 177.9) 
140   
(117.2, 152) 
(90.9, 176) 
 113.2  
(104.6, 180.2) 
(82.7, 209.8) 








 523.4  
(427, 541) 
(274, 885) 
 539.4  
(495.1, 625.8) 
(400.4, 882.3) 
 571.9  
(485.1, 685) 
(428.9, 852) 
 554.8  
(497.1, 578.4) 
(401.7, 698.1) 





 348.7  
(310.9, 365.8) 
(280.2, 396.4) 
 324.3  
(289.4, 345.7) 
(285.8, 367.6) 
 297.4  
(274.1, 369.3) 
(233.2, 425.4) 
 329.4  
(315.1, 350.6) 
(249.2, 435.7) 











 912.5  
(897.5, 937.5) 
(816.9, 950.2) 
 918.9  
(892.6, 950.6) 
(874.4, 959.1) 





 183.5  
(166.9, 227.2) 
(128.3, 262.7) 
 168.8  
(151.6, 194) 
(142.6, 218.5) 
 161.3  
(152.1, 227.9) 
(114.7, 266.7) 
 190.1  
(161, 196.3) 
(125.3, 243.1) 







 263.1  
(239,3, 283.7) 
(211.1, 309) 
 241.4  
(223.2, 250.3) 
(205, 284) 
 221.1  
(202.9, 312.9) 
(162, 330.7) 








 138.1  
(117.5, 181.3) 
(71.7, 231.2) 
 120.4  
(114.5, 157.7) 
(96.3, 180.9) 
 123.4  
(113.1, 170.1) 
(82.5, 232.1) 
 146.1  
(114.7, 146.7) 
(77.5, 197.5) 
 132.9  
(114, 172.1) 
(71.7, 232.1) 
Meta inner trabecular 
density 
(no units) 












 1.83  
(1.65, 2.03) 
(1.34, 2.95) 
Trabecular BV/TV (no 
units)   
 0.15  
(0.14, 0.19) 
(0.10, 0.22) 
 0.14  
(0.13, 0.16) 
(0.11, 0.18) 
 0.13  
(0.13, 0.19) 
(0.09, 0.22) 
 0.16  
(0.13, 0.16) 
(0.10, 0.20) 





 1.81  
(1.46, 2.23) 
(1.30, 2.57) 
 1.93  
(1.62, 2.15) 
(1.53, 2.32) 
 2.03  
(1.67, 2.30) 
(1.30, 2.53) 
 1.83  
(1.49, 2.01) 
(1.13, 2.53) 
 1.91  
(1.6, 2.23) 
(1.13, 2.57) 
Trabecular  thickness 
(mm) 
 0.09  
(0.08, 0.10) 
(0.06, 0.10) 
 0.08  
(0.07, 0.08) 
(0.06, 0.09) 
 0.08  
(0.07, 0.09) 
(0.05, 0.10) 
 0.08  
(0.08, 0.09) 
(0.05, 0.11) 





 0.47  
(0.37, 0.59) 
(0.30, 0.66) 
 0.44  
(0.39, 0.54) 
(0.36, 0.57) 
 0.42  
(0.36, 0.52) 
(0.30, 0.68) 








of trabecular number) 
 0.21  
(0.16, 0.26) 
(0.12, 0.35) 
 0.19  
(0.17, 0.24) 
(0.15, 0.27) 
 0.17  
(0.15, 0.23) 
(0.13, 0.32) 
 0.2  
(0.19, 0.26) 
(0.12, 0.39) 





 1.23  
(1.1, 1.39) 
(1.05, 1.74) 
 1.26  
(1.15, 1.48) 
(1.05, 1.70) 
 1.18  
(1.11, 1.63) 
(0.77, 1.68) 
 1.29  
(1.21, 1.61) 
(1.04, 1.81) 





 98.3  
(90.6, 102.5) 
(75.9, 126.7) 
 104.9   
(97.9, 107) 
(86.7, 125.4) 
 105.1  
(94.8, 114.5) 
(89.4, 129.1) 
 102.3    
(96, 107.9) 
(88.2, 118) 
 102  
(95.8, 108) 
(75.9, 129.1) 
Cortical porosity  
(no units) 
 0.02  
(0.02, 0.04) 
(0.008, 0.05) 
 0.03  
(0.02, 0.04) 
(0.01, 0.05) 
 0.02  
(0.02, 0.05) 
(0.008, 0.06) 












 2.71  
(1.58, 4.52) 
(0.84, 6.72) 
 2.05  
(1.79, 3.36) 
(1.12, 4.58) 





 0.16  
(0.15, 0.17) 
(0.14, 0.16) 
 0.16  
(0.15, 0.17) 
(0.14, 0.21) 
 0.16  
(0.15, 0.17) 
(0.14, 0.19) 
 0.16  
(0.15, 0.18) 
(0.11, 0.21) 
 0.16  
(0.15, 0.17) 
(0.11, 0.21) 
SD mean cortical 
diameter 
(µm) 
 0.06  
(0.06, 0.07) 
(0.05, 0.08) 
 0.07  
(0.06, 0.08) 
(0.05, 0.11) 
 0.06  
(0.06, 0.08) 
(0.05, 0.08) 






Cortical tissue density 
(mg/ccm) 
 1034  
(1019, 1041) 
(976, 1049) 
 1036  
(1021, 1048) 
(1004, 1075) 
 1036  
(1021, 1048) 
(955, 1068) 











 0.28  
(0.16, 0.39) 
(0.08, 0.78) 
 0.25  
(0.13, 0.47) 
(0.10, 0.82) 
 0.19  
(0.15, 0.29) 
(0.07, 0.32) 
 0.28  
(0.15, 0.35) 
(0.07, 1.03) 
Stiffness (KN/mm)  212.1  
(197.9, 290.3) 
(155.9, 344.8) 
 241.1  
(196.3, 256.3) 
(151.2, 336.5) 
 200.1  
(183.3, 312.2) 
(171.4, 413.7) 
 248.2  
(198.2, 286.9) 
(172.7, 307.4) 
 228.6  
(192.3, 288.6) 
(151.2, 413.7) 
Estimated failure load 
(KN) 
 10.5  
(9.8, 14.2) 
(7.8, 17.3) 
 12.1  
(9.9, 12.7) 
(7.5, 16.9) 
 10.1  
(9.0, 14.6) 
(8.6, 20.4) 
 10  
(8.9, 12.4) 
(8.6, 15.1) 
 11.6  
(9.6, 14.2) 
(7.5, 20.4) 
Distal trabecular ratio 
load (%) 
 61.3  
(52.8, 65.7) 
(26.2, 74.6) 
 54.5  
(49.9, 64.4) 
(46.9, 69.8) 
 54.4  
(52.7, 64.9) 
(46.1, 69.6) 
 56.5  
(51.6, 59.4) 
(47.7, 63.9) 




ratio load (%) 
 38.5  
(30.4, 41.3) 
(14.9, 52.3) 
 31.1  
(28.9, 40.1) 
(27.4, 47.7) 
 34.8  
(31.2, 40.1) 
(25.4, 47.3) 
 34.9  
(30.2, 38.7) 
(26.1, 40.8) 








Table 4.3: Classification of vitamin D levels at baseline 
Category  Serum 25 (OH) 
Level  
Number*  % 
Deficiency   < 30 nmol/L 26 65% 
Insufficiency 30 to 50 nmol/L 7 17.5% 
Sufficiency  > 50 nmol/L 6 13% 
 


















4.3 Group variables at baseline and after 12 weeks  
Group variables at baseline and after 12 weeks are presented as box-and-whisker 
plots showing the median, interquartile range and any outliers.  
 
4.3.1 HR-pQCT parameters  
Cortical and trabecular areas  
Cortical area and trabecular area at baseline and post-intervention for all groups are 
shown in Figure 4.2 (below). 
 
  
Figure 4.2: Cortical area (left image) and trabecular area (right image) by randomization 













Total, cortical and trabecular densities 
The total volumetric density at baseline and post-intervention for all groups are 
shown in Figure 4.3 (below). Cortical density (Figure 4.4) and trabecular density 
(Figure 4.5) are also shown below.  
  
              
 
 







Figure 4.3: Total density by 
randomization group 




Trabecular bone microarchitecture 
Trabecular bone parameters at baseline and at 12 weeks for all groups are 
summarised in the following figures (Figures 4.6 to 4.13). These parameters 
included meta trabecular density, inner meta trabecular density, meta/inner 
trabecular density, trabecular bone volume/tissue volume (BV/TV), trabecular 
number, trabecular thickness, trabecular separation and trabecular inhomogeneity. 
 
                                                                       
 
   
 
 




Figure 4.6: Meta trabecular density by 
randomization group. 
 
Figure 4.7: Inner meta trabecular 
density by randomization group 
 
Figure 4.8: Meta/inner trabecular 
density ratio by randomization group 























Figure 4.11: Trabecular number by 
randomization group.  
Figure 4.10: Trabecular thickness by 
randomization group. 
Figure 4.13: Trabecular separation by 
randomization group 




Cortical bone microarchitecture 
Cortical bone microarchitecture at baseline and at 12 weeks for all groups are 
summarised in the following figures (Figures 4.14 to 4.21). These parameters 
included cortical thickness, cortical perimeter, cortical porosity, mean cortical 
diameter, SD of mean cortical diameter, cortical tissue mineral density and 
connectivity density.  
 




    
  








Figure 4.15: Cortical thickness by 
randomization group. 
Figure 4.14: Cortical perimeter by 
randomization group 
Figure 4.17: Cortical porosity by 
randomization group 
Figure 4.16: Percentage (%) of cortical 





















Figure 4.18: Cortical diameter by 
randomization group. 
Figure 4.19: SD of mean cortical diameter 
by randomization group 
Figure 4.21: Cortical tissue mineral density 
by randomization group 




FEA Analysis outcome 
FEA model was applied to estimate bone strength. FEA analysis outcome 
measures include stiffness, estimated failure load, distal ratio load and proximal 
ratio load. The changes in these parameters are summarised in Figures 4.22 to 


















Figure 4.23: Estimated ultimate failure load 
by randomization group.  
Figure 4.22: Stiffness by randomization 
group.  
Figure 4.24: Distal ratio of the load taken 
by the trabeculae in relation to the total 
load by randomization group. 
Figure 4.25: Proximal ratio of the load 
taken by the trabeculae in relation to the 
total load by randomization group 
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4.3.2 Anthropometric data 
Height and weight were recorded at baseline and at the final study visit in order to 
calculate the BMI as described in Chapter 2. Weight and BMI at baseline and at 12 
weeks for all groups are summarised below (Figure 4.26 and Figure 4.27, below).  
 
 











4.3.3 Biochemical parameters 
Biochemistry included total serum 25 (OH) D (Figure 4.28, below), PTH (Figure 
4.29, below) and bone profile. Bone profiles (corrected calcium, phosphate, alkaline 










Figure 4.28: Total 25 (OH) D by 
randomization group. 
Figure 4.29: PTH by randomization group.  
154 
 
       
       
    
 












Figure 4.33: Alkaline phosphatase by 
randomization group. Alkaline phosphatase 
levels were within the normal range (30–130 
U/L) at baseline and at 12 weeks for all 
groups.   
Figure 4.32: Albumin by randomization 
group. Albumin levels were within the 
normal range (35–50 g/L) at baseline and 
after 12 weeks for all participants. 
Figure 4.30: Corrected calcium by 
randomization group. One subject was 
slightly hypocalcemic at baseline and 
another subject was hypocalcemic after 
12 weeks. Patients’ general practitioners 
were informed of these results. 
Figure 4.31: Phosphate by 
randomization group.  
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4.4 Change in HR-pQCT parameters over 12 weeks  
 
Cortical area 
No significant changes were found in any group after 12 weeks (Table. 4.4 and 
Figure 4.34, below).   
Table 4.4: Cortical area change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline cortical 
area, baseline PTH, baseline 25(OH) D and baseline BMI.  
Randomization 
group 
Mean change 12 




Placebo ) with 95% 
CI (mm2) 
p-value 
Placebo  -0.05 Reference  
WBV 0.63 0.68(-0.54,1.91) 0.26 
Vit D  0.81 0.86(-0.40,2.13) 0.17 
Vit D +WBV  0.87 0.92(-0.29,2.14) 0.13 
F [3,28]=0.98 
p=0.41 
   
 
 
Figure 4.34: Percentage change in cortical area from baseline. 





No significant changes were found in any group after 12 weeks (Table 4.5, and 
Figure 4.35, below).  
Table 4.5: Trabecular area change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline trabecular 
area, baseline PTH, baseline 25(OH)D and baseline BMI.   
Randomization 
group 





Placebo) with 95% 
CI (cm2) 
p-value 
Placebo  -0.49 Reference  
WBV -1.04 -0.54(-5.19,4.1) 0.81 
Vit D  -1.69 -1.2(-6.04,3.63) 0.61 
Vit D +WBV  1.35 1.85(-2.8,6.51) 0.42 
F [3,28]=0.61, 
p=0.61 
   
 
 
Figure 4.35: Percentage change in trabecular area from baseline. 








A weak but significant association was found between vitamin D (Vit D group) and 
total density (p = 0.05) (Table 4.6, Figure 4.36, below). 
Table 4.6: Total density change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline total 
density, baseline PTH, baseline 25(OH) D and baseline BMI.  
Randomization 
group 
Mean change 12 




Placebo) with 95% 
CI (mg/cm3) 
p-value 
Placebo  -1.15 Reference  
WBV 1.02 2.17(-0.45,4.8) 0.10 
Vit D  1.54 2.7(-0.00,5.41) 0.05 
Vit D +WBV  0.36 1.51(-1.08,4.12) 0.24 
F [3,28]=1.54, 
p=0.22 
   
 
 
Figure 4.36: Percentage change in total density from baseline.  








No significant changes were observed in any group at 12 weeks 
Table 4.7: Cortical density change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline cortical 
density, baseline PTH, baseline 25(OH)D and baseline BMI.  
Randomization 
group 
Mean change 12 




Placebo) with 95% 
CI (mg/cm3) 
p-value 
Placebo  -0.36 Reference  
WBV 0.92 1.28(-3.01,5.59) 0.54 
Vit D  1.19 1.56(-2.94,6.07) 0.48 
Vit D +WBV  -0.25 0.11(-4.14,4.37) 0.95 
F [3,28]=0.25, 
p=0.85 
   
 
 
Figure 4.37: Percentage change in cortical density from baseline.   














No significant changes were observed in any group at 12 weeks.  
Table 4.8: Trabecular density change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline trabecular 
density, baseline PTH, baseline 25(OH)D and baseline BMI.  
Randomization 
group 
Mean change 12 




Placebo) with 95% 
CI (mg/cm3) 
p-value 
Placebo  -0.8 Reference  
WBV -0.11 0.69(-1.12,2.5) 0.44 
Vit D  0.41 1.21(-0.65,3.08) 0.19 
Vit D +WBV  0.15 0.95(-0.81,2.72) 0.27 
F [3,28]=0.69, 
p=0.85 
   
 
 
Figure 4.38: Percentage change in trabecular density from baseline.   







No significant changes in trabecular number were found at 12 weeks in any group 
(Table 4.9 and Figure 4.39, below).   
Table 4.9: Trabecular number change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline trabecular 
number, baseline PTH, baseline 25(OH)D and baseline BMI.  
Randomization 
group 





Placebo) with 95% CI 
(1/mm) 
p-value 
Placebo  0.0017 Reference  
WBV -0.035 -0.0367(-0.158,0.085) 0.54 
Vit D  0.0298 0.028(-0.112,0.168) 0.68 
Vit D +WBV  0.0163 0.0.145(-0.105,0.134) 0.80 
F [3,28]=0.50, 
p=0.68 
   
 
 
Figure 4.39: Percentage change in trabecular number from baseline.   








No significant changes in trabecular separation were found (Table 4.10 and Figure 
4.40, below).  
Table 4.10: Trabecular separation change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline trabecular 
separation, baseline PTH, baseline 25(OH)D and baseline BMI.  
Randomization 
group 





Placebo) with 95% CI 
(mm) 
p-value 
Placebo  0.0001 Reference  
WBV 0.0104 0.0102(-0.0206,0.0412) 0.50 
Vit D  -0.0122 -0.0123(-0.0466,0.0219) 0.46 
Vit D +WBV  -0.0083 -0.0084(-0.0393,0.0223) 0.57 
F [3,28]=1.00, 
p=0.40 
   
 
 
Figure 4.40: Percentage change in trabecular separation from baseline.   







No significant changes in trabecular thickness were found (Table 4.11 and Figure 
4.41, below).  
Table 4.11: Trabecular thickness change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline trabecular 
thickness, baseline PTH, baseline 25(OH) D and baseline BMI.  
Randomization 
group 
Mean change 12 
weeks to 
baseline (mm) 
Adjusted mean difference 
(from Placebo ) with 95% 
CI (mm) 
p-value 
Placebo  -0.0012 Reference  
WBV 0.0008 0.002(-0.0045,0.0086) 0.52 
Vit D  -0.0004 0.0007(-0.006,0.007) 0.81 
Vit D +WBV  -0.0037 -0.0025(-0.0089,0.0039) 0.43 
F [3,28]=0.73, 
p=0.54 
   
 
 
Figure 4.41: Percentage change in trabecular thickness from baseline.   








No significant changes in cortical thickness were found (Table 4.12 and Figure 
4.42, below).  
Table 4.12: Cortical thickness change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline cortical 
thickness, baseline PTH, baseline 25(OH)D and baseline BMI.  
Randomization 
group 
Mean change 12 
weeks to 
baseline (mm) 
Adjusted mean difference 
(from Placebo) with 95% 
CI (mm) 
p-value 
Placebo  -0.0008 Reference  
WBV 0.0054 0.0063(-0.0043,0.0169) 0.23 
Vit D  0.0073 0.0082(-0.0028,0.0192) 0.13 
Vit D +WBV  0.0083 0.0091(-0.0014,0.0197) 0.08 
F [3,28]=1.23, 
p=0.31 
   
 
 
Figure 4.42: Percentage change in cortical thickness from baseline.    







Cortical tissue mineral density 
No significant changes in trabecular thickness were found (Table 4.13 and Figure 
4.43, below).  
Table 4.13: Cortical tissue mineral density change from baseline: regression 
analysis by randomization group. . Means and their differences adjusted by 
baseline cortical tissue mineral density, baseline PTH, baseline 25(OH)D and 
baseline BMI.  
Randomization 
group 
Mean change 12 
weeks to baseline 
(mg/ccm) 
Adjusted mean difference 
(from Placebo) with 95% 
CI (mg/cm) 
p-value 
Placebo  -2.4 Reference  
WBV -2.29 0.10(-9.16,9.36) 0.98 
Vit D  3.21 5.61(-4.09,15.31) 0.24 
Vit D +WBV  -0.78 1.61(-7.8,11.03) 0.72 
F [3,28]=0.71, 
p=0.55 
   
 
 
Figure 4.43: Percentage change in cortical tissue mineral density from baseline.    





Cortical porosity (%) 
No significant changes in cortical porosity were found (Table 4.14 and Figure 
4.44, below).  
 
Table 4.14: Cortical porosity (%) change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline cortical 
porosity (%) baseline PTH, baseline 25(OH)D and baseline BMI.  
Randomization 
group 
Mean change 12 
weeks to 
baseline (%) 
Adjusted mean difference 
(from Placebo) with 95% 
CI (%) 
p-value 
Placebo  0.0142 Reference  
WBV 0.0338 0.0196(-0.325,0.365) 0.90 
Vit D  -0.0826 -0.096(-0.458,0.264) 0.58 
Vit D +WBV  0.0001 -0.014(-0.362,0.334) 0.93 
F [3,28]=0.19, 
p=0.90 
   
 
 
Figure 4.44: Percentage change in cortical porosity from baseline.    







No significant changes in stiffness were found in any group at 12 weeks (Table 
4.15 and Figure 4.45, below). 
Table 4.15: Stiffness change from baseline: regression analysis by randomization 
group. Means and their differences adjusted by baseline stiffness, baseline PTH, 




Figure 4.45: Percentage change in stiffness from baseline.    






Mean change 12 
weeks to baseline 
(Kn/mm) 
Adjusted mean difference 
(from Placebo) with 95% 
CI (Kn/mm) 
p-value 
Placebo  -0.12 Reference  
WBV 0.66 0.78(-2.78,4,35) 0.65 
Vit D  -0.56 -0.44(-4.15,3.27) 0.80 
Vit D +WBV  -0.74 -0.62(-4.19,2.93) 0.72 
F [3,28]=0.29, 
p=0.83 





Estimate failure load 
 No significant changes were found in any group at 12 weeks (Table 4.16 and Figure 
4.46, below). 
Table 4.16: Estimate failure load change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline estimated 
failure load, baseline PTH, baseline 25(OH)D and baseline BMI.  
Randomization 
group 
Mean change 12 
weeks to 
baseline (KN) 
Adjusted mean difference 
(from Placebo) with 95% 
CI (KN) 
p-value 
Placebo  0.030 Reference  
WBV 0.031 0.001(-0.27,0.27) 0.99 
Vit D  0.072 0.042(-0.24,0.32) 0.76 
Vit D +WBV  0.0047 -0.025(-0.29,0.24) 0.85 
F [3,28]=0.08, 
p=0.96 
   
 
 
Figure 4.46: Percentage change in estimate failure load from baseline.    





4.5 Change in serum 25(OH)D and PTH levels over 12 weeks  
 
Total 25(OH)D 
Significant increases were found in two groups, vitamin D group and vitamin D+ 
WBV group at the end of the study in comparison with the placebo group (p= 0.001 
and p= 0.007, respectively) (Table 4.17 and Figure 4.47).  
Table 4.17: Total 25(OH)D change from baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline value 









Placebo) with 95% 
CI (nmol/L) 
p-value 
Placebo  -3.14 Reference  
WBV -2.53 0.61(-9.47,10.7) 0.90 
Vit D  20.14 23.29(12.80,33.77) 0.001 
Vit D +WBV  10.90 14.05(3.98,24.13) 0.0079 
F [3,29]= 11.05, 
p=0.0001 
   
 
 
Figure 4.47: Percentage change in serum 25(OH) D from baseline.    





A significant decrease in PTH level after 12 weeks was found in vitamin D only 
group in response to 150,000 IU of vitamin D3 (Table 4.18, and Figure 4.48)  
Table 4.18: PTH change from 12 weeks to baseline: regression analysis by 
randomization group. Means and their differences adjusted by baseline PTH plus 
baseline 25(OH)D and baseline BMI.  
Randomization 
group 





Placebo) with 95% 
CI (ng/L) 
p-value 
Placebo  27.94 Reference  
WBV 2.73 -25.21(-54.65,4.21) 0.09 
Vit D  -11.61 -39.55(-70.14,-8.97) 0.013 
Vit D +WBV  11.21 -16.73(-46.12,12.65) 0.09 
F [3,29]=2.38, 
p=0.09 
   
 
 
Figure 4.48: Percentage change in serum PTH from baseline.    




4.6 Estimates of effect size 
 
Table 4.19: Estimates of effect size from linear regression as described previously. 
Outcome measures  
12 weeks-baseline 
Effect size n/group* 
25(OH)D nmol/L 0.691 34 
PTH ng/L 0.443 82 
Total density mg/cm3 0.333 145 




*n/group makes no allowance for loss-to-follow-up. 80% power, 5% significance (2-
tailed).  For 90% power (5% significance, 2-tailed) multiply n/group by 1.33. 
 
 
4.7 Safety assessment  
4.7.1 Vitamin D safety  
Second void urine Samples were available for 37 participants. The sample for one 
participant was lost in the testing laboratory and one participant withdrew from the 
study without providing a sample. This participant was given the option to provide 
the sample without continuing in the study, but declined to do so. In addition, one 
sample was excluded because the participant did not follow the correct instructions 
in providing the sample (the last page in Appendix i). This participant was requested 
to provide another sample but declined. Therefore, 37 samples were available for 
analysis. No hypercalciuria was detected in any subject. The average 
calcium:creatinine ratio was 0.18 mmol/mmol creatinine (range 0.04-0.42), (lab 
reference = 0.00-0.70 mmol/mmol creatinine).   
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4.7.2 WBV safety  
No serious adverse events were reported. However, some mild adverse events were 
reported in the first few weeks after starting WBV training (Table 4.20, below). The 
WBV protocol was well tolerated by the study population.  
 
4.7.3 Mild adverse events 










Reassured the participant, gave cold water to drink, 
and sat the participant in a comfortable position 




during or just 
after WBV) 
19 
Participants were monitored at each WBV session. 
This symptom disappeared by the end of the second 
week of WBV for 6 participants, by the end of the 
third week for 11 participants, and by the end of the 























   
   
Figure 4.49: Left tibia of a 19-year-old female volunteer who was randomised to the 
vitamin D and WBV group. a: axial 2D image slice, b: reconstructed 3D image.  
 
Baseline: Tot.vBMD=329.6 mg/cm3, Ct.vBMD= 920.9 mg/cm3, Tb.vBMD = 161 mg/cm3 











       
   
Follow-up: 
    
Figure 4.50: Left tibia of a 30-year-old male volunteer who was randomised to the to the 
vitamin D and WBV group. a: axial 2D image slice, b: reconstructed 3D image.  
 
Baseline: Tot.vBMD=343.4 mg/cm3, Ct.vBMD=907.8 mg/cm3, Tb.vBMD=194.7 mg/cm3  





































































The current study was primarily aimed at determining the effect of a large dose of 
vitamin D and 12 weeks of high intensity WBV on HR-pQCT parameters of the 
distal tibia, and to compare and contrast this to the effect of vitamin D alone, WBV 
alone, and no intervention.  In addition, the current study aimed to determine the 
effect of a large dose of vitamin D and 12 weeks of high intensity WBV on the 
levels of serum 25 (OH)D and serum PTH, and to compare such an effect to the 
effect of vitamin D alone, WBV alone or no intervention. Furthermore, the current 
study aimed to assess the safety of both the large dose of vitamin D and the high 
intensity WBV on an apparently healthy adult MENA population who live in the 
UK. In order to achieve the study’s aims and objectives, four groups of participants 
of equal number were created with the same number of males and females in each 
group. The study groups received one of the following treatments: WBV alone, 
placebo, vitamin D alone or vitamin D and WBV. To our knowledge, this is the first 
study to investigate the combined effect of vitamin D and WBV on bone density, 
microarchitecture and strength using this design. In addition, to the best of our 
knowledge, the current study is the first study to determine HR-pQCT parameters 
alongside serum levels of vitamin D, PTH and bone profile as part of a wider 
assessment of the impact of these interventions.  
The main finding of this study is that there were no significant effects of WBV and 
vitamin D on bone density, microarchitecture or bone strength parameters after 12 
weeks. However, a non-significant increase in total bone density in all treatment 
groups relative to controls was found. In addition, a weak correlation was found 
between vitamin D + WBV and an increase in cortical thickness. In contrast with 
three previous RCTs, which examined the effect of WBV and vitamin D on bone 
density, the results of the current study is consistent with two studies (Slatkovska 
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et al., 2011, Kiel et al., 2015), which found no effect of WBV and daily vitamin D 
on bone density after 12 and 24 months, respectively. However, the result of the 
current study is not consistent with another study, which reported a significant 
improvement in hip BMD after 6 months of WBV and daily vitamin D and calcium 
(Verschueren et al., 2011). However, in this latter study (Verschueren et al., 2011), 
WBV and vitamin D were not superior to vitamin D alone as significant 
improvements were also reported in the group that received vitamin D with no 
WBV.  It should be noted though, that participants in Verschueren et al. (2011) 
performed dynamic exercises while standing on the platform, which caused it to be 
extremely difficult - if not impossible - to distinguish between the effect of WBV 
and the effect of dynamic exercises.  
It should also be noted that all these previous studies (Slatkovska et al., 2011, 
Verschueren et al., 2011, Kiel et al., 2015) included no control group for vitamin 
D. Therefore, the effect of vitamin D alone on bone density was not ascertained 
against control group. Furthermore, these three studies used a daily vitamin D 
dosing regime and allowed the adherence to the regime to be self-reported. Our trial 
thus contains major differences from these previous studies. We have included a 
group with no treatment that served as a control for all study groups. Moreover, our 
study used one large dose administered orally under direct supervision instead of 
the daily dosing regimen.  In addition, our study determined serum 25(OH)D, PTH 
and bone profile at baseline and at the end of the study alongside HR-pQCT 
scanning parameters. Another key difference is that our study used high intensity 
WBV protocol with a higher compliance (84%) than the three previous trials. 




In comparison with exercise trials that used vitamin D as co-intervention, the result 
of our study is similar to the result of another trial, which showed no effect of 
calcium–vitamin-D3-fortified milk plus exercise in improving bone density in older 
males (50 -79 years) after 12 and 18 months (Kukuljan et al., 2009, Kukuljan et al., 
2011). However, our results differ from those of another study which found that 
military training and calcium and vitamin D supplementation significantly 
improved volumetric bone mineral density at the tibia compared to exercise alone 
in 46 military recruits (Gaffney-Stomberg et al., 2014). It may be that this difference 
is due to the difference between military training and the WBV protocol that was 
used in our study in terms of the intensity and duration of the exercise.  
Although our study used the most advanced technique for high-resolution imaging 
of bone, namely HR-pQCT, to determine the effect of the intervention, our study 
did not find significant improvements in HR-pQCT parameters of the distal tibia in 
response to WBV and vitamin D or WBV alone. However, a weak correlation was 
found between the administration of 150,000 IU of vitamin D3 and an improvement 
in total density of the distal tibia after 12 weeks relative to control group. This 
increase in total density was borderline for statistical significance (p=0.05). Several 
previous trials have found significant effects of both conventional and large doses 
of vitamin D on areal bone density (Dawson-Hughes et al., 1995, Ooms et al., 1995, 
Islam et al., 2010, Macdonald et al., 2013, Dawson-Hughes et al., 1991). However, 
these trials ran over a longer period than our trial (12 months to 24 months). The 
current study indicates that the benefits of vitamin D supplementation might be 
more pronounced after only 12 weeks when using high-resolution imaging to 
determine the effect of vitamin D on bone density. 
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Our results found a weak association between administering high doses of vitamin 
D and an improvement in total density of the distal tibia. In contrast, Harwood et 
al. (2004), showed significant improvement in lumber spine and hip BMD after 
administering a high dose of vitamin D2. However, two previous studies showed 
no significant effects of large doses of vitamin D on bone density (Jorde et al., 2010, 
Reid et al., 2017). This variation in the outcomes may have been caused by the 
baseline serum 25(OH)D levels of participants in these studies. For instance, most 
of the participants in our study and in Harwood et al. (2004) were vitamin D 
deficient compared to the other two studies where most participants were vitamin 
D sufficient at baseline (Jorde et al., 2010, Reid et al., 2017). This finding is 
consistent with two previous reviews, which reported that the effect of vitamin D 
supplementation on bone density is determined by baseline vitamin D levels (Reid 
et al., 2014, Winzenberg et al., 2011). It should be noted that our study did not show 
any meaningful changes in other HR-pQCT parameters in response to the large dose 
of vitamin D. In contrast, Lima et al. (2018) reported a significant increase in the 
trabecular number and a decrease in trabecular separation in response to vitamin D 
dose of 50,000 IU/week for 24 weeks in juvenile-onset systemic lupus 
erythematosus (JoSLE) patients. The reason our study did not report these changes 
may have been due to the shorter duration of the intervention or perhaps due to the 
difference in vitamin D dosing strategy between the trials. This is purely conjecture 
however, since trials investigating the effect of vitamin D supplementation on HR-
pQCT parameters are very limited.   
In terms of the WBV alone intervention, this did not lead to significant 
improvement in bone density, strength and microarchitecture after 12 weeks.  This 
finding is consistent with several previous studies which reported no overall 
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positive effect of WBV on bone density. For instance, the result of the current study 
is consistent with Liphardt et al. (2015), who used HR-pQCT to investigate the 
effect of high intensity WBV for 12 months in 42 healthy postmenopausal women 
and found no significant effect on bone microarchitecture and strength despite the 
fact that our study recruited younger population and used higher intensity and 
higher frequency WBV protocol. This suggests that it is not easy to define an 
effective WBV protocol or identify a target population that can benefit most from 
WBV.  
In spite of the fact that our study accounted for vitamin D deficiency and included 
vitamin D as a co-intervention, there were still no advantages for WBV with vitamin 
D as an intervention. However, the current study measured the effect of the 
intervention at one skeletal site (the distal tibia). Some studies, which measured 
bone density at other skeletal sites, have shown positive effects of WBV on bone 
density. For instance, Lai et al. (2013) found a significant improvement in DXA 
lumbar spine BMD after 6 months of WBV. It possible that a significant effect 
might have been present in lumber spine in our cohort. However, due to the limited 
duration of our study, changes in areal BMD may not have had time to occur. 
Furthermore, due to the limited finical resources in our study, measurements were 
limited to one skeletal site (the distal tibia) and one modality (HRpQCT). 
Apart from the correlation found between the high dose of vitamin D and the 
increase in total density, it is important to highlight that we did not witness 
significant changes in any of the other HR-pQCT parameters in any group. The 
small sample size of the current trial may have hindered our ability to detect 
statistically significant changes or it could be true a finding i.e. that there is no 
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significant effect of WBV and vitamin D on bone. Since there was no similar 
previous WBV study to our study with four arms (as far as we know), it is hard to 
compare these results with any from the literature. Future trials in this area based 
on power calculation are therefore recommended. This current study will provide a 
foundation to enable such larger trials.  
 As was predicted, the majority of participants were vitamin D deficient at baseline 
(serum 25(OHD) < 30 nmo/L). The median serum total 25 (OH)D was 23 nmol/L 
for all samples, and all four groups were considered vitamin D deficient at baseline. 
This finding is constant with the literature, which reports widespread vitamin D 
deficiency among MENA populations (Fuleihan and Deeb, 1999, Meddeb et al., 
2005, Saadi et al., 2006, Elsammak et al., 2010, Botros et al., 2015, Chakhtoura et 
al., 2018). As a consequence of this vitamin D deficiency, the participants’ serum 
PTH levels were slightly elevated. These are worrying findings as having a low 
vitamin D level and high PTH over a long period may lead to poor musculoskeletal 
health. What is more worrying is the fact that we recruited apparently healthy 
adults, most of whom were attending university and thus may be supposed as having 
some awareness from the media about the importance of vitamin D to their bone 
health. Vitamin D deficiency is therefore likely to be more common in the MENA 
population who may have limited access to the information about vitamin D and 
health. It is therefore recommended that further steps be taken to address this issue 
and to increase the awareness of the importance of vitamin D for the health of the 
MENA population living in the UK. This could be done in collaboration with GPs, 
community leaders’ and school and university societies. Introducing screening 
programmes for individuals at risk of vitamin D deficiency may also be a good 
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strategy to tackle this issue, but such a programme would be associated with an 
increased financial burden to the health services.  
Moving now to the results related to the use of a large dose of vitamin D and its 
effect on serum 25(OH) and PTH. This was effective in increasing vitamin D levels 
even 12 weeks after administration. Serum 25 (OH)D levels increased significantly 
in the two groups that received vitamin D (vitamin D only and vitamin D+WBV). 
The increase in total 25(OH) D was 20.14 nmol/L (p= 0.001 relative to the Placebo 
group) in vitamin D group and 10.90 (p=0.0079 nmol/L relative to the Placebo 
group) in vitamin D+WBV group. This finding is consistent with the literature, 
which indicates that a single large dose of vitamin D is effective in increasing 
vitamin D levels in individuals with low vitamin D. For instance, Gopal‐
Kothandapani et al. (2018) found a single dose of vitamin D3 (150,000 IU, similar 
to our dose) increased 25(OH)D levels by around 56 nmol/L, 4 weeks after dosing 
in a cohort of Caucasian and Asian adults. Our study measured serum 25 (OH)D 
levels at week 13 after dosing and the effect of vitamin D was still significant at this 
time point. Although vitamin D rose in among the volunteers who received both 
WBV and vitamin D, we found that the increase in serum 25(OH)D level was lower 
than the increase found the volunteers who received who received vitamin D only.  
This difference in circulating serum 25(OH)D between the active / non-active 
groups who received vitamin D has been found in a previous exercise trial 
(Kukuljan et al., 2009). Despite the fact that the baseline levels of vitamin D in our 
cohort were greatly lower than the cohort recruited in this trial, (Kukuljan et al., 
2009) found around 50% greater increase in the absolute change in serum 25(OH)D 
in the group that received vitamin D only compared to the group who received 
vitamin D and did undertake exercise. This suggests that WBV and vitamin D may 
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have the same effect of exercise and vitamin D on serum 25(OH)D status. There 
could therefore be an interaction between physical stimulation and vitamin D which 
leads to a reduction in the circulating serum 25(OH)D. However, the mechanism of 
such proposed interaction is not clear.  
Another key finding is that PTH decreased significantly in vitamin D group. 
(decreased by 11.61 ng/L at week 13 after administrating the large dose of vitamin 
D). Due to the low vitamin D levels at baseline among our cohort, vitamin D dose 
used in our study might not have been high enough to cause a sharp decrease in 
PTH level. It has been reported that higher doses of vitamin D in the range of 
200,000 to 300,000 IU may be required to effectively suppress PTH levels (Kearns 
et al., 2013). However, previous studies reported adverse events after administering 
200,000 IU of vitamin D2 (Tellioglu et al., 2012) and 300,000 IU of vitamin D3 
(Premaor et al., 2008) such as gastrointestinal complications. Thus, the current 
study attempted to strike a balance between the safety of vitamin D and effectively 
increasing serum 25(OH)D and therefore it was felt that 150,000 IU was a suitable 
dose on the basis of doses used in previous studies. This high dose of vitamin D 
was well tolerated. No adverse events were found in any participant as a result of 
administrating 150,000 IU of vitamin D3. Although this is consistent with some 
previous studies that used the same dose and reported no adverse events (Oliveri et 
al., 1996, Gopal‐Kothandapani et al., 2018), the ethnicity of the participants in the 
current study is different from the ethnicities in the two previous studies.  Therefore, 




WBV alone led to only a slight increase in PTH level. This is somewhat similar to 
the finding reported by (Kukuljan et al., 2011): a reduction in PTH level in response 
to exercise alone. However, this study lasted for 18 months while our study lasted 
for far less time - 3 months only. A similar effect of WBV to the effect of exercise 
on PTH might be observed in longer WBV trails. Since this study is the first study 
to determine the relation between PTH and WBV, including PTH in the future 
WBV is recommended. Interestingly, PTH level rose from baseline in the group 
that received WBV and vitamin D. This result does not agree with (Kukuljan et al., 
2011) in terms of the reduction in PTH level in the group which received vitamin 
D and did exercise in this latter study.  This difference may have been caused by 
the extreme difference in the baseline level of vitamin D between our trial and 
Kukuljan et al’s. (2011) trial.  It is therefore hypothesised that WBV and vitamin D 
supplements in vitamin D deficient populations increase PTH level and may 
indicate the need to optimise vitamin D and PTH levels before undertaking a WBV 
training regime but this needs to be investigated further.   
Finally, the MENA population was chosen as a target population in this study due 
to the lack of research in this population despite the widespread vitamin D 
deficiency and the higher prevalence of osteoporosis among this ethnicity (Arabi et 
al., 2010, Hilger et al., 2014, Chakhtoura et al., 2018, Sadat-Ali et al., 2012).  This 
study may provide a platform for further research in the MENA population in either 
Europe or in the MENA countries. The recruitment rate was better than was initially 
expected and the study was completed earlier than had been planned. This can be 
attributed to several factors. First of all, the target population was involved in the 
study design. A public involvement (PI) event was held by the present researcher 
in the setting-up phase of the study to determine the convenience of the study’s 
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location, the timing of the study visits and the timing of the WBV sessions. 
Accordingly, the PhD student liaised with the CRF manager to accommodate the 
potential participants’ preferences. In addition, participants in the PI event were 
involved in designing the materials which were used to advertise the study and in 
wording the information sheet. The recruitment methods that were used (via 
university email database and poster distribution) may have also contributed to the 
effective recruitment. It is also possible that the university students are more 
interested in research and that recruiting from the general MENA public in the UK 
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6.1 Conclusion  
The main aim of the current project was to determine the combined effect of a 
150,000 IU single oral dose of vitamin D3 and 12 weeks of high intensity WBV on 
the HR-pQCT parameters of the distal tibia. The main findings of this work indicate 
that a large single oral dose of vitamin D and 12 weeks of high intensity side-
alternating WBV did not improve bone density, bone microarchitecture or bone 
strength. Similarity, 12 weeks of high intensity WBV without vitamin D did not 
improve bone density, bone microarchitecture or bone strength. However, a positive 
association was found between administrating a large dose of vitamin D without 
WBV and an improvement in total volumetric BMD at the distal tibia. 
The large dose of vitamin D was effective in increasing serum 25(OH)D in a healthy 
adult population, who were mostly vitamin D deficient and had immigrated from 
the MENA region to the UK. This large dose of vitamin D without WBV was found 
to reduce PTH. A slight increase in PTH levels was found in response to WBV 
without vitamin D. However, a more pronounced increase in PTH levels was found 
in response to WBV and a large dose of vitamin D at the end of the study. 
The 150,000 dose of vitamin D3 administered to the participants was found to be 
safe in this MENA population. The dose was well tolerated, and there were no 
observed adverse effects in any participants following its administration. In 
addition, no hypercalciuria or hypercalcemia were found as a result of 
administrating 150,000 IU of vitamin D3. The high intensity side-alternating WBV 
was well tolerated. No serious adverse events were found in any participant as a 
result of undertaking the WBV training regime for 12 weeks. The compliance of 
the participants to 3 WBV sessions each week for 12 weeks was very good. This 
indicates that WBV is feasible and safe in MENA populations living in the UK. 
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6.2 Strengths and limitations  
The major strength of the current study is its prospective and interventional nature, 
as well as its use of the randomised controlled trial design. Furthermore, the MENA 
population recruited in the current study is another unique point.  In addition, our 
study included four different groups with a group without treatment/intervention, 
which served as a control group for the other three. Therefore, it was possible to 
ascertain the impact of each intervention and to compare and contrast the effect of 
each against the control group. We used HR-pQCT, which is the state-of-the art 
imaging modality for assessing bone structure non-invasively without exposing our 
participants to a high amount of ionising radiation. Beyond this, administering a 
large single dose of vitamin D under direct supervision eliminated the issue of 
adherence to daily doses of that vitamin. Similarly, all WBV sessions were 
supervised; therefore, it was possible to accurately record the participants’ 
compliance and to ensure that the correct WBV positioning was performed, 
including posture and positioning of the feet on the platform.  
However, the current study has some limitations that should be considered. We used 
strict inclusion and exclusion criteria for participation; therefore, the results may 
not represent the general MENA population living in the UK. For instance, it is 
possible that the result would have changed had we recruited children or elderly 
cohorts.  In addition, it was not possible to obtain a sham device due to the limited 
funding for the current study.  The advantage of double blinding is well known, and 
in WBV studies involves using a training device (Fregni et al., 2010). It has been 
suggested that a sham WBV may not totally mask the true WBV (Rubin et al., 
2004). We did not have access to sham/training device, therefore double blinding 
was not possible for the WBV intervention used in our study. 
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Another limitation of our study is the fact that we did not perform additional 
measurements at timepoints between baseline and the end of the study 
interventions. This is especially correct for serum 25(OH)D and PTH, which would 
be expected to respond sooner than bone to a large dose of vitamin D. The effect of 
the large dose of vitamin D on serum 25(OH)D would be expected to be highest 
during the first 4 weeks following its administration (Kearns et al., 2013). We 
sought additional external funding in order to perform more measurements, but our 
application was not successful.  Therefore, measurements were restricted to two 
time points at the beginning and at the end of the study due to the limited financial 
resources and the limited timescale to complete the current PhD project. 
Additionally, although the vast majority of data was collected during winter 
(including all baseline vitamin D data), some data was collected during summer 
months. Therefore, seasonal variations in serum 25(OH)D cannot be totally 
eliminated as some participants may have synthesised vitamin D by exposing 
themselves to the sun during the brighter months. However, this is doubtful in the 
MENA population due to the conservative clothing style as well as culture and 
religious reasons.   
Measurements for bone density were taken at one skeletal site only, which 
represents a further limitation. Although we used the most advanced imaging 
modality to determine the effect of the intervention and hypothesised that the 
greatest effect would be observed at the distal tibia since this is the long bone closest 
to the platform, we cannot eliminate the possibly that a significant effect might have 
been detected at another skeletal site further away from the platform. However, the 
same limited financial reason hindered our ability to perform additional scans at 
various skeletal sites.  
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Another limitation of our study was the small sample size. This may have limited 
our ability to detect significant changes in HR-pQCT parameters at the distal tibia. 
However, there was no prior data that could be used to conduct a power calculation. 
Our study therefore should be regarded as a pilot trial. Among the several 
approaches to determine a sample size for a pilot trial, we have chosen a sample 
size of 40 because we felt that this approach was most suitable for our aims and 
available resources. The data generated from this study can be now used to power 
a larger definitive trial.  Finally, our study only covered a relatively short period, 
and the results obtained were in the context of a 3 month intervention.  The long-
term effect of WBV in the MENA population living in the UK remains unknown. 
Moreover, the compliance and the dropout rate may have been higher had the WBV 
training protocol lasted for a longer period.  
6.3 Recommendations and future directions 
Some blood samples for our participants have been withdrawn and stored within 
the Sheffield Teaching Hospital (STH) biorepository, which is licenced to store 
human tissue for the purposes of research. The samples are stored at -80C and will 
be kept for a maximum period of 5 years. They include two blood samples for each 
participant: one at baseline and the other at the end of the study. The next step will 
be applying for a grant in order to carry out additional analyses on the stored 
samples. These analyses may include vitamin D binding protein (DBP), vitamin D 
binding protein (DBP) genotyping and markers of bone turnover. 
Future trials examining the effect of WBV on bone should pay special attention to 
the vitamin D status and PTH levels. We have generated and estimates of effect size 
based in our data in the result chapter. This is can be used to power a larger trial 
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using the same design as used in our trial is recommended to understand the 
interaction between WBV and vitamin D and their effects on bone density, bone 
microarchitecture, bone strength, serum 25(OH)D level and PTH levels. In 
addition, future trials may consider using different WBV intensities or targeting a 
different age group or population. Furthermore, future studies should aim to 
conduct the WBV over a longer period and consider the value of taking 
measurements for bone density at more than one skeletal site.  
The baseline serum 25(OH)D indicated that the vast majority of participants were 
suffering from vitamin D deficiency. Despite the issue of low levels of vitamin D 
among MENA populations being well known for many years, it was noticed that 
12 participants (30%) had extremely low levels of serum 25(OH)D (<15 nmol/L), 
without any symptoms alarming them to visit their doctors. There is a need for 
future research in the MENA population living in the UK. The evident vitamin D 
deficiency among our participants indicated the fact that more research is needed to 
understand the causes for this phenomenon among the MENA population who live 
in developed country such as in the UK. This may identify some strategies to 
optimise vitamin D status among this population. Our study assessed the effect of 
150,000 IU of vitamin D3 for a period of 3 months, and our study found it to be a 
safe dose. A future study is recommended to determine the safety and effectiveness 
of higher doses of vitamin D on vitamin D status among the MENA population. 
Our study did not find WBV to be effective in improving bone density among the 
apparently healthy MENA population who live in the UK. Therefore, based on our 
results, a future trial of WBV among the apparently healthy MENA population is 
not recommended. An alternative approach such as exercises trails aiming to 
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Appendix vii: The procedure in case of undesirable effects and reporting via the 
Yellow Card Scheme 
 
